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Abstract
The safety and effectiveness of different methods of 
earwax removal: a systematic review and economic 
evaluation
AJ Clegg,* E Loveman, E Gospodarevskaya, P Harris, A Bird, J Bryant, 
DA Scott, P Davidson, P Little and R Coppin
Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, 
Southampton, UK
*Corresponding author
Background:  Build-up of earwax is a common 
reason for attendance in primary care. Current 
practice for earwax removal generally involves the 
use of a softening agent, followed by irrigation of the 
ear if required. However, the safety and benefits of 
the different methods of removal are not known for 
certain.
Objectives:  To conduct evidence synthesis of the 
clinical effectiveness and cost-effectiveness of the 
interventions currently available for softening and/
or removing earwax and any adverse events (AEs) 
associated with the interventions.
Data sources:  Eleven electronic resources were 
searched from inception to November 2008, 
including: The Cochrane Library; MEDLINE (OVID), 
PREMEDLINE In-Process & Other Non-Indexed 
Citations (OVID), EMBASE (OVID); and CINAHL.
Methods:  Two reviewers screened titles and 
abstracts for eligibility. Inclusion criteria were applied 
to the full text or retrieved papers and data were 
extracted by two reviewers using data extraction 
forms developed a priori. Any differences were 
resolved by discussion or by a third reviewer. Study 
criteria included: interventions – all methods of 
earwax removal available and combinations of these 
methods; participants – adults/children presenting 
requiring earwax removal; outcomes – measures of 
hearing, adequacy of clearance of wax, quality of life, 
time to recurrence or further treatment, AEs and 
measures of cost-effectiveness; design – randomised 
controlled trials (RCTs) and controlled clinical trials 
(CCTs) for clinical effectiveness, cohort studies for 
AEs and cost-effectiveness, and costing studies for 
cost-effectiveness. For the economic evaluation, a 
deterministic decision tree model was developed 
to evaluate three options: (1) the use of softeners 
followed by irrigation in primary care; (2) softeners 
followed by self-irrigation; and (3) a ‘no treatment’ 
option. Outcomes were assessed in terms of benefits 
to patients and costs incurred, with costs presented by 
exploratory cost–utility analysis.
Results:  Twenty-six clinical trials conducted in 
primary care (14 studies), secondary care (8 studies) 
or other care settings (4 studies), met the inclusion 
criteria for the review – 22 RCTs and 4 CCTs. The 
range of interventions included 16 different softeners, 
with or without irrigation, and in various different 
comparisons. Participants, outcomes, timing of 
intervention, follow-up and methodological quality 
varied between studies. On measures of wax clearance 
Cerumol, sodium bicarbonate, olive oil and water are 
all more effective than no treatment; triethanolamine 
polypeptide (TP) is better than olive oil; wet irrigation 
is better than dry irrigation; sodium bicarbonate drops 
followed by irrigation by nurse is more effective than 
sodium bicarbonate drops followed by self-irrigation; 
softening with TP and self-irrigation is more effective 
than self-irrigation only; and endoscopic de-waxing 
is better than microscopic de-waxing. AEs appeared 
to be minor and of limited extent. Resuts of the 
exploratory economic model found that softeners 
followed by self-irrigation were more likely to be 
cost-effective [£24,433 per quality-adjusted life-year 
(QALY)] than softeners followed by irrigation at 
primary care (£32,130 per QALY) when compared 
with no treatment. Comparison of the two active 
treatments showed that the additional gain associated 
with softeners followed by irrigation at primary care 
over softeners followed by self-irrigation was at a 
cost of £340,000 per QALY. When compared over 
a lifetime horizon to the ‘no treatment’ option, the 
ICERs for softeners followed by self-irrigation and Abstract
iv
of softeners followed by irrigation at primary care 
were £24,450 per QALY and £32,136 per QALY, 
respectively.
Limitations:  The systematic review found limited 
good-quality evidence of the safety, benefits and 
costs of the different strategies, making it difficult 
to differentiate between the various methods for 
removing earwax and rendering the economic 
evaluation as speculative.
Conclusions:  Although softeners are effective, which 
specific softeners are most effective remains uncertain. 
Evidence on the effectiveness of methods of irrigation 
or mechanical removal was equivocal. Further 
research is required to improve the evidence base, 
such as a RCT incorporating an economic evaluation 
to assess the different ways of providing the service, 
the effectiveness of the different methods of removal 
and the acceptability of the different approaches to 
patients and practitioners.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Background
Earwax is a normal secretion, the purpose of 
which is generally thought to be to protect the 
ear from particles entering the deeper part of 
the ear. Normally, earwax moves these particles 
to the outer ear. Sometimes this process fails 
and significant build-up of earwax can occur. 
This can affect anyone, but appears to be more 
prevalent in the elderly, children and those with 
learning disabilities. Estimates suggest anything 
from 700,000 to 2 million adults in England and 
Wales may have a build-up of earwax. While not 
all of these people will consult with a health-care 
practitioner, it is believed to be a common reason 
for attendance in primary care. Current practice 
for the removal of earwax varies. In general, a 
softening agent is usually recommended, leading 
up to irrigation of the ear if required. However, 
there are a variety of different agents for softening 
the earwax, and with no national guidelines on 
the removal of earwax many procedures are based 
on local custom and practice rather than a strong 
clinical evidence base. The relative safety and 
benefits of the different methods of removal are 
not known for certain.
Objectives
The objectives of this evidence synthesis were 
to conduct a systematic review of the evidence, 
assessing the clinical effectiveness and cost-
effectiveness of the interventions that are currently 
available for softening and/or removing earwax 
in children or adults. To systematically search 
for, appraise and summarise clinical trial and 
observational evidence for the harms or adverse 
events (AEs) associated with interventions for 
softening or removing earwax. To construct an 
economic model for the UK to estimate the relative 
cost-effectiveness of those interventions that are 
considered to be clinically effective. To identify 
future cost-effective research in the management 
of earwax through a value of information analysis, 
specifying key elements in the design of future 
studies.
Methods
A systematic review of the evidence on the 
clinical effectiveness and cost-effectiveness and 
an economic evaluation were undertaken using a 
priori methods.
Data sources
Eleven electronic resources (including MEDLINE, 
EMBASE, CINAHL, BIOSIS, etc.) were searched 
from inception to November 2008. Bibliographies 
of related papers were assessed and experts were 
contacted to identify additional published and 
unpublished references. These were used for the 
systematic review and to inform the development 
and population of the economic model.
Study selection
Studies were included if they fulfilled the following 
criteria:
•  Interventions  All methods of earwax removal 
or softening, including drops, irrigation, 
other mechanical removal, other methods and 
combinations of these methods.
•  Participants  Adults or children presenting with 
build-up of earwax requiring removal.
•  Outcomes  Measures of hearing, adequacy 
of clearance of wax, quality of life, time to 
recurrence or further treatment, AEs and 
measures of cost-effectiveness.
•  Design  Randomised controlled trials (RCTs) 
and controlled clinical trials (CCTs) for clinical 
effectiveness, cohort studies for AEs and cost-
effectiveness, and costing studies for cost-
effectiveness.
Studies identified were assessed for inclusion 
through two stages, with titles and abstracts and 
full papers of retrieved studies assessed by two 
reviewers, with differences in decisions resolved 
through discussion or through recourse to a third 
reviewer.
Executive summaryExecutive summary
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Data extraction and quality 
assessment
Data were extracted by two reviewers using 
data extraction forms developed a priori, with 
any disagreements resolved through discussion 
or through recourse to a third reviewer. The 
methodological quality of the studies included in 
the systematic review of clinical effectiveness and 
cost-effectiveness was assessed using recognised 
quality assessment tools. The quality criteria 
used were applied by two reviewers, with any 
disagreements resolved through discussion or 
through recourse to a third reviewer.
Data synthesis
Studies were synthesised through a narrative review 
with full tabulation of the results of all included 
studies.
Economic model
The economic evaluation developed a deterministic 
decision tree model to evaluate three alternative 
options, specifically the use of softeners followed 
by irrigation in primary care, softeners followed 
by self-irrigation and a ‘no treatment’ option. It 
assumed a UK National Health Service (NHS) 
perspective, focused on an adult population aged 
35–44 years with no contraindications to treatment 
and assessed outcomes over different time horizons 
(7 weeks to 45 years). Outcomes were assessed in 
terms of benefits to patients (i.e. successful removal 
of earwax and quality of life) and costs incurred, 
with costs presented in terms of a cost–utility 
analysis [cost per quality-adjusted life-year (QALY) 
and incremental cost-effectiveness ratio (ICER)].
Results
Clinical effectiveness
A total of 26 clinical trials conducted in primary 
care (14 studies), secondary care (8 studies) or 
other care settings (4 studies), met the inclusion 
criteria for the review. Of these studies, there were 
22 RCTs and 4 CCTs. A range of interventions was 
used in the studies – some 16 different softeners 
with or without irrigation in various different 
comparisons were used. In addition to the wide 
range of interventions used, studies were diverse in 
terms of the participants and outcomes used, and 
also varied on timing of the intervention, duration 
of follow-up and methodological quality (in part 
a reflection of the age of many of the included 
studies), including use or not of any statistical 
analysis of their data.
Considering the studies that report statistical 
significance testing and ignoring any variations in 
methodological quality, results assessing clearance 
of wax show that: Cerumol, sodium bicarbonate, 
olive oil and water are all more effective than no 
treatment; triethanolamine polypeptide (TP) is 
better than olive oil; wet irrigation is better than 
dry irrigation; sodium bicarbonate drops followed 
by irrigation by nurse is more effective than sodium 
bicarbonate drops followed by self-irrigation; 
softening with TP and self-irrigation is more 
effective than self-irrigation only; and endoscopic 
de-waxing is better than microscopic de-waxing. 
Results assessing ease of subsequent irrigation as 
the outcome show that: Cerumol is better than 
dioctyl, TP and sodium bicarbonate and Audax 
are better than Earex. AEs appear to be minor and 
limited in extent, and mainly related to irrigation. 
No studies reported serious adverse events (SAEs). 
Minor pain, discomfort and irritation/itching of the 
ear were the main AEs.
Cost-effectiveness
The systematic review of cost-effectiveness did not 
identify any economic evaluations. The de novo 
economic model developed for this assessment 
found that softeners followed by self-irrigation were 
more likely to be cost-effective (£24,433 per QALY) 
than softeners followed by irrigation at primary 
care (£32,130 per QALY) when compared with no 
treatment. Comparison of the two active treatments 
showed that the additional gain associated with 
softeners followed by irrigation at primary care 
over softeners followed by self-irrigation was at a 
cost of £340,000 per QALY. When compared over 
a lifetime horizon to the ‘no treatment’ option, the 
ICERs for softeners followed by self-irrigation and 
of softeners followed by irrigation at primary care 
were £24,450 per QALY and £32,136 per QALY, 
respectively. Sensitivity and scenario analyses 
showed the results are fairly robust to changes in 
the cost of irrigation in primary care, although 
changes in the utility associated with loss of hearing 
may have some effect. However, caution should be 
taken in interpreting the results of the economic 
evaluation due to the paucity of evidence on the 
safety, benefits and costs of the different strategies. 
As a consequence, the results of the economic 
evaluation should be regarded as exploratory and DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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should not be used as a basis for changing policy 
and practice.
Conclusions
The systematic review of clinical effectiveness 
and cost-effectiveness found limited good-quality 
evidence, making it difficult to differentiate 
between the various methods for removing earwax 
in terms of clearing wax, improving quality of life 
and satisfaction, AEs or cost-effectiveness. Although 
it showed that softeners have an effect in clearing 
earwax in their own right and as precursors to 
irrigation, which specific softeners have an effect 
remains uncertain. Evidence on the effectiveness 
of methods of irrigation or mechanical removal 
was equivocal. The limited evidence on benefits 
and costs of methods of earwax removal meant 
that the economic evaluation was speculative and 
for illustration only. Its findings should not be 
used for policy decisions. As such, further research 
is required to improve the evidence base. A well 
conducted RCT incorporating an economic 
evaluation would appear to provide the most 
appropriate method to assess the different ways of 
providing the service (i.e. practice nurse provision 
in primary care versus self-care) as well as the 
effectiveness of the different methods of removal 
(i.e. softeners and mechanical removal). As part of 
such research it would be important to assess the 
acceptability of the different approaches to patients 
and practitioners to ensure the most appropriate 
structure to the research. Other studies could be 
considered to improve specific data (e.g. a costing 
study of primary care costs); however, the poor 
quality of the evidence suggests additional research 
would be required.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Aim
The project will evaluate the clinical effectiveness 
and cost-effectiveness of the different methods 
for the removal earwax in adults and children. It 
will review systematically the evidence assessing 
the clinical effectiveness and cost-effectiveness 
of interventions that are currently available for 
softening and/or removing earwax, including the 
use of drops, irrigation, mechanical removal and 
other methods. The project will systematically 
search for, appraise and summarise evidence on 
the safety of the different methods, identifying any 
significant harms or adverse events (AEs). If the 
systematic review of cost-effectiveness shows that 
there are no appropriate good-quality economic 
evaluations, a new economic model relevant to the 
UK setting will be developed. Also, it will identify 
any research needs and use value-of-information 
approaches to help in prioritising them.
Description of the health 
problem
Earwax (cerumen) is a normal secretion in the 
external ear canal, produced by small glands in the 
ear. The purpose of earwax is generally thought to 
be to protect the ear by trapping any particles in 
the ear canal and preventing them from entering 
the deeper part of the ear. Particles may include 
dirt, dead skin or other fragments. Normally, 
earwax moves particles to the outer ear at a rate 
that prevents any significant build-up. When this 
process fails, there can be an excessive build-up 
of wax, which can block or occlude the auditory 
canal.1,2 Although this can be a relatively minor 
problem, it can result in several other related 
problems, including hearing loss, discomfort, 
balance disorders, tinnitus and even infection.3,4 It 
is often these symptomatic conditions that are the 
key concern for the person suffering from excessive 
earwax.
Although people with an excessive build-up of 
earwax can experience any of these conditions, 
hearing loss and the associated discomfort are 
probably the most frequent that occur.5 The effects 
on hearing can be significant. Severity of hearing 
loss is measured by how well an individual can hear 
the frequencies or intensities of sound [measured 
by decibel (dB)] most often associated with speech. 
A person who can hear within the normal range 
can perceive sounds at a threshold intensity as 
low as 20 dB. Blockage of the ear from wax may 
elevate the hearing threshold to 40–45 dB.6,7 In 
those presenting with age-related hearing loss, 
some will have earwax that, if removed, can reduce 
the hearing loss by around 10 dB.8 The sense of 
blockage of the ear, the effects of hearing loss and 
the other comorbidities can cause discomfort and 
irritation to the person.
The occurrence of these related comorbidities 
provide evidence of the extent and severity of the 
build-up of earwax. Often people will present prior 
to the development of severe symptoms. In such 
instances, assessment of their condition is usually 
made based on the degree of occlusion of the 
auditory canal or tympanic membrane (TM), the 
extent of impaction of earwax, and the nature and 
characteristics of the earwax itself. These are often 
thought to be proportionally related to the severity 
of comorbidities.7 Assessment of these symptoms 
is usually undertaken through direct visualisation 
of the ear canal with an otoscope.9 There do not 
appear to be any documented standard criteria 
on which to base such judgements, meaning that 
they are open to variation in their measurement, 
reporting and interpretation. Such differences 
make judging the extent and severity of the earwax 
uncertain.
Aetiology
There are a number of possible causes of excess 
earwax or of the retention of earwax.5,10–12 Small 
amounts of earwax are normal in the ear canal and 
excessive cleaning may interfere with the natural 
production of earwax. Other factors, such as the 
rate of earwax accumulation,10 use of hearing 
aids,11 small ear canals or skin conditions may 
also increase the risk of a build-up of earwax. In 
addition, different people appear to be at a higher 
risk of suffering from accumulation of earwax, 
with an increased risk for the elderly, men, people 
with intellectual impairment and secondary-care 
populations.5,12
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As people age, the cerumen glands atrophy 
(decline in effectiveness) and earwax becomes drier, 
making it a more extensive problem in the older 
age group.1 Excessive earwax may also present as 
a problem in hearing assessments, blocking the 
view of the TM (or ear drum) during examination, 
and it can interfere with the fitting of hearing aids. 
Some 80% of patients attending a hearing aid 
repair department do so because of problems with 
earwax.13 Recurrence of the problem does not seem 
uncommon and it is suggested that around 30% of 
elderly and mentally impaired individuals14 require 
regular treatment.
Pathology
Earwax is composed of the outer layers of the skin, 
which are discarded as part of a normal process 
of skin turnover and glandular secretions.11 The 
skin is made up of three different layers, with 
the epidermis being the outermost layer.15 The 
epidermis consists of different cells, the major 
cell type of which is keratinocytes. As part of the 
normal cycle of skin turnover, these cells push up 
through the epidermis and are eventually shed.15 
An over production of keratin or a failure in the 
separation of keratinocytes are thought to be 
possible factors leading to excessive earwax. For 
example, in a study of 20 patients with earwax, 
keratin was seen to account for up to 60% of 
the earwax plug.16 Other research suggests that 
carotenoids (fat-soluble pigments) might contribute 
to the mechanism of the production of excessive 
earwax, but this requires further confirmation.10,11
Earwax has two phenotypes. Wet wax is far more 
common in Caucasians17 and Africans,18 consisting 
of approximately 50% lipid (fat).10 Dry wax is 
more frequent in East Asians,19 and only contains 
about 20% lipids.20 There appear to be few other 
biochemical differences between the two types of 
wax.10 Also, wax colour may vary from person to 
person.
Epidemiology
Although earwax and its associated problems are 
thought to be a common reason for attending 
primary care practices, data on its epidemiology 
in the general population are limited. Prevalence 
rates appear to vary widely, due in part to the 
different population groups under study, the likely 
variation in the interpretation of the degree of 
earwax present, and differences in the methods 
used to ascertain the data.
In an adult hearing screening study in Denmark, 
earwax was judged to be occluding in 2.1% of 
participants aged between 30 and 49 years.21 This 
is similar to the rate of acoustically obstructing 
earwax (2.3%) identified in an earlier UK adult 
hearing screening study.22 However, another 
estimate suggests that excessive or ‘impacted’ 
earwax is likely to be present in up to 5% of normal 
healthy adults, with higher rates in children, 
older people living in nursing homes and those 
with learning difficulties (approximately 10%, 
57% and 36% of people in these three groups, 
respectively).9,14 One of the limitations of the two 
screening studies is that the populations were those 
who agreed (from a random sample) to be screened 
for hearing loss and hence the estimates may not 
be representative of the general population. The 
latter study was a review of a number of different 
epidemiological studies but the estimates are also 
limited owing to differences in the methodologies, 
sample sizes and age of their included studies. This 
may explain the wide variation in ranges seen.
In a single-centre study of children aged  
3–10 years in one region of the UK, the prevalence 
of partially occluding or totally occluding earwax 
was reported to be 43%.23 The study suggested 
that the prevalence tends to decrease with age and 
that there is no difference in prevalence between 
gender. The authors of the study point out, 
however, that the sample was not a random one 
and the collection of data was undertaken during 
the winter months, which may explain the higher 
rates of earwax.
In older people who are admitted to an elderly 
care evaluation unit, 19% of those found to have 
a hearing impairment on assessment (55% of the 
total sample) had earwax occluding both ears.24 
The prevalence of bilateral earwax increased with 
age, from 9% in those aged 55–64 years and  
65–74 years, to 13% in those aged 75–84, and 
to 27% in those over the age of 85 years. A UK 
survey of 300 consecutive general practice referrals 
of patients >60 years for hearing aids found a 
29% prevalence of occluding wax.25 However, it 
should be noted that these rates are from those 
with hearing impairment, rather than general 
population rates. It is also not clear whether the 
earwax was the cause of the hearing impairment. 
In another study of elderly participants (mean 
age 81 years) who had been identified as having 
hearing loss on screening, the occurrence of 
‘impacted’ earwax was reported as 15.7% of ears.26 
One further study of hospitalised elderly patients DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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in the USA reported that 35% of its sample 
suffered with ‘impacted’ earwax, 15% unilaterally 
and nearly 20% bilaterally.5 Similar caveats 
apply to these latter two studies regarding the 
generalisability of their populations with that of the 
general population.
It is clear that these studies show a wide variation 
in their estimates of the prevalence of earwax 
and also their definition of the extent of the 
earwax. It is unclear, however, whether all of 
these people would have viewed their earwax 
as problematic or symptomatic, particularly in 
the studies that identified their estimates from 
a screened population. However, to generate an 
estimate of the numbers of people in the general 
population with earwax that potentially may be 
problematic (‘impacted’ or ‘occluding’), these 
estimates have been applied to the UK population 
size. An estimate of the prevalence in adults 
(aged 16–59 years) based on a figure of 2–5%9,21,22 
and a UK adult population of 36,122,100 (taken 
from mid-2006 estimates27) suggests somewhere 
between 722,000 and 1,800,000 adults may have 
problematic earwax. Taking a range of 10–43%9,23 
in children aged less than 16 years and a UK 
child population of 11,537,100,27 the range of 
the prevalence of potentially problematic earwax 
would be in the region of 1,154,000–4,961,000. In 
those older than 60 years there may be somewhere 
between 2,069,000 and 7,369,000 people with 
potentially problematic earwax (based on a range 
of 16–57%9,24,26 and a population of 12,928,10027). 
The wide ranges of these estimates, based on a 
number of different prevalence rates from different 
studies, each with their own particular limitations, 
illustrate the difficulty of pinpointing the extent 
of the earwax problem in the UK. Not all of these 
people will consult a health-care professional, but 
recent estimates suggest that health professionals 
perform up to 2 million ear irrigations in England 
and Wales per year.11
Current service provision 
and description of 
interventions
Despite the problems associated with the 
accumulation of excessive earwax and the 
demands placed upon primary care within the 
UK National Health Service (NHS), it appears 
that there are no nationally agreed guidelines for 
its diagnosis and treatment. As a consequence, 
it is likely that services will vary with many based 
primarily on local custom and practice rather 
than a strong clinical evidence base. Some locally 
and internationally based guidelines have been 
developed28 and these, along with opinions from 
clinicians, including practice nurses, provide a 
basis for understanding the clinical pathway that 
may be followed by people who are suffering from 
the problems associated with excessive earwax. 
Problems that may lead a person to seek help 
include a feeling of a blockage, discomfort, hearing 
loss in one or both ears, tinnitus and/or dizziness.
In the UK, people requiring the removal of earwax 
have traditionally attended primary care practices 
for confirmation of the diagnosis and treatment. 
The method of treatment should take account 
of the severity of the condition, the possibility 
of any contraindications (e.g. perforations) or 
comorbidities (e.g. tinnitus), the skills of the 
practitioner and the setting for treatment. The 
majority of practitioners currently advise the use 
of some form of drops or softeners as a first stage. 
The British National Formulary (BNF) lists several 
preparations, including almond oil, olive oil, 
sodium bicarbonate drops, Cerumol®, Exterol®, 
Molcer®, Otex® and Waxsol®. Other softeners may 
also be used. A summary of different preparations 
is presented in Table 1, grouping them into water-
based, oil-based or non-water-non-oil-based 
products, using the classification adopted by Hand 
and Harvey.29 Not all of these preparations are 
currently available in the UK. Brand names will 
be used throughout the report unless those are 
unclear, when the generic name will be reported.
The intention of these remedies or drops is to 
either soften the wax prior to removal at the 
clinic or to help remove the wax on its own. 
Their specific action varies. For example, in vitro 
studies suggest that preparations including urea or 
glycerine increase water penetration of the earwax, 
while preparations including peroxide break up 
the earwax through the release of gas/bubbles, 
therefore aiding mechanical removal.30 Limited 
data are available to guide people’s choice of drops 
in particular clinical situations. AEs differ for each 
intervention but are generally thought to be mild. 
It is usually suggested that people allow between 
3 and 7 days for these remedies or drops to take 
effect, although for some it may take longer (i.e.  
14 days of drops) or several cycles.
If the wax has not dissolved or dissipated using 
drops or remedies, people are recommended 
to attend the primary care practice to have the Aim and background
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TABLE 1  Summary of investigated preparations
Key ingredient Preparation Background information
Water-based preparations
Acetic acid (otic) EarCalm Acetic acid (glacial) ear spray. Ph Eur 2% w/w, ethoxylated, stearyl alcohol, 
ethylparahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), 
purified water. Supply 5 ml
Dose: 1 metered dose (60 mg, 0.06 ml) sprayed into the affected ear at least 
3 times daily, maximum 1 spray every 2–3 hours for 2 days after symptoms 
have disappeared but for no longer than 7 days (from age 12 years)
Side effects/allergic reaction: Hives, difficulty breathing, swelling of face, lips, 
tongue or throat
Contraindication: Hypersensitivity to acetic acid otic solution or perforated 
TM
Internet price: Around £5.99
Docusate sodium Molcer® Docusate sodium 5%. Includes propylene glycol. Supply 15 ml
Dose: Fill ear with solution and remain in position for a few minutes, repeat 
for 2 nights after which the wax can be removed (from age 12 years)
Side effects/allergic reaction: Occasional skin irritations
Contraindication: Perforated TM
OTC cost: Around £1.90
Waxsol® Docusate sodium 0.5%. Glycerine, water and phenonip (a preservative). 
Supply 10 ml
Dose: 2 drops per night (from age 6 years)
Side effects/allergic reaction: Occasional stinging or soreness
Contraindication: Perforation of the TM or inflammation of the ear
OTC cost: Around £1.26
Colace® Liquid docusate sodium stool softener (not available in the UK)
Dioctyl-medo® or 
Diocytl
Liquid docusate sodium stool softener and maize oil (not available in the UK)
Sodium bicarbonate Care® (generic 
sodium 
bicarbonate 
may be used in 
practice)
Sodium bicarbonate BP 5% w/v. Supply 10 ml
Dose: 3–4 drops, 3–4 times per day, for 3–5 days (from age 5 years)
Side effects/allergic reaction: Dryness inside the ear, mild stinging sensation
Contraindication: Unknown
OTC cost: Around £2.20
Triethanolamine 
polypeptide oleate 
condensate
No longer available 
in the UK and 
discontinued in the USA
Cerumenex® or 
Xerumenex®
Triethanolamine polypeptide oleate condensate (10%). Inactive ingredients – 
chlorobutanol 0.5%, propylene glycol and water. Supplied in 6 ml and 12 ml
Dose: 5 drops, 2–3 times daily, for up to 3 days; limit exposure to the ear 
canal to 15–30 minutes (age unknown)
Side effects/allergic reaction: Temporary burning, skin rash, itching, pain in or 
around the ears, dizziness or hearing trouble
Contraindication: Perforated TM, otitis media or hypersensitivity to 
triethanolamine polypeptide, seborrhoeic dermatitis and eczema affecting 
the external ear
Only available over the internet
Cost: Around £3.08 (not OTC)
Sodium chloride 
(saline)
Generic solutions 
available
Sodium chloride 0.9%. Supply 20 × 0.5 ml
Dose: 3–4 drops, 3–4 times per day, for 3–5 days (from age 6 months).
Side effects/allergic reaction: None reported
Contraindication: Unknown.
OTC cost: Around £4.92DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Oil-based preparations
Chlorobutanol 
solution
Cerumol® Chlorobutanol 5%, paradichlorobenzene 2%, arachis (peanut) oil 57.3%. 
Supply 11 ml
Dose: 5 drops twice per day for 3 days (adults and children)
Side effects/allergic reaction: Uncommon – can experience tingling sensation or 
temporary mild deafness when applied
Contraindication: Otitis externa, seborrhoeic dermatitis and eczema affecting 
the outer ear, perforated TM and allergy to peanuts
OTC cost: Around £2.85
Glycerine/glycerin Earex (same as 
Otocerol)
Almond oil BP 33.33%,  Arachis (peanut) oil BP 33.33% and rectified camphor 
oil 33.33%. Supply 10 ml
Dose: 4 drops twice daily for up to 4 days (from the of age 1 year)
Side effects/allergic reaction: Temporarily stinging or burning when first applied
Contraindication: Allergy to peanuts or soya, inflamed or infected ear
OTC cost: Around £2.29
Almond oil Generic solutions 
available
Almond oil. Supply 10 ml
Dose: 3–4 drops, 3–4 times per day, for 3–5 days (from age of 6 months)
Side effects/allergic reaction: None reported
Contraindication: Allergy to almonds
OTC cost: Around £2.07
Olive oil Earol (generic 
olive oil may be 
used in practice) 
Olive oil ear drops. Supply 92 ml with 10-ml dropper
Dose: 3–4 drops, 3–4 times per day, for 3–5 days (from age of 6 months)
Side effects/allergic reaction: None reported
Contraindication: Unknown
OTC cost: Around £2.25
Non-water-non-oil-based preparations
Choline salicylate 
solution
Audax® Choline salicylate 21.61%, glycerol 12.62%. Supply 10 ml
Discontinued from use
Earex Plus (same 
as Audax®)
Choline salicylate 21.6% and glycerol 12.62%. Supply 10 ml
Dose: Fill ear twice daily for up to 4 days (from age 1 year)
Side effects/allergic reaction: None reported
Contraindication: Perforated or bleeding TM
OTC cost: Around £4.29
Urea–hydrogen 
peroxide
Otex (UK brand 
name, same as 
Exterol®)
Urea–hydrogen peroxide complex 5%, ear drops: 8-hydroxy-quinoline and 
glycerol. Supply 8 ml
Dose: 5 drops twice daily for at least 3–4 days (from the age of 5 years)
Side effects/allergic reaction: Unpleasant taste in mouth, temporary bubbling 
sensation, can aggravate the painful symptoms of excessive earwax, including 
some loss of hearing, dizziness and tinnitus
Contraindication: Damaged TM, dizziness, pain, discharge, inflammation, 
infection and tinnitus within 2–3 days of irrigation or with history of ear 
problems
OTC cost: Around £1.83
continued
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Carbamide peroxide
Not available in the 
UK; available as OTC 
ear drops in the USA
Debrox® Carbamide peroxide 6.5% (urea peroxide). Supply 15 ml
Dose: 5–10 drops twice per day for up to 4 days (from the age of 12 years)
Side effects/allergic reaction: rare or uncommon – burning, itching, redness, 
worsening ear pain, rash, abnormal sensation while putting the drops in the 
ear and temporary reduction in hearing
Contraindication: Perforated TM any signs of infection or injury, pain or other 
irritation, drainage, discharge or bleeding from the ear
Internet cost:  Around US$7.89 (around £5.28)
Murine Ear® Carbamide peroxide 6.5% and otic solution. Supply 15 ml
Dose: 5–10 drops twice daily for up to 4 days (from the age of 12 years)
Side effects/allergic reaction: Temporary decrease in hearing, dizziness, ear 
pain or other irritation, decreased hearing for a prolonged period of time, or 
discharge or bleeding from the ear
Contraindication: Perforated TM, ear drainage, discharge, pain, rash, irritation 
or dizziness
Internet cost: Around US$6.49 (around £4.35)
BP, British Pharmaceutical grade; OTC, over the counter; Ph Eur, European Pharmacopeia; w/v, weight to volume; w/w, 
weight to weight.
TABLE 1  Summary of investigated preparations (continued)
wax removed by mechanical removal, through 
either irrigation or curettage.11 In irrigation, a 
pressurised flow of water is used to remove the 
earwax. Although flushing wax with metal piston 
syringes (e.g. Reiner-Alexander ear syringe) 
was common practice in primary care practices, 
these have largely been replaced with electronic 
irrigators, such as the oral jet irrigator, nebuliser or 
Propulse ear irrigator.31,32 The use of metal piston 
syringes is no longer recommended.33 Irrigation 
is contraindicated in people with perforated 
ear drums, history of ear surgery or chronic ear 
conditions. Reported harms of irrigation are 
pain, infection and injury to the ear, including 
TM perforation and tinnitus.34,35 Curettage, which 
allows the removal of earwax under direct vision, 
using various implements, such as cerumen spoons, 
hooks, loops and probes, is rarely undertaken 
in primary care practices. Although it has the 
advantage of not using water to remove the earwax, 
and so perhaps lessening the risk of infection, it 
can be a difficult procedure, requiring specialist 
skill and time.36
Increasingly the role of the general practitioner 
(GP) has been taken over by the practice nurse 
(or, for the house-bound, the district nurse), who 
can confirm the problem by examination of the 
ear, recommending/prescribing the use of the 
drops or remedies and then removing any wax 
by irrigation.31 On most occasions irrigation will 
successfully remove earwax on the first attempt; 
however, for a limited proportion of people it may 
prove more difficult and these people may need 
to attend on several occasions. Rarely, when it 
proves impossible for the primary care practice to 
remove the earwax, the person will be referred to a 
hospital-based specialist.
With the availability of several different softeners 
and proprietary drops, some people decide to self 
treat. As with their use in primary care practices, 
drops provide the possibility of treating the wax 
to allow it to dissipate or dissolve without further 
treatment. While such preparations offer the 
opportunity for self-treatment, caution needs 
to be exercised when used in combination with 
cotton wool swabs, as inadvertent damage to the 
inner ear canal or TM can occur. People may make 
several attempts to clear the wax with drops before 
consulting their primary care practice. Having self-
treated with drops, people subsequently consulting 
the primary care practice for treatment may be 
able to have their earwax removed without further 
delay. Although not currently recommended, and 
not widely available within the UK, some forms 
of syringes for self-treatment are available. Soft 
bulb irrigators can be used by people after drops 
to flush their own ears. These can be purchased 
from suppliers through the internet and over the 
counter (OTC) in some European countries and 
in the USA. Other syringes for self-treatment are 
available, including plastic piston syringes (e.g. The 
Real McCoy and Master Blaster).DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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A minority of people who are unable to have their 
ears cleared through self-care or at the primary 
care practice, or have particular clinical conditions 
(e.g. cholesteatoma), or contraindications to 
standard treatment (e.g. pre-existing perforations 
of the TM) may be referred to specialist care. 
Ear, nose and throat (ENT) or otolaryngology 
departments use techniques such as microsuction 
or curettage through direct microscopic or 
endoscopic vision to clear earwax.33,37,38 These 
methods are used in combination with suction 
or the use of a Jobson-Horne probe and a 
St Bartholomew’s wax hook, or crocodile 
forceps.38 This requires specialist equipment 
and considerable skill.33,39 In very rare instances 
where clearance of earwax is prevented due to 
a narrowing of the external auditory canal, for 
example, surgery may be required.11
In addition to the above technologies, 
complementary therapies can also be used (e.g. ear 
candling).DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Methods for reviewing 
effectiveness
The a priori methods for systematically reviewing 
the evidence of clinical effectiveness and cost-
effectiveness are described in the research 
protocol (Appendix 1), which was sent to experts 
for comment. Although helpful comments were 
received relating to the general content of the 
research protocol, there was none that identified 
specific problems with the methods of the review. 
The methods outlined in the protocol are briefly 
summarised below. Methods for the economic 
evaluation are outlined in Chapter 5 (see Methods 
of the economic valuation).
Search strategy
A sensitive search strategy was developed, tested 
and refined by an experienced information 
specialist. Separate searches were conducted to 
identify studies of clinical effectiveness, cost-
effectiveness, quality of life, AEs, resource use/
costs and epidemiology/natural history. Sources 
of information and search terms are provided in 
Appendix 2. The most recent search was carried 
out in November 2008.
Searches for clinical effectiveness and cost-
effectiveness were from database inception. 
Electronic databases searched included: The 
Cochrane Database of Systematic Reviews (CDSR); 
The Cochrane Central Register of Controlled 
Trials (CENTRAL); Centre for Reviews and 
Dissemination (CRD) (University of York) Database 
of Abstracts of Reviews of Effectiveness (DARE); 
Health Technology Assessment (HTA) database 
and the NHS Economic Evaluation Database (NHS 
EED); MEDLINE (OVID), PREMEDLINE In-
Process & Other Non-Indexed Citations (OVID), 
EMBASE (OVID); CINAHL; BIOSIS; Web of 
Knowledge Science Citation Index (SCI); Web of 
Knowledge ISI Proceedings; Current Controlled 
Trials and the National Research Register 
(Historical).
Primary care conferences were searched for 
recent abstracts (from 2004). The searches had no 
language restrictions. Any non-English language 
articles were set to one side in a separate foreign 
language reference database (see Appendix 2). 
Bibliographies of related papers were screened for 
relevant studies, and experts were also contacted 
to identify any additional relevant published or 
unpublished studies that were not identified on 
searches.
Inclusion and data extraction 
process
Titles and abstracts of studies identified by 
the search strategy were assessed for potential 
eligibility by two independent reviewers. The full 
text of relevant papers was then obtained and 
inclusion criteria were applied by two independent 
reviewers. Any disagreements over eligibility were 
resolved by consensus or, if necessary, by arbitration 
to a third reviewer. Data were extracted by one 
reviewer using a standard data extraction form and 
checked by a second reviewer.
Inclusion criteria
Patients
Adults or children presenting with build-up of 
earwax requiring removal.
Interventions
All methods of earwax removal or softening, 
including:
•  drops
•  irrigation (e.g. syringing, electronic irrigators)
•  mechanical removal other than syringing (e.g. 
suction, probes and forceps)
•  other methods
•  combinations of above methods.
Outcomes
Studies were included if they reported one or more 
of the following outcome measures:
•  measures of hearing
•  adequacy of clearance of wax
•  quality of life
•  time to recurrence or further treatment
•  AEs
•  cost-effectiveness.
Chapter 2  
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It was noted that measures assessing the extent or 
severity of earwax and the adequacy of clearance 
are often related to the degree of impaction. 
Although this term is frequently used, there is often 
no clear definition provided. It may or may not 
refer to wax that occludes the TM, to wax that is 
symptomatic to the individual and/or to a hardened 
plug of wax. As such, this systematic review will 
only use the term ‘impacted’ when there is either 
no definition or a lack of clarity in the definition 
provided in the study report. Also, where other 
outcomes are used with no clear definition this will 
be highlighted in the reporting of results.
Types of studies
Randomised controlled trials (RCTs) and 
controlled clinical trials (CCTs) (i.e. prospective 
non-randomised studies with a concurrent control 
group) were included for the assessment of the 
clinical effectiveness and, additionally, cohort 
studies were included for the assessment of AEs. 
Studies published only as abstracts or conference 
presentations were also considered for eligibility 
if sufficient information was presented to allow 
an appraisal of the methodology and assessment 
of results. Systematic reviews were used for 
background and as a source of references. For the 
review of cost-effectiveness any costing studies or 
cost-effectiveness evaluations (including modelling 
studies) were also eligible for inclusion.
Quality assessment
The quality of included RCTs and CCTs was 
assessed using criteria recommended by CRD.40 
Quality criteria were applied by one reviewer 
and checked by a second reviewer. At each stage, 
any differences in opinion were resolved through 
discussion or consultation with a third reviewer.
Data synthesis
Data were synthesised through a narrative review 
with tabulation of results of all included studies. 
Full data extraction forms are presented in 
Appendices 3–5. It was not considered appropriate 
to combine the included studies in a meta-analysis 
due to heterogeneity of the patient groups and 
comparator treatments (see Chapter 3, Quantity 
and quality of research available, for further 
details).DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Quantity and quality of 
research available
A total of 202 records of publications were 
identified through literature searching. Of these, 
158 were excluded on title and abstract. Full 
reports for the remaining 45 were requested 
for more in-depth screening. Of these, 19 were 
excluded (see list of excluded studies in  
Appendix 6). An inclusion flow chart can be  
seen in Appendix 2.
Twenty-six published studies met the inclusion 
criteria – of these, 22 were RCTs and four were 
CCTs. These trials fell into three categories: studies 
undertaken in primary care (14 studies41–54), studies 
undertaken in secondary care (eight studies4,54–60), 
and studies of self-care or those undertaken 
in other care settings (four studies61–64). Where 
the setting was in emergency care this has been 
grouped under primary care in the present review 
because it was assumed that this was the first 
point of contact with a health professional. In 
some other cases the setting was not made explicit 
within the publication; where this was the case an 
assumed grouping was used based on the author(s) 
affiliation (e.g. if they worked in an outpatient 
clinic this was assumed to be a secondary care 
setting). Additionally, studies are also grouped 
by participant group (children, mixed adults and 
children, and adult groups). In some cases the 
study did not indicate who the target population 
was and these were classed under the mixed group 
as population ‘unknown’. In some of these studies 
a mean age of the study participants was given 
but no range or measure of variance was reported 
and so these were also classed under the mixed 
population group. The subsequent discussion of 
these studies (below) will follow these conventions 
(Table 2).
There is very little consistency among the included 
studies, which makes it difficult to fully summarise 
the results and in many studies some basic data 
were not available. Across all of these studies 
there are variations in the characteristics of the 
participants recruited, in terms of age and, to 
some extent, gender, and in terms of the extent of 
the earwax problem. In many studies there is very 
limited discussion of baseline characteristics, which 
makes it difficult to establish the representativeness 
of the respective populations. Many of the included 
studies (eight studies4,42,43,46,51,55,57,61) were presented 
as either a short paper format (less than two sides), 
an abstract format or a conference proceeding, 
and, where this was the case, the available data 
were further limited.
Study sample sizes were typically small, varying 
from 36 participants45 to 237 participants,63 and 
only a few studies reported undertaking a sample 
size calculation (7 out of 24 studies45,47,49,52,53,56,63). 
In some studies the overall population sample size 
was not reported, rather the numbers of ears were 
presented.42,43,60 Seventeen studies were two-arm 
comparisons,41–45,48–54,56,58,59,63,64 five were three-arm 
studies,46,47,55,57,62 and there was one study each with 
four,4 five61 and six60 intervention arms.
There were also a wide range of interventions used 
between the included studies and differences in the 
length of follow-up used. For ease of understanding 
the review that follows is also divided into studies 
of immediate follow-up and delayed follow-up 
(the exact length of follow-up will be discussed for 
each study individually) and into studies where the 
intention was to use a softening agent alone (even 
when subsequent irrigation was used, if this was 
after initial outcome assessment) and those where 
the intention was always to use a softening agent 
and an irrigation as the intervention. Owing to the 
wide variation in interventions and comparisons 
used in the included studies the review has not 
been split by the different comparisons. However, 
each comparison is reported in sequence, in line 
with the conventions discussed above (setting, 
population, follow-up, softening agent with or 
without irrigation).
The outcome measures used also varied across the 
included studies. Often information concerning 
the definitions of the outcome measures used was 
limited and in many cases it was not possible to 
assess how valid, objective or consistently applied 
these different measures were. In the instances 
where this was clear the review has made note of 
this; for all other studies it should be assumed 
that care is required in the interpretation of the 
Chapter 3  
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outcomes. For the purpose of this review, the 
range of outcomes have been categorised as 
far as possible into those measuring the degree 
of occlusion; those measuring the ease of wax 
removal; those measuring participant satisfaction; 
those measuring recurrence of earwax; and AEs. 
Measures of the type and consistency of earwax 
removed were tabulated but not reported in the 
narrative synthesis. In many cases the baseline 
values were not presented for a particular outcome, 
which makes the interpretation of the evidence 
of the effectiveness of the interventions more 
difficult. Where pretreatment and post-treatment 
measurements of an outcome were reported this 
has been discussed (e.g. a study might report the 
varying degrees of occlusion before and after 
intervention). However, in many cases it is not clear 
how the final outcome is related to the finding at 
baseline (how many in the ‘no change category’ 
post intervention started in the fully occluded 
category pretreatment, how many were in the 
partially occluded and so on). Many of the studies 
also did not report measures of variance around 
the estimates presented.
A number of studies also did not report results of 
any statistical significance testing, and, of those 
that did, a number did not report the statistical 
analytical approach taken. As noted above, in some 
cases the allocation to interventions was undertaken 
on the basis of the number of ears rather than the 
number of participants. Also, in some studies where 
allocation was based on the number of participants, 
the analysis was undertaken on the number of 
ears. Where this is the case the present review has 
identified these studies. Care is recommended 
when interpreting the outcomes of these studies, as 
it is unclear whether valid statistical analyses (where 
reported) will have been undertaken (see Cochrane 
Handbook for Systematic Reviews of Interventions for 
discussion of appropriate analyses of these types 
of data65). Finally, there was a wide range in the 
publication dates of the included studies (1950–
2007), and eleven studies were undertaken more 
than 20 years ago,41,43,48,50,51,54,57,59–61,64 which may 
affect the generalisability of the studies to current 
practice (and account for some of the other issues 
already raised above). It is likely in current practice 
that an irrigator rather than a metal syringe will be 
used for the removal of earwax; however, syringes 
were used for many of the included studies, 
although this may not always be clear because 
‘syringing’ and ‘irrigation’ may sometimes be 
used interchangeably. The present report refers to 
‘syringing’ only where this was the term reported 
by the included study. In the case of self-treatment, 
the present report uses the term ‘irrigation’ when 
a soft bulb was used, as these are not syringes, even 
if the study authors have referred to this as a self-
syringe.
Studies in primary care 
settings
Characteristics of the primary care studies are 
shown in Table 3. Seven RCTs41,42,46–49,51 followed 
participants up immediately after interventions, 
and seven RCTs43–45,50,52–54 had a delay between 
intervention and follow-up.
Two RCTs46,47 compared docusate sodium (DS) 
versus triethanolamine polypeptide (TP) versus 
saline in children, while one RCT compared DS 
versus TP in a mixed population of adults and 
children.49 Another trial51 compared TP versus 
carbamide peroxide in an unspecified population. 
All of these had immediate follow-up after 
treatment.
Of two RCTs44,50 comparing Cerumol, Dummer and 
colleagues44 compared Cerumol with Audax in an 
adult population. This RCT had a delayed follow-
up, averaging 4 days between the first and second 
visit (range 3–7 days). The second study by Jaffe 
and Grimshaw50 compared Cerumol with Otocerol 
in a mixed population of adults and children. This 
study had a delayed follow-up, but the length was 
unspecified, with participants requested to revisit 
after three instillations. Cerumol was further 
compared with Waxsol in an RCT48 with a mixed 
population of adults and children. This RCT had 
an immediate follow-up after treatment. Another 
comparison, of Audax with Earex,45 was an RCT 
in a population of adults aged 16 years and above, 
and had a delayed follow-up of 5 days. A CCT by 
Fahmy and Whitefield54 compared Exterol with 
Cerumol in an unspecified population and had a 
delayed follow-up of 1 week. The trial consisted of 
three studies, but only study three was in a primary 
care setting (for study one and study two see 
Studies in secondary care settings, below).
One RCT52 compared aqueous sodium bicarbonate 
with aqueous acetic acid in a mixed population of 
children and adults. This trial had a delayed follow-
up of 14 days. An RCT by the General Practitioner 
Research Group,41 as well as a CCT by Burgess,43 
compared dioctyl-medo ear drops with oil in 
adults. These studies had an immediate follow-up 
and delayed follow-up of between 2 and 7 days 
after the intervention, respectively.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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TABLE 2  Overview of the study classifications used in the report 
Study Settings Population
Primary objective 
(SO or SI)
Primary care
Studies with immediate follow-up for softeners only
Meehan, 200246 Emergency care Children SO
Whatley, 200347 General paediatric clinic and children’s hospital 
emergency department
Children SO
Singer, 200049 Emergency department in care centre Adults and children SO
Studies with delayed follow-up for softeners only
Dummer, 199244 Primary care Adults SO
Jaffe, 197850 Primary care Adults and children SO
Carr, 200152 Primary care – self treatment Adults and children SO
Fahmy, 198254 Primary carea Unknown SO
Studies with immediate follow-up for softeners plus irrigation
General 
Practitioner 
Research Group, 
196541
Primary care Adults SI
Pavlidis, 200542 Primary care Adults SI
General 
Practitioner 
Research Group, 
196748
Primary care Adults and children SI
Amjad, 197551 Primary care Unknown SI
Studies with delayed follow-up for softeners plus irrigation
Burgess, 196643 Primary care Adults SI
Lyndon, 199245 Primary care Adults SI
Eekhof, 200153 Primary care (follow-up: oil delayed, water 
immediate)
Unclear SI
Secondary care
Studies with delayed follow-up for softeners only
Keane, 19954 Secondary care Unknown SO
Fahmy, 198254 Secondary carea Unknown SO
Studies with immediate follow-up for softeners plus irrigation
Caballero, 200555 Secondary care Adult SI
Dubow, 195957 Secondary care Children SI
Chaput de 
Saintonge, 197359
Secondary care Unknown SI
Studies with delayed follow-up for softeners plus irrigation
Fraser, 197060 Secondary care Unknown SI
Studies with delayed follow-up for other types of extraction
Pothier, 200656 Otolaryngology outpatient clinic (follow-up: 
immediate, but delayed if softeners used for 
endoscopic de-waxing)
Adult N/A
Saloranta, 200558 Secondary care plus community home (preventative 
study)
Adults and children N/A
continuedAssessment of clinical effectiveness
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Study Settings Population
Primary objective 
(SO or SI)
Other care
Studies with immediate follow-up for softeners plus irrigation
Hinchcliffe, 195561 Military research Adults SI
Roland, 200462 Corporate research clinic Adults SI
Studies with delayed follow-up for self-care
Coppin, 200863 Self-treatment/primary care  
(self-irrigation/nurse irrigation)
Adults N/A
Harris, 196864 Self-treatment/primary care Adults N/A
N/A, not applicable; SI, ‘softeners plus irrigation’ as the primary objective; SO, ‘softeners only’ as primary objective – 
treatment can include subsequent irrigation.
a  Fahmy and Whitefield54 reported three separate studies within their publication: one based in primary care and two in 
secondary care.
TABLE 2  Overview of the study classifications used in the report  (continued)
Eekhof and colleagues53 compared the instillation 
of water at body temperature with a group self-
administering oil. The population for this RCT 
was unspecified, but had a mean age of 51 years 
for all participants. Follow-up was immediate after 
the water treatment, but delayed by 3 days for the 
oil arm of the study. There was only one RCT42 
comparing either ‘wet’ (with prior instillation of 
warm tap water) syringing or ‘dry’ syringing (no 
prior instillation of water) in an adult population. 
Follow-up was immediately after treatment.
The methodology and quality of reporting of 
included studies was generally poor (Table 4). 
A number of studies pre-date RCT reporting 
guidelines, but this may also reflect set word 
limits for some of the publications. Only three 
RCTs47,49,52 were assessed as adequate for their 
randomisation procedure, with one assessed as 
partially meeting this criteria.42 For several studies 
the method was judged inadequate,46,51,53 but for 
the majority41,44,45,48,50 it was not possible to judge 
due to a distinct lack of information. The same 
three studies47,49,52 that were judged adequate for 
their randomisation procedures were also judged 
as adequate in their concealment allocation. For 
the remaining RCTs, concealment of allocation 
was either inadequate42,53 or unknown,41,44–46,48,50,51 
making it impossible to rule out selection bias.
None of the studies were judged as adequate 
in their method for blinding caregivers or 
participants. While the difficulties in blinding 
for some of the interventions could have been 
addressed somewhat by blinding the assessor 
of the outcomes, none of the studies did so 
adequately. Measurement bias can therefore not 
be ruled out for the majority of included studies. 
With only 4 out of 14 studies reporting baseline 
characteristics,42,47,49,50 it is also not possible to 
judge the similarities between the treatment groups 
at baseline for the majority of the studies. Four 
studies were judged adequate for the description 
of missing values,45,47,49,52 but none of the studies 
reported an adequate intention-to-treat (ITT) 
analysis. Caution should be exercised in the 
interpretation of the results of these studies, as 
overall these appear to be at a high risk of bias, 
which may affect the direction of any effects shown.
Likewise, the CCTs (Table 5) appear at risk to bias 
and their results have to be interpreted with care. 
The two included studies43,54 were of low quality, 
with unreported baseline characteristics in both 
and blinding of outcome assessors adequate 
in only one study.43 Neither study was judged 
to be adequate for eligibility criteria, primary 
outcome results, ITT analysis, missing values or 
representativeness of the populations.
Results of studies in primary care 
with immediate follow-up
The results of the studies in primary care are 
reported in Table 6.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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TABLE 3  Table of characteristics of studies, primary care
Study Interventions Participants Outcomes
Immediate follow-up
Author: Meehan and 
colleagues, 200246
Country: USA
Number of centres: 1
Design: RCT
Setting: Emergency care
Follow-up: Immediate
1. DS: 1 ml (n = 15)
2. TP: 1 ml (n = 17)
3. NS: 1 ml (n = 16)
Target population: Cooperative 
patients, aged 1–18 years, presenting 
in a paediatric emergency department, 
with complete or partial TM occlusion
Baseline characteristics:
Age, mean years: 4.6 overall (no 
individual group details)
Gender, M/F: 24 : 24 overall (no 
individual group details)
Amount of TM visualised
AEs
Author: Whatley and 
colleagues, 200347
Country: USA
Number of centres: 2
Design: RCT
Setting: Children’s hospital 
emergency department 
or large general paediatric 
clinic in same town
Follow-up: Immediate
1. DS: 1 ml (n = 35)
2. TP: 1 ml (n = 30)
3. Saline control: 1 ml 
(n = 28)
Target population: Children aged 
6 months to 5 years with complete or 
partial cerumen obstruction of the TM
Baseline characteristics:
Age, mean (SD):
1. 36.4 (19.1) months
2. 30.9 (15.2) months
3. 36.7 (19.5) months
Overall range: (16 months–5 years)
Gender M/F (%):
1. 14 : 20 (41 : 59)
2. 13 : 17 (43 : 57)
3. 15 : 13 (54 : 46)
Proportion achieving 
complete visualisation of 
the TM
AEs
Author: Singer and 
colleagues, 200049
Country: USA
Number of centres:1
Design: RCT
Setting: Emergency 
department
Follow-up: Immediate
1. DS: 1 ml (n = 27)
2. TP: 1 ml (n = 23)
Target population: (e.g. inclusion 
criteria)
≥ 1 year with ear canal partially or 
totally occluded by cerumen, medically 
requiring visualisation of ear canal 
(i.e. earache, hearing loss, fever) 
and presenting in the emergency 
department
Baseline characteristics:
Age, mean years (SD):
1. 38.7 (30.7)
2. 46.1 (29.1)
Gender M/F (%):
1. 16 (59):11 (41)
2. 16 (70):7 (30)
Proportion of ears in 
which TM totally visible 
with or without irrigation 
or irrigation with 100 ml 
of irrigant
Presence of AEs
Author: General 
Practitioner Research 
Group, 196541
Country: UK
Number of centres: 14
Design: RCT
Setting: Primary care
Follow-up: Immediate
1. Dioctyl-medo (oil 
based), no dose 
stated (n = 77)
2. Control: Oil-base 
alone, no dose stated 
(n = 73)
Target population: UK primary care 
practice patients, no details on 
severity of occlusions
Baseline characteristics:
Age, maximum incidence:
Males: 31–50 years
Females: 51–70 years
32% new patients, 53% without 
syringing for over 12 months
Gender, all patients, M/F: 1.3 : 1
Volume of water for 
syringing and syringefuls 
used
Ease of wax removal
Character of syringed wax
continuedAssessment of clinical effectiveness
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Study Interventions Participants Outcomes
Author: Pavlidis and 
Pickering, 200542
Country: Australia
Number of centres: 1
Design: RCT
Setting: Primary care
Follow-up: Immediate
1. Wet syringing (n = 22 
ears)
2. Dry syringing (n = 17 
ears)
Target population: UK adult patients 
with earwax partially or totally 
occluding one or both ears, which 
would normally be syringed by their 
GP
Baseline characteristics:
Age, mean years (SD):
1. 63 (8)
2. 65 (20)
Gender M/F (%):
1. 15 (68) : 7 (32)
2. 11 (65) : 6 (35)
Mean number of syringing 
attempts
Mean time to syringing 
(minutes)
AEs
Author: General 
Practitioner Research 
Group, 196748
Country: UK
Number of centres: 10
Design: RCT
Setting: Primary care
Follow-up: Immediate
1. Waxsol: 6–7 drops 
self administered 
nightly (n = 47)
2. Cerumol: 6–7 drops 
self administered 
nightly (n = 60)
Target population: UK primary care 
practice patients with all cases of 
earwax apart from minor degrees of 
wax easily removed without softening 
agent
Baseline characteristics:
Age groups, % of all patients:
10–30 years, 27
31–50 years, 34
51–70 years, 31
71 years and over, 8
Gender: Not reported
Volume of water for 
syringing
Ease of wax removal
Character of wax
AEs
Author: Amjad and 
Scheer, 197551
Country: USA
Number of centres: Not 
reported
Design: RCT
Setting: Primary care
Follow-up: Immediate
1. TP: 1 dose (amount 
not reported) (n = 40)
2. Carbamide peroxide: 
1 dose (amount not 
reported) (n = 40)
Target population: Patients with hard or 
impacted earwax
Baseline characteristics:
Age: Not reported
Gender: Not reported
Degrees of wax removal
AEs (subjective and 
observations of objective 
side effects)
Delayed follow-up
Author: Dummer and 
colleagues, 199244
Country: UK
Number of centres: 1
Design: RCT
Setting: Primary care
Follow-up: Median number 
of days between visits 1 
and 2 was 4 days (range 
3–7 days)
1. Audax: Dose not 
reported (n = 27)
2. Cerumol: Dose not 
reported (n = 23)
Target population: Adults between 19–
90 years presenting in primary care 
practice with impacted or hardened 
earwax
Baseline characteristics:
Age, mean (years):
1. 51
2. 55
Gender M/F:
1. 18 : 9
2. 14 : 9
Amount, colour and 
consistency of wax
Symptoms
Hearing
Global impression of 
treatment efficacy (patient 
and investigator)
Tolerability of treatment
TABLE 3  Table of characteristics of studies, primary care (continued)DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Study Interventions Participants Outcomes
Author: Jaffe and 
Grimshaw, 197850
Country: UK
Number of centres: Up 
to 15
Design: RCT
Setting: Primary care
Follow-up: Patients asked 
to revisit GP after 3 
instillations
1. Otocerol: 4 drops 
at night for 3 nights 
(n = 53)
2. Cerumol: 5 drops 
at night for 3 nights 
(n = 53)
Target population: Patients presenting 
at primary care practice with 
earwax and who would normally be 
prescribed a cerumenolytic
Baseline characteristics:
Age distribution (years):  
group 1, group 2
0–9: 0, 1
10–19: 5, 1
20–29: 4, 9
30–39: 8, 6
40–49: 7, 5
50–59: 12, 15
60–69: 9, 6
70–79: 7, 7
80–89: 1, 3
Gender M/F:
1. 32 : 21
2. 25 : 28
Ease of syringing
Doctors overall 
impression
AEs
Author: Fahmy and 
Whitefield, 198254
Country: UK
Number of centres: 
Multicentre, but number 
of centres not reported
Design: CCT
Setting: Studies 1 and 2 in 
secondary care, study 3 in 
primary care
Follow-up: 1 week
Study 3:* n = 160 (286 
ears)
1. Exterol: 5–10 
drops × 2 daily 
(ears = 157)
2. Cerumol: 5–10 
drops × 2 daily 
(ears = 129)
*Studies 1 and 2 are 
reported in Table 7 
– assessing earwax 
removal in secondary 
care settings
Target population: Patients presenting 
with earwax problems in secondary 
care for studies 1 and 2 and primary 
care in study 3
Baseline characteristics:
Age: Not reported
Gender: Not reported
Wax occlusion
Wax consistency
Ease of syringing
Author: Carr and 
Smith, 200152
Country: USA and/or 
Canada
Number of centres: 
Unclear
Design: RCT
Setting: Primary care – 
self-treatment
Follow-up: 14 days
1. Aqueous sodium 
bicarbonate (10%): 
4 drops daily for 14 
days (n = 35, 70 ears)
2. Aqueous acetic acid 
(2.5%): 4 drops daily 
for 14 days (n = 34, 68 
ears)
Target population: Those suffering 
with occlusive cerumen in at least 
1 ear (most presenting with other 
complaints and ceruminosis was noted 
incidentally)
Baseline characteristics:
Age, mean years for all (36 children 
and 33 adults):
1. 27.0
2. 25.3
Age, mean years for children:
1. 8.7
2. 7.26
Gender: Not reported
Degree of cerumen
continued
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Study Interventions Participants Outcomes
Author: Lyndon and 
colleagues, 199245
Country: UK
Number of centres: 
Unclear
Design: RCT
Setting: Primary care
Follow-up: 5 days
1.  Audax: self 
administered am and 
pm for 4 days (n = 19, 
38 ears)
2. Earex: self 
administered) am and 
pm for 4 days (n = 17, 
34 ears)
Target population: Patients aged 16 
years or over presenting in general 
practice with symptoms of hardened 
earwax, in either or both ears, 
requiring cerumenolytic treatment
Baseline characteristics:
Age, mean years for all patients 
(range): 52 (19–86)
Gender, M/F for all patients: 19 : 17
Degree of impaction
Ease of syringing
Global impression of 
efficacy
Side effects/discomfort
Author: Burgess 196643
Country: UK
Number of centres:1
Design: CCT
Setting: Primary care
Follow-up: Between 2 and 
7 days
1. Dioctyl-medo (in 
maize oil): 1 capsule 
(0.5 ml) am and pm 
(n = 33 ears)*
2. Maize oil capsules: 
(n = 41 ears)*
*Patients received 1 
box (10 capsules) and 
capsules were instilled 
4–10 times
Target population: Patients in primary 
care with more than one-half of an ear 
occluded by wax
Baseline characteristics:
Age range for all patients, years: 
18–75
Gender, M/F all patients: 32 : 18
Average total of water 
used
Ease of removing wax
Character of wax
Side effects
Author: Eekhof and 
colleagues, 200153
Country: The Netherlands
Number of centres: 4
Design: RCT
Setting: Primary care
Follow-up: Immediate for 
water group but 3 days for 
oil group
1. Water at body 
temperature (n = 22)
2. Self administered ‘oil’ 
(n = 20)
Target population: All patients with 
complaints resulting from earwax 
were offered syringing. After each 
attempt at syringing the auditory 
canal was checked with an auriscope 
and the extent of blocking was noted 
(obstruction levels of 0–25%, 25–49%, 
50–74% and 75–100% were used). If 
earwax was persistent (> 75% after 5 
attempts at syringing) patients were 
eligible to be included in the study
Baseline characteristics:
Age, mean years for all patients (SD): 
51 (16)
Gender, M/F for all patients: 20 : 22
Number of syringing 
attempts needed to 
remove wax
DS, docusate sodium; F, female; M, male; NS, normal saline; SD, standard deviation; TM, tympanic membrane; TP, 
triethanolamine polypeptide.
TABLE 3  Table of characteristics of studies, primary care (continued)
Softeners only studies
Adults
No studies were identified assessing an adult 
population comparing the use of softeners alone, 
with an immediate participant follow-up after 
treatment.
Children
Two studies46,47 with immediate follow-up in 
children aimed to assess the use of a softening 
agent alone and fall under the softener-only 
category. After initial assessment of the outcome 
from the use of the softening agent both of these 
studies subsequently used an irrigation technique 
and reassessed outcomes. Both studies compared 
DS, TP and saline.
Measures of occlusion
Meehan and colleagues46 reported the number of 
children with complete, partial or no occlusion 
after DS, TP or saline alone in attendees at an 
emergency care department. Thirteen per cent of 
children were rated as clear in the DS treatment 
group; 41% were clear in the TP treatment 
group and 13% in the saline treatment group. 
The corresponding proportions with complete 
obstruction at baseline for the three groups, 
respectively, were 73%, 65% and 56%, with 
27%, 35% and 44%, respectively, having partial 
obstruction of the TM. While it would appear that 
more children in the TP group had clear TMs 
after treatment, no statistical significance testing 
was reported of the difference between effects of DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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TABLE 4  Quality of studies, primary care
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Ad, adequate; In, inadequate; Par, partial; Rep, reported; Un, unknown. (See Appendix 1.)
the different softening agents. Thirty-three per 
cent, 29% and 31% of participants, respectively, for 
DS, TP and saline were still completely occluded, 
and 53%, 29% and 56% partially occluded for the 
three groups, respectively. Of these participants, 
irrigation was then used with varying results  
(Table 6). In around 50% of participants in all three 
groups the TM remained occluded or partially 
occluded after two irrigations.
Whatley and colleagues47 also reported the number 
and proportion of children with clear TM after use 
of the treatments. Twelve per cent of participants 
in the DS treatment group, 13% in the TP and 4% Assessment of clinical effectiveness
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in the saline treatment group were reported as 
clear after softening treatment. The corresponding 
proportions of participants with complete occlusion 
of the TM at baseline for the three groups, 
respectively, were 91%, 80% and 79%. Similarly to 
the Meehan and colleagues study,46 some 32–57% 
of participants remained occluded after two 
irrigations. This study reported statistical testing 
only for the proportions clear after the second 
irrigation, which was not statistically significant.
Measures of ease of wax removal
Meehan and colleagues46 and Whatley and 
colleagues47 did not report this outcome.
Measures of patient satisfaction
Meehan and colleagues46 and Whatley and 
colleagues47 did not report this outcome.
Measures of recurrence
Meehan and colleagues46 and Whatley and 
colleagues47 did not report this outcome.
Adverse events
Ten (21%) participants in the Meehan study46 had 
pain with irrigation and one (1%) participant in 
the Whatley study47 had a small ear bleed after 
irrigation.
Mixed or unknown populations
One study49 was identified assessing a mixed 
population with the a priori intention of comparing 
softeners alone, coupled with an immediate 
participant follow-up after treatment. This study 
compared DS with TP.
Measures of occlusion
Singer and colleagues49 assessed the number of 
ears with complete visualisation after DS or TP in 
a mixed population of adults and children. The 
TM was completely visualised in 19% of DS and 9% 
of TP treated participants, respectively; however, 
the difference was not statistically significant [% 
difference DS–TP 9.8; 95% confidence interval 
(CI) –8.8 to 28.5]. At baseline 78% of participants 
in the DS arm and 78% of participants in the TP 
arm had completely obstructed TMs. Complete 
TM visualisation after treatment, with or without 
subsequent irrigation with normal saline solution, 
was statistically significantly greater for DS than TP 
[82% versus 35%, respectively; difference 46.7% 
(95% CI 22.3–71.1%)]. Results were also presented 
for numbers with a clear TM after a first and 
then second irrigation. This showed that a higher 
proportion of participants in the TP arm (79%) 
than the DS arm (42%) were still not completely 
clear after two irrigations. However, this was not 
tested for statistical significance between the two 
groups.
Measures of ease of wax removal
Singer and colleagues49 did not report this 
outcome.
Measures of patient satisfaction
Singer and colleagues49 did not report this 
outcome.
Measures of recurrence
Singer and colleagues49 did not report this 
outcome.
Adverse events
Singer and colleagues49 found no cases of pain, 
vertigo, nausea or hearing loss.
Softeners and irrigation studies
Adults
There were two studies where the intention was 
to compare different softeners, which were then 
followed by syringing in an adult population, 
with an immediate participant follow-up after 
treatment.41,42 The General Practitioner Research 
Group41 compared dioctyl-medo with an oil-based 
control, and Pavlidis and Pickering42 compared use 
of water prior to syringing (wet syringing) to no 
water prior to syringing (dry syringing). Neither 
of these studies reported on the baseline degree of 
occlusion in their populations.
Measures of occlusion
Neither the General Practitioner Research Group41 
or Pavlidis and Pickering42 reported on these 
outcomes.
Measures of ease of wax removal
The General Practitioner Research Group41 
study reported on the number (or fractions) of 
syringefuls required to remove wax after using 
dioctyl-medo drops or an oil-based control. The 
mean amount of water required for the dioctyl-
medo treatment group was 122 ml compared with 
165.5 ml for the oil-based control group. The 
statistical significance of the difference between 
the two groups was, however, not tested. The study 
does report that there was an outlier for the control 
group and that removal of the outlier resulted in 
there being little difference between the treatment 
groups. Syringe capacity varied – 57, 85 and 112 ml 
– and the authors state that an exact analysis in 
relation to the number of syringefuls used, and 
in respect of each syringe size, was made. The DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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study also categorised ease of wax removal (easy or 
difficult, partial or failed), with wax removal classed 
as easy for 70% of participants receiving dioctyl-
medo and 57% of control participants receiving oil-
based control treatment. The study did not report 
any statistical significance testing on these data. 
No baseline values of the degree of earwax were 
reported.
Pavlidis and Pickering42 reported on the mean 
number of syringing attempts for those in the ‘wet’ 
and ‘dry’ syringing groups. Wet syringing needed 
7.5 attempts (mean), while dry syringing needed 
25.4. This was seen to be statistically significantly 
different (p = 0.043). Pavlidis and Pickering42 
suggest that the number of syringing attempts 
are unusually high due to the small volume of the 
syringe used (25 ml), which is smaller than syringes 
used by GPs (> 120 ml). No baseline values of the 
degree of earwax were reported
Measures of patient satisfaction
The General Practitioner Research Group41 
reported that 92% of the dioctyl-medo group and 
86% of the oil-based control group found the 
procedure tolerable. Pavlidis and Pickering42 did 
not report on this outcome.
Measures of recurrence
Neither the General Practitioner Research Group41 
nor Pavlidis and Pickering42 reported on these 
outcomes.
Adverse events
The General Practitioner Research Group41 found 
no AEs in 91% of the dioctyl-medo group and 
89% of the oil-based control group. AEs were 
entirely related to the procedure of syringing, 
but no further details about the nature of these 
are reported. Pavlidis and Pickering42 reported 
transient dizziness for one participant only, after 
having both ears syringed, with all TM being intact 
at the end of syringing.
Children
No studies were identified assessing children and 
comparing softeners followed by syringing, with an 
immediate participant follow-up after treatment.
Mixed or unknown populations
Two studies48,51 were included that assessed the use 
of a softening agent and a syringing agent in mixed 
populations over a delayed period of follow-up. 
The General Practitioner Research Group48 study 
compared Waxsol with Cerumol, and the Amjad 
and Scheer51 study compared TP with carbamide 
peroxide.
Measures of occlusion
Amjad and Scheer51 assessed degree of wax 
removal using TP and carbamide peroxide in 
an unspecified population. Excellent removal 
was reported for 68% of TP participants and 
5% of carbamide peroxide participants, with 
good removal in 20% and 12% of participants, 
respectively. Effective removal (combining 
excellent and good) was reported for 88% of the 
TP-treated participants and 17% in the carbamide 
peroxide-treated participants. At baseline, 90% 
of participants in the TP group and 80% of 
participants in the carbamide peroxide group 
had complete obstruction of the TM, with 10% 
and 20% having partial obstruction for the two 
groups, respectively. The study also reports degree 
of wax removal as a function of pretreatment 
wax. This showed that in the TP group effective 
(rated as excellent or good) wax removal was 
achieved in 100% of participants with soft or loose 
pretreatment wax, whereas the corresponding 
value in the carbamide peroxide group was 33%. In 
those with hard or impacted wax at baseline some 
88% and 84% (for the two categories respectively) 
in the TP group had ‘effective’ clearance. The 
corresponding rates in the carbamide peroxide 
group were 19% for those with hard wax 
pretreatment and 11% for those with impacted 
wax pretreatment. The study did not report any 
statistical significance testing of the data (Table 6).
Measures of ease of wax removal
The General Practitioner Research Group48 
assessed the volume of water needed for 
syringing after the use of Waxsol and Cerumol in 
a population of adults and children. The mean 
volume per participant for the Waxsol treatment 
group was 156 ml [5.5 fluid ounces (fl oz)] per 
participant and for the Cerumol treatment group 
was 240 ml (8.4 fl oz). Ease of wax removal (easy 
or difficult removal, partly or failed removal) was 
also assessed by this study, with 83% of participants 
in the Waxsol treatment group and 80% in the 
Cerumol treatment group judged to have easily 
removed earwax. The study did not report if this 
outcome was tested for statistical significance. 
No baseline degree of occlusion were reported 
in the General Practitioner Research Group48 
study. Amjad and Scheer51 did not report on this 
outcome.Assessment of clinical effectiveness
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TABLE 6  Outcomes of studies, primary care
Immediate follow-up – children – softeners alone as primary objective
Meehan and colleagues, 200246
DS TP Saline p-value
TM occlusion
n = 15 n = 17 n = 16
Not reported
Complete 5 5 5
Partial 8 5 9
Clear 2 7 2
TM occlusion after first irrigation
n = 13 n = 15 n = 15
Not reported
Complete 4 4 4
Partial 6 3 5
Clear 3 8 6
TM occlusion after second irrigation
n = 12 n = 15 n = 15
Not reported
Complete 3 4 3
Partial 4 3 4
Clear 5 8 8
Whatley and colleagues, 200347
DS TP Saline p-value
n = 35 n = 30 n = 28
Clear TM after 
agent, n (%)
4 (12) 4 (13) 1 (4) Not reported
Clear TM after first 
irrigation, n (%)
13 (38) 12 (40) 12 (43) Not reported
Clear TM after 
second irrigation, 
n (%)
18 (53) 13 (43) 19 (68) Not significant
Immediate follow-up – mixed population – softeners alone as primary objective
Singer and colleagues, 200049
DS (n = 27) TP (n = 23)
Difference 
(95% CI)
Completely 
visualised ears after 
solvent only, n (%)
5 (19) 2 (9) 9.8  
(–8.8 to 28.5)
Completely 
visualised ears after 
solvent with or 
without irrigation, 
n (%)
22 (82) 8 (35) 46.7  
(22.3 to 71.1)
TM visualisation, n (%)
Complete Incomplete Complete Incomplete Not reported
After solvent only 5 (19) 22 (81) 2 (9) 21 (91)
First 50-ml ear 
irrigation
10 (45) 12 (55) 2 (10) 19 (90)
Second 50-ml ear 
irrigation
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Immediate follow-up – adult population – softeners and irrigation at primary objective
General Practitioner Research Group, 196541
Dioctyl-medo (n = 77) Oil-based control (n = 73)
p-value
No. of 
cases
Total 
quantity 
(ml)
Mean 
per case
No. of 
cases
Total 
quantity 
(ml)
Mean per 
case
Number of syringefuls used
0.25–1 35 2123 60 26 1732 65 Not tested
1.25–2 13 1718 130.5 17 2329 136 Not tested
2.5–4 12 2243 187.5 17 3487 207 Not tested
5–15 6 2045 341 4 2613 653 Not tested
Total 66 8129 122 64 10,181 165.5 Not tested
Ease of wax removal, N (%)
Easy 54 (70) 42 (57)
Difficult 17 (22) 23 (32)
Partial 3 (4) 6 (8)
Failed 2 (3) 2 (3)
Character of syringed wax, N (%)
Liquid 14 (19) 10 (14)
Shredded 34 (46) 28 (40)
Hard lumps 26 (35) 32 (46)
Failed 3 2
Not recorded 0 1
Pavlidis & Pickering, 200542
Wet syringing (n = 22) Dry syringing (n = 17) p-value
Mean number of 
syringing attempts 
(SD)
7.5 (7.3) 25.4 (39.4) 0.043
Mean time to 
syringing (minutes)
6.5 15.4 ns but p-value 
not reported
Immediate follow-up – mixed populations – softeners and irrigation as primary objective
General Practitioner Research Group, 196748
Volume of water 
(fl oz)
Waxsol (n = 47) Cerumol (n = 60)
p-value
No. of 
participants Total volume
No. of 
participants Total volume
0.5 0 0 1 0.5 Not reported
1 6 6.0 2 2.0
2 13 26.0 4 8.0
2.5 1 2.5 1 2.5
3 3 9.0 5 15.0
4 3 12.0 8 32.0
continued
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5 0 0 1 5.0
6 6 36.0 4 24.0
7 2 14.0 2 14.0
8 3 24.0 12 96.0
9 0 0 2 18.0
10 1 10.0 2 20.0
12 6 72.0 8 96.0
14 1 14.0 2 28.0
16 2 32.0 2 32.0
18 0 0 1 18.0
24 0 0 1 24.0
26 0 0 1 26.0
40 0 0 1 40.0
Totals 47 257.5 60 501.0
Mean volume per 
participant:
5.5 fl oz (156 ml) 8.4 fl oz (240 ml) Not reported
No. of participants (%) No. of participants (%) p-value
≤ 56 ml (2 fl oz) 19 (40) 7 (12) p < 0.05
> 56 ml 28 (60) 53 (88)
Proportion of 
participants needing: 
14–112 ml: 55% 35%
p < 0.05
Ease of removal, n (%)
Easily removed 39 (83) 48 (80) No p-values 
reported Removed with 
difficulty
6 (13) 9 (15)
Partly removed 1 (2) 1 (2)
Failed 1 (2) 2 (3)
Character of wax (% of participants)
Liquid 17 17 No p-values 
reported Shredded 46 35
Hard lumps 37 24
Amjad and Scheer, 197551
Degree of wax removal, n (%)
TP (n = 40) Carbamide peroxide (n = 40) p-value
Excellent (E) 27 (68) 2 (5) Not reported
Good (G) 8 (20) 5 (12)
Fair (Fr) 2 (5) 4 (10)
Poor (Pr) 3 (7) 29 (73)
Effective (E + G: 
excellent + good)
35 (88) 7 (17)
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Efficacy to pretreatment wax
No. E + G Fr Pr E + G (%) No. E + G Fr Pr
E + G 
(%) p-value
Impacted 19 16 1 2 84 18 2 0 16 11 Not reported
Hard 16 14 1 1 88 16 3 2 11 19
Loose 1 1 0 0 100 3 1 0 2 33
Soft 4 4 0 0 100 3 1 2 0 33
Complete 
obstruction
36 31 2 3 86 32 4 3 25 13
Partial obstruction 4 4 0 0 100 8 3 1 4 38
Delayed follow-up – adult population – softeners alone as primary objective
Dummer and colleagues, 199244
Audax (n = 27, ears n = 54) Cerumol (n = 23, ears n = 46) p-value
Amount of wax (n, ears)
Increased 0 0 Not reported 
across groups No change 24 (44%) 22 (48%)
Decreased 28 (52%) 24 (52%)
Missing data 2 (4%) 0
Colour of wax (n, ears)
Darkened 0 0 States ns, but 
p-value not 
reported
No change 10 9
Lightened 42 36
Missing data 2 1
Consistency (n, ears)
Hardened 0 0 States ns, but 
p-value not 
reported
No change 6 5
Softened 46 40
Missing data 2 1
Objective hearing (n, ears)
Improved 7 (13%) 2 (4%) States ns, but 
p-value not 
reported
No change 45 (83%) 44 (96%)
Worsened 0 0
Missing data 2 (4%) 0
Overall assessment
Investigator rated 
‘effective’ (n, pts)
36 22 Unclear if 
tested
Overall assessment
Participant rated 
‘effective’ (n, pts)
25 (93%) 23 (100%) States ns, but 
p-value not 
reported
continued
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Delayed follow-up – mixed populations – softeners alone as primary objective
Jaffe and Grimshaw, 197850
Otocerol (n = 53) Cerumol (n = 53) p-value
Syringing needed Yes: 39, no 14 Yes: 47, no 6 N requiring 
syringing 
p < 0.05
Syringing needed by grade at entry
Mild Yes 6, no 7 Yes 6, no 4 Not reported
Moderate Yes 19, no 7 Yes 30, no 2
Severe Yes 14, no 0 Yes 11, no 0
Doctor reported ease of syringing
30/39 (76.9%) 34/47 (72.3%) χ2 = 0.25, ns
Ease of syringing by grade at entry
Mild Easy 5, not easy 1 Easy 5, not easy 1 Not reported
Moderate Easy 14, not easy 5 Easy 25, not easy 5
Severe Easy 11, not easy 3 Easy 4, not easy 7
Overall judgement effectiveness
Success 38 33 ns
Failure 10 13
Partial 5 7
Fahmy and Whitefield, 198254 (see Table 10 for study 1 and 2 results in secondary care)
Exterol (n = 157) Cerumol (n = 129) p-value
Initially hard Initially soft Initially hard Initially soft
Wax dispersed 
without syringing
45 19 12 15 p < 0.001
Syringed easily 60 22 52 14
Syringed with 
difficulty
9 2 33 3
Carr and Smith, 200152
10% sodium bicarbonate (n = 35) 2.5% acetic acid (n = 34) p-value
Mean change degree 
of cerumen 0.66 0.78
States ns but 
p-value not 
reported
Mean maximum 
change
1.00 1.00
Delayed follow-up – adult populations – softeners and irrigation as primary objective
Lyndon and colleagues, 199245
Audax (n = 19, 38 ears) Earex (n = 17, 34 ears) p-value
Degree of impaction
None 10 6 States ns but 
p-value not 
reported
Mild 17 11
Moderate (Mod) 9 12
Severe (Sev) 2 3
Missing data 0 2
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Post-treatment Post-treatment
p-value None Mild Mod Sev None Mild Mod Sev
Degree of impaction at end point by pretreatment score
None 1 1 0 0 1 0 0 0 States ns but 
p-value not 
reported
Mild 3 4 0 0 2 4 0 0
Moderate 6 12 8 0 3 7 11 1
Severe 0 0 1 2 0 0 1 2
Audax (n = 38 ears) Earex (n = 34 ears) p-value
Ease of syringing, ears
Not required 15 7 p < 0.005 for 
score of ‘not 
required’ or 
‘easy’
Easy 22 12
Difficult 1 11
Impossible 0 0
Missing data 0 4
Audax (n = 19) Earex (n = 17)
Global impression of efficacy, investigator* n = pts
Completely effective 8 5
Very effective 9 1
Fairly effective 2 7
Not effective 0 3
Missing data 0 1
Total 19 17
Global impression of efficacy, participant* n = pts
Completely effective 8 5
Very effective 9 2
Fairly effective 2 7
Not effective 0 2
Missing data 0 1
Total 19 17
*Investigators’ and participants’ own global impression of efficacy merged categories (not effective and fairly effective) 
were significantly in favour of Audax (p < 0.01).
Burgess, 196643
Dioctyl-medo (n = 33 ears) Maize oil (n = 41 ears) p-value
Average water used
111 ml 81 ml Not reported
Ease of removal, N ears
Easy 19 33 Not reported
Difficult 11 5
Partial 3 3
Failed 1 0
continued
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Character wax, N ears
Liquid 1 4 Not reported
Shredded 5 6
Lumps 27 31
Delayed follow-up – mixed populations – softeners and irrigation as primary objective
Eekhof and colleagues, 200153
Water (n = 22) Control ‘oil’ (n = 20) p-value
Mean number syringing attempts
3.0 (95% CI 2.4 to 3.6) 2.4 (95% CI 1.7 to 3.1) Difference 0.6 
(95% CI –0.3 to 
1.5); p = 0.18
Mean number syringing attempts per participant by number earwax removed
Number removed Number removed p-value
1 4 6 Not reported 
to be tested 1.5 1 2
2 2 5
2.5 3 1
3 2 2
3.5 4 0
4 2 0
5 3 4
6 1 0
CI, confidence interval; DS, docusate sodium; ns, not significant; SD, standard deviation; TP, triethanolamine 
polypeptide.
TABLE 6  Outcomes of studies, primary care (continued)
Measures of patient satisfaction
Eighty-nine per cent of participants in the 
Waxsol treatment group and 95% in the Cerumol 
treatment group were reported to have found the 
treatment tolerable in the General Practitioner 
Research Group study.48 No statistical analysis 
of the differences in this data was provided, 
however. Amjad and Scheer51 did not report on this 
outcome.
Measures of recurrence
The General Practitioner Research Group48 
and Amjad and Scheer51 did not report on this 
outcome.
Adverse events
Seven per cent of participants in the Waxsol and 
5% in the Cerumol treatment group reported AEs 
in the General Practitioner Research Group study, 
but no details about the nature of these events or 
statistical testing of results are given.48 There were 
no reported cases of AEs in the Amjad and Scheer 
study.51
Results of studies in primary 
care with delayed follow-up
The results of the studies in primary care are 
reported in Table 6.
Softeners only studies
Adults
One study44 in adults, which had the initial 
objective to use softeners alone to clear the earwax, 
was included. Dummer and colleagues44 compared 
Audax and Cerumol and delayed participant 
follow-up for 4 days.
Measures of occlusion
Dummer and colleagues44 measured the number of 
ears with post-treatment changes in the amount of 
wax present (increased, no change and decreased). 
Fifty-two per cent of ears for both treatments 
(Audax 28 ears, Cerumol 24 ears) were judged to 
have a reduced amount of wax. In both groups 
there were more than 40% with no change in 
the amount of wax present after treatment. No DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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statistical analysis of the differences across the 
groups appeared to have been undertaken on 
these outcomes, however, and no baseline values 
of the degree of wax present were reported. Post-
treatment performance-based hearing and change 
in performance-based hearing were assessed 
through a variety of tests. In the Audax group 13% 
of ears demonstrated improved hearing, whereas 
in the Cerumol group the figure was only 4%. 
There was no change in objective hearing in 83% 
of ears in the Audax group and 96% of ears in the 
Cerumol group. The paper states that there were 
no statistically significant differences between the 
groups; however a p-value was not reported. A 
global investigator impression of efficacy for the 
treatments was also undertaken; however, there 
appears to be a reporting error in terms of the 
number of participants in the groups and therefore 
care should be taken in the interpretation of this 
outcome. It is also unclear how this outcome was 
assessed.
Measures of ease of wax removal
Dummer and colleagues44 did not report on this 
outcome.
Measures of patient satisfaction
In a global impression assessment of the efficacy 
of the treatments, Dummer and colleagues44 found 
that 93% of participants rated the treatment as 
effective in the Audax treatment group and 100% 
rated it as effective in the Cerumol treatment 
group. The authors reported no statistically 
significant difference between the treatment 
groups, but no p-value was given. It was also 
unclear how this assessment was measured.
Measures of recurrence
Dummer and colleagues44 did not report on this 
outcome.
Adverse events
In the study by Dummer and colleagues,44 a 
slight irritation to the ear was reported by two 
participants in the Audax treatment group, while 
in the Cerumol treatment group one participant 
experienced a slight itch and another a buzzing 
noise shortly after use. No further details of these 
events were reported.
Children
No studies were identified assessing children in 
a comparison of softeners alone, with a delayed 
participant follow-up.
Mixed or unknown populations
Three studies50,52,54 with mixed or unknown 
populations were included. All had a delayed 
follow-up and an intention to assess outcomes 
after softeners only. Carr and Smith52 compared 
a 10% solution of aqueous sodium bicarbonate 
with a 2.5% solution of acetic acid. The study 
had a 14-day follow-up. Fahmy and Whitefield54 
compared Exterol and Cerumol, and participants 
were followed-up 1 week later. This study was one 
of three and, as previously mentioned, study one 
and two are covered under Studies in secondary 
care settings, below. Jaffe and Grimshaw50 assessed 
Otocerol and Cerumol with a revisit after three 
instillations of the interventions.
Measures of occlusion
Carr and Smith52 measured the change in the 
degree of earwax, based on a scale of 1–4, where 
higher scores relate to higher degrees of occlusion. 
The mean change in the degree of cerumen was 
reported to be 0.66 in the 10% sodium bicarbonate 
group and 0.78 in the 2.5% acetic acid group. 
The study reports that the difference was not 
statistically significant, but no p-value was provided. 
No baseline values of the degree of occlusion were 
presented in the study.
Fahmy and Whitefield54 found the number of ears 
not requiring syringing was statistically significantly 
greater after treatment with Exterol (p < 0.001), 
with wax dispersal occurring in 41% of ears in the 
Exterol treatment group and 21% of ears in the 
Cerumol treatment group.
Jaffe and Grimshaw50 did not report on these 
outcomes.
Measures of ease of wax removal
After treatment, Fahmy and Whitefield54 found 
that ears were syringed easily in 52% of ears in 
the Exterol treatment group and 51% in the 
Cerumol treatment group. No data analysis of the 
differences between groups was presented. Exterol 
was statistically significantly superior to Cerumol, 
when the number of ears not requiring syringing 
(above) was combined with the number syringed 
easily (p < 0.001). Seven per cent of ears in the 
Exterol treatment group and 28% of ears in the 
Cerumol treatment group remained difficult to 
syringe after treatment. At baseline, 97 ears in the 
Exterol group and 86 ears in the Cerumol group 
were reported to be totally or subtotally occluded 
with earwax. The remaining ears (60 Exterol, Assessment of clinical effectiveness
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43 Cerumol) were rated as partially occluded 
at baseline. There are no data reporting post-
treatment outcome in relation to pretreatment 
outcome, however.
Jaffe and Grimshaw50 wanted to establish if, after 
treatment with Otocerol or Cerumol, syringing 
was required. There was a statistically significant 
difference in favour of Otocerol, only 73% of 
Otocerol participants needed syringing compared 
with 89% of Cerumol participants (p < 0.05). At 
baseline the grade of impaction was assessed 
as mild, moderate or severe in 13, 26 and 14 
participants in the Otocerol group, respectively, 
and in 10, 32 and 11 participants in the Cerumol 
group, respectively. Of the 26% of participants in 
the Otocerol group that did not require syringing 
after treatment, all of these were rated as mild or 
moderate at the start of the study. However, 11% 
of participants categorised as mild at baseline and 
36% of participants categorised as moderate at 
baseline did require syringing after treatment with 
Otocerol. All of the participants in the Otocerol 
group with severe impaction at baseline (26%) 
required syringing post-treatment. In the Cerumol 
group a similar pattern emerged. Of the 11% of 
participants that did not require syringing after 
treatment, all had been rated as mild or moderate 
at the start of the study. However, 11% and 57% of 
participants rated as mild or moderate occlusion 
at baseline did require syringing after treatment. 
Finally, all of the 21% of participants with severe 
impaction at baseline required syringing post-
treatment. No statistical analysis of this data was 
reported, however. Where syringing was required, 
the clinician’s rating of the ease of syringing 
was also reported (76.9% Otocerol versus 72.3% 
Cerumol were ‘easy to syringe’). This was not 
statistically significantly different between the 
treatment groups.
In the Jaffe and Grimshaw study,50 an overall 
judgement of effectiveness was categorised into 
success (defined as those in whom syringing was 
not required or where it was easy and no reports 
of side effects), failure (defined as those in whom 
syringing was difficult with or without side effects) 
and partial (defined as those who reported side 
effects, but in whom the doctor found it easy to 
syringe and had no reservations about using the 
product again). In the Otocerol group 72% were 
judged to be successes, 19% were judged to be 
failures and 9% were classed as partial successes. 
In the Cerumol group these figures were 62%, 25% 
and 13% for success, failure and partial categories, 
respectively. The overall judgement of effectiveness 
between the treatment groups was not statistically 
significant.
Carr and Smith52 did not report on this outcome.
Measures of patient satisfaction
These outcomes were not reported by Carr and 
Smith,52 Jaffe and Grimshaw50 or Fahmy and 
Whitefield.54
Measures of recurrence
These outcomes were not reported by Carr and 
Smith,52 Jaffe and Grimshaw50 or Fahmy and 
Whitefield.54
Adverse events
Adverse events were divided into pain (0% 
Otocerol; 2% Cerumol) and irritation (6% 
Otocerol, 15% Cerumol) on application, and 
pain (2% Otocerol, 2% Cerumol) and irritation 
(8% Otocerol, 8% Cerumol) during use in the 
Jaffe and Grimshaw study.50 There was one case 
(2%) of slight giddiness (no further details) in the 
Otocerol group. Thirteen per cent of participants 
suffered AEs in the Otocerol treatment group and 
19% in the Cerumol treatment group, but one 
case included under Cerumol AEs was related to 
the unpleasant smell of the treatment.50 The most 
common AEs were irritation on application, pain 
during use and irritation during use. The result 
was reported as statistically non-significant, but no 
p-value was given. Carr and Smith52 reported no 
cases of otitis externa or external auditory canal 
dermatitis for their treatments groups, while Fahmy 
and Whitefield54 did not report AEs.
Softeners and irrigation studies
Adults
There were two studies43,45 in which the intention 
was to compare different softeners, which were then 
followed by syringing in an adult population, with 
a delay in participant follow-up after treatment. 
Lyndon and colleagues study45 compared self-
administered Audax and Earex followed by 
syringing, with a delayed follow-up of 5 days. 
Burgess43 compared dioctyl-medo and maize oil 
followed by syringing, with a delayed follow-up of 
2–7 days.
Measures of occlusion
Lyndon and colleagues’ study45 measured the 
degree of impaction from none to severe. After 
treatment, 26% of ears in the Audax treatment 
group and 18% of ears in the Earex treatment DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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group had no wax impaction, but no p-value was 
reported. At baseline, 5% of ears in the Audax 
treatment group and 3% of ears in the Earex group 
had no impaction. Eighteen per cent, 68% and 8% 
of ears in the Audax group were rated as having 
mild, moderate and severe impaction at baseline, 
respectively. In the Earex group, these figures were 
24%, 65% and 9%, respectively. Analysis of pre- 
and post-treatment impaction scores between the 
groups was reported as non-significant, with a trend 
towards less impaction for the Audax treatment; 
however, no p-value was given. Investigators also 
completed a global impression of efficacy rating 
(completely effective, very effective, fairly effective 
and not effective). This was statistically significant 
in favour of Audax (p < 0.01) for the merged 
categories of ‘not effective’ and ‘fairly effective’, but 
it was unclear whether this was for the investigator 
rating alone, participant rating alone (see below) or 
a combination of the two.
Measures of ease of wax removal
Burgess43 measured ease of removal and average 
water used. The diocytl-medo treatment group 
used on average 111 ml and the maize oil treatment 
group used 81 ml for syringing the wax. Ease of 
wax removal was measured for the number of ears, 
categorised as easy (58% dioctyl-medo, 80% maize 
oil) or difficult (33% dioctyl-medo, 12% maize 
oil), partial (9% diocytl-medo,7% maize oil) or 
failed. The only reported case of failure was for the 
dioctyl-medo group. This study did not report any 
statistical significance testing on the data. Burgess43 
only reported baseline characteristics for all 
participants combined, where the study reports that 
80% of ears were completely occluded at baseline. 
Consequently, there were no data reporting post-
treatment outcome in relation to pretreatment 
outcome. Lyndon and colleagues45 also measured 
ease of syringing and found a statistically 
significant difference in favour of Audax, in that 
syringing was more frequently scored as ‘not 
required’ or ‘easy’ (97% ears in the Audax group, 
56% ears in the Earex group, p < 0.005).
Measures of patient satisfaction
In the study by Lyndon and colleagues,45 
participants completed a global impression of 
efficacy rating. Forty-two per cent of participants 
in the Audax treatment group and 29% of 
participants in the Earex treatment group rated the 
treatment as completely effective. The authors state 
that there was a statistically significant difference 
in favour of Audax (p < 0.01) for the ‘not effective’ 
and ‘fairly effective’ categories merged together, 
but it was unclear from the report whether this 
included the investigator rating alone (as above), 
participant rating alone or a combination. 
Burgess43 did not report on this outcome.
Measures of recurrence
Burgess43 and Lyndon and colleagues45 did not 
report on this outcome.
Adverse events
There were no AEs found for either treatment 
in the Burgess study.43 Lyndon and colleagues45 
report two AEs for Earex alone, one being a slight 
irritation and one based on the unacceptable smell 
of the treatment.
Children
There were no studies assessing children in a 
comparison of softeners followed by syringing, with 
a delayed participant follow-up.
Mixed or unknown populations
One study53 assessed an unspecified population 
(although reported a mean age of 51 years for 
all participants). Warm water as a softener was 
compared with oil, followed by syringing for both 
treatment groups. The study had an immediate 
follow-up for the warm water intervention, but a 
delayed follow-up of 3 days for the control group 
using oil.
Measures of occlusion
Eekhof and colleagues53 did not report on this 
outcome.
Measures of ease of wax removal
Eekhof and colleagues53 reported the mean 
number of syringing attempts between the water 
and oil-control groups [water: 3.0 (95% CI 2.4 to 
3.6), oil-control: 2.4 (95% CI 1.7 to 3.1)]. As the 
difference between means was not statistically 
significant (p = 0.18), warm water was reported 
to be as effective as oil as a softening agent. 
However, the study was not powered to test for 
statistical equivalence and so caution is required in 
interpreting this outcome. No baseline degree of 
earwax was reported.
Measures of patient satisfaction
Eekhof and colleagues53 did not report on this 
outcome.
Measures of recurrence
Eekhof and colleagues53 did not report on this 
outcome.Assessment of clinical effectiveness
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TABLE 7  Characteristics of included studies in secondary care
Study Interventions Participants Outcomes
Immediate follow-up
Author: Caballero 
and colleagues, 200555
Country: Spain
Number of centres: One
Design: RCT
Setting: Secondary care
Follow-up: Immediate
1. Chlorobutanol: 2 ml (n = 32)
2. Sodium carbonate: 2 ml (n = 29)
3. Saline: 2 ml (n = 28)
Target population: Adults with 
total cerumen obstruction
Baseline characteristics:
Age: 19–78 years
Gender: Not reported
Primary outcomes:
Proportion of TM 
completely visualised
Author: Dubow, 
195957
Country: USA
Number of centres: At 
least two
Design: RCT
Setting: Secondary care
Follow-up: Immediate
1. Hydrogen peroxide 3% solution: 
dose not reported (n = 20)
2. Mineral oil: Dose not reported 
(n = 20)
3. TP: Dose not reported (n = 20)
Target population: Children 
with at least one completely 
cerumen-occluded ear canal, 
disregarding other disorders, 
presenting in a paediatric clinic 
and in ‘office practice’
Baseline characteristics:
Age range, years: 3–12 overall 
(no individual group details)
Gender: Not reported
Wax clearance
Author: Chaput 
De Saintonge and 
Johnstone, 197359
Country: UK
Number of centres: One
Design: RCT
Setting: Secondary care
Follow-up: Immediate
1. TP: dose not reported (n = 32)
2. Olive oil: Dose not reported 
(n = 35)
Target population: any patient 
with impacted wax attending 
outpatients
Baseline characteristics:
Age: Not reported
Gender: Not reported
Total volume of water
Amount of wax 
removed
Delayed follow-up
Author: Keane and 
colleagues, 19954
Country: Ireland
Number of centres: One
Design: RCT
Setting: Secondary care
Follow-up: 5-day trial
1. Cerumol: 4 drops twice daily 
(n = 24, 40 ears)
2. Sodium bicarbonate: 4 drops 
twice daily (n = 25, 39 ears)
3. Sterile water: 4 drops twice 
daily (n = 24, 38 ears)
4. Control: No treatment (n = 38)
Target population: Hospitalised 
patient with one or both ears 
impacted
Baseline characteristics:
Age: not reported
Gender: not reported
Primary outcomes:
Percentage clearance 
and number of ears 
(clearance is explained 
by the ‘natural 
expulsion of earwax’)
Secondary outcomes:
AEs
Author: Fahmy and 
Whitefield, 198254
Country: UK
Number of centres: One
Design: CCT
Setting: Studies 1 and 2 
in secondary care
Follow-up: 1 week
Study 1: n = 40 (80 ears)
1. Exterol: 5–10 drops × 2 daily 
(n = 20)
2. Glycerol control: 5–10 drops × 2 
daily (n = 20)
Study 2: n = 50 (100 ears)
1. Exterol: 5–10 drops × 2 daily 
(n = 25)
2. Cerumol: 5–10 drops × 2 daily 
(n = 25)
Study 3: Reported in Table 3
Target population: patients 
presenting with earwax
Baseline characteristics:
Age: Not reported
Gender: Not reported
Wax occlusion
Wax consistency
Ease of syringingDOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
33
Study Interventions Participants Outcomes
Author: Fraser, 197060
Country: UK
Number of centres: Six 
hospitals
Design: RCT
Setting: Secondary care
Follow-up: At least 3 
days
1. Sodium bicarbonate: Once daily 
for 3 days (dose not stated) 
(n = 124 ears)
2. Olive oil: Once daily for 3 days 
(dose not stated) (n = 25 ears)
3. Cerumol: Once daily for 3 days 
(dose not stated) (n = 24 ears)
4. Waxsol: Once daily for 3 days 
(dose not stated) (n = 26 ears)
5. TP: 15–30 minutes prior to 
syringing (n = 24 ears)
6. Dioctyl capsules: Once daily for 
3 days (dose not stated) (n = 25 
ears)
One ear per person provided a 
test and control ear
Target population: Geriatric 
attendees at hospitals, with 
bilateral hard earwax that 
occludes the external auditory 
meatus in both ears
Baseline characteristics:
Age: Not reported
Gender: Not reported
Ease of syringing
Frequency of syringing
Appearance of wax 
removed
De-waxing techniques
Author: Pothier and 
colleagues, 200656
Country: UK
Number of centres: One
Design: RCT
Setting: Otolaryngology 
outpatient clinic
Follow-up: Treated and 
assessed on initial visit, 
unless cerumenolytics 
used and then 
unspecified delay
1. Endoscopic otoendoscope 
de-waxing (diode light source) 
(n = 50)
2. Microscopic de-waxing (aural 
speculum) (n = 50)
Target population: Patients 
requiring removal of earwax 
from the ear canal to allow full 
view of TM, with a history of 
earwax
Baseline characteristics:
Age, mean years (SD, range):
1. 57.2 (16.86, 16–87)
2. 58.3 (17.3, 18–91)
Gender M/F:
1. 60:40
2. 62:38
Levels of pain and 
discomfort for patient
Ease of de-waxing
Time taken to de-wax
Prevention of recurrence after removal earwax
Author: Saloranta 
and colleagues, 200558
Country: Finland
Number of centres: Two
Design: RCT
Setting: Secondary care 
and community home 
for people with learning 
difficulties
Follow-up: 12 months 
(visits also at 3 months 
and at a point of 
recurrence)
1. Skin oil Ceridal lipolotion: 2 ml, 
self administered, except in 
those with learning difficulties 
(n = 20)
2. No treatment (n = 19)
Target population: Patients with 
learning difficulties. Had to have 
a history of impacted cerumen 
with symptoms like impaired 
hearing or sensation of blocked 
ear canal more often than once 
per year, and earwax completely 
obstructing the ear canal at the 
point of inclusion
Baseline characteristics (learning 
difficulties):
1. n = 13, 16 ears (n = 9)
2. n = 19, 29 ears (n = 10)
Age, mean years (range):
1. 34 (4–52)
2. 44 (1–74)
Gender M/F:
1. 7:6
2. 8 : 10
Recurrence of 
cerumen impaction
AEs
AEs, adverse events; CCT, controlled clinical trial; F, female; M, male; SD, standard deviation; TM, tympanic membrane.
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Adverse events
Eekhof and colleagues53 did not report on this 
outcome.
Studies in secondary care 
settings
Eight studies undertaken in secondary care settings 
were identified (Table 7): seven were RCTs and one 
was a CCT. Three RCTs55,57,59 followed participants 
up immediately after interventions. One57 was a 
three-arm trial in children, of hydrogen peroxide, 
mineral oil or TP; one other55 was a three-arm trial 
in adults, of chlorobutanol, sodium carbonate and 
saline. The third study59 compared TP with olive 
oil; the participant group was not described in this 
study. Three included studies had a longer delay in 
their follow-up. Keane and colleagues’4 RCT, which 
appears to be in elderly adults, was a four-arm 
trial of Cerumol, sodium bicarbonate, sterile water 
and no treatment (control). The interventions 
were administered for 5 days, after which the 
participants were reassessed. Fraser60 assessed 
sodium bicarbonate, olive oil, Cerumol, Waxsol, 
TP and dioctyl to a within-participant control (one 
ear test, one ear control) in elderly participants 
over a period of 3 days follow-up. The third study, 
a CCT by Fahmy and Whitefield,54 included three 
separate studies, one of which was in participants 
from primary care and was discussed previously 
(Chapter 3, Studies in secondary care settings). 
Of the other two studies, one compared Exterol 
with glycerol and the other Exterol with Cerumol. 
The target population for these studies was not 
clear in the publication, but the ear drops were 
given over a one-week period before follow-up. 
In addition to the studies comparing the use of 
different softening agents, two other studies were 
included that either compared two de-waxing 
techniques56 or the application of a skin oil with no 
treatment.58 In the first of these RCTs adults in an 
otolaryngology clinic requiring removal of earwax 
were randomised to endoscopic otoendoscopic de-
waxing or microscopic de-waxing. In the second 
RCT, participants had their earwax removed and 
were then randomised to either Ceridal lipolotion 
skin oil or no treatment to assess the recurrence of 
cerumen. This study was undertaken in adults and 
children with learning difficulties and follow-up was 
for 12 months.
The quality of reporting and methodology of 
the included studies was generally poor (see 
Tables 8 and 9). Of the seven RCTs, none of 
the studies was assessed as having an adequate 
generation of the randomisation sequence. In 
one RCT the generation of the randomisation 
schedule was judged to be partially met,56 in 
three this was judged to be inadequate,57,58,60 and 
in the remainder it was not possible to judge 
due to a lack of information.4,55,59 Only one RCT 
adequately met the criteria for concealment of 
allocation.59 Therefore, most of these studies may 
be subject to selection bias, with the allocation 
sequence open to possible manipulation. Double-
blinding (participant and caregiver) was assessed 
as being adequate only in one study.59 While 
double-blinding may have been difficult for some 
interventions, blinding of the outcome assessors 
could have been undertaken; however, there 
were no studies that were assessed as adequately 
blinding the outcome assessors. This factor is 
particularly important when subjective outcome 
measures are used and therefore this may mean 
the studies are subject to measurement bias. Many 
studies did not present baseline characteristics of 
the participants within their intervention arms so it 
is unclear how similar the groups were at baseline. 
The description of withdrawals were assessed 
as being adequate in four studies,4,56–58 but only 
one of these studies also described an adequate 
ITT analysis.56 Overall these studies are at a high 
risk of bias, which may affect the direction of any 
effects shown, and care should be taken in the 
interpretation of the results.
The CCT54 was similarly judged to be only of low 
quality, the baseline characteristics between the 
study arms were unknown, the blinding of outcome 
assessors was unclear, and the report does not refer 
to withdrawals and dropouts or any ITT analysis. 
The results of this study should also be interpreted 
cautiously due to the high risk of bias.
Results of studies in secondary 
care with immediate follow-up
The results of studies in secondary care are 
reported in Table 10.
Softeners only studies
There were no studies that assessed the use of 
softeners alone and followed participants up 
immediately.
Softeners and irrigation studies
Adults
One study55 was included that compared the use of 
chlorobutanol, sodium carbonate and saline (and 
subsequent irrigation) in an adult population and 
followed participants immediately afterwards.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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TABLE 8  Quality of included RCTs, secondary care studies
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Ad, adequate; In, inadequate; ITT, intention to treat; Par, partial; Rep, reported; Un, unknown. (See Appendix 1.)
TABLE 9  Quality of included CCT, secondary care studies
Study
B
a
s
e
l
i
n
e
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
E
l
i
g
i
b
i
l
i
t
y
B
l
i
n
d
i
n
g
 
o
f
 
a
s
s
e
s
s
o
r
s
R
e
p
o
r
t
i
n
g
 
o
u
t
c
o
m
e
s
I
T
T
W
i
t
h
d
r
a
w
a
l
s
 
e
x
p
l
a
i
n
e
d
R
e
p
r
e
s
e
n
t
a
t
i
v
e
n
e
s
s
Fahmy, 198254 Un Par Un Par Un Un Un
ITT, intention to treat; Par, partial; Rep, reported; Un, unknown. (See Appendix 1.)
Measures of occlusion
Caballero and colleagues55 reported the proportion 
of participants in which the TM was completely 
visualised after treatment and irrigation. The study 
reports that there were no statistically significant 
differences among treatments with chlorobutanol, 
sodium carbonate or saline (66%, 55% and 43% 
for the three groups, respectively), although it was 
unclear from the study what the statistical analysis 
was testing. No baseline measures of the degree of 
occlusion were presented.
Measures of ease of wax removal
Caballero and colleagues55 did not report these 
outcomes.
Measures of participant satisfaction
Caballero and colleagues55 did not report these 
outcomes.
Measures of recurrence
Caballero and colleagues55 did not report these 
outcomes.
Adverse events
Caballero and colleagues55 did not report AEs.
Children
One study57 comparing hydrogen peroxide, 
mineral oil or TP in children, with an immediate 
follow-up, was included.
Measures of occlusion
Dubow57 reported the number of children 
with clearance of cerumen after treatment and 
syringing. The proportions of children rated 
as clear were 35% in the hydrogen peroxide 
group, 42% in the mineral oil group, and 70% Assessment of clinical effectiveness
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in the TP group. The study did not report 
statistical significance testing on this data. No 
baseline measures of the degree of occlusion were 
presented.
Measures of ease of wax removal
Dubow57 did not report these outcomes.
Measures of participant satisfaction
Dubow57 did not report these outcomes.
Measures of recurrence
Dubow57 did not report these outcomes.
Adverse events
One child in the Dubow57 study was reported to 
have an itching erythematous eruption of the 
external auditory meatus and surrounding area of 
the pinna of the ear. It was not clear to which group 
this child was allocated.
Mixed or unknown populations
One study59 in a mixed-population group 
immediately followed up participants having either 
TP or olive oil and subsequent syringing.
Measures of occlusion
Comparing TP with olive oil, Chaput de Saintonge 
and Johnstone59 reported that 63% of participants 
in the TP group and 60% of participants in the 
olive oil group had complete removal of earwax at 
immediate follow-up. Rates of those with partial 
wax removal were 38% and 29% for the two groups, 
respectively. There were no participants in the 
TP group and 11% of participants in the olive oil 
group for whom the amount of wax removed was 
classified as negligible. The study reports that there 
were no statistically significant differences between 
the two intervention groups but the p-value was not 
presented. No baseline measures of the degree of 
occlusion were presented.
Measures of ease of wax removal
Chaput de Saintonge and Johnstone59 report 
that the volume of water used for syringing was 
statistically significantly less in the TP intervention 
arm than in the olive oil arm of their study; 
p < 0.05.
Measures of participant satisfaction
Chaput de Saintonge and Johnstone59 did not 
report these outcomes.
Measures of recurrence
Chaput de Saintonge and Johnstone59 did not 
report these outcomes.
Adverse events
Chaput de Saintonge and Johnstone59 did not 
report AEs.
Results of studies in secondary 
care with delayed follow-up
The results of studies in secondary care are 
reported in Table 10.
Softeners only studies
Adults
One study4 was included that included adults and 
had the intention to assess outcomes after the 
use of only a softening agent, after a period of 
follow-up. The study compared Cerumol, sodium 
bicarbonate, water and no treatment, and follow-up 
was after 5 days.
Measures of occlusion
Keane and colleagues’4 comparison of Cerumol, 
sodium bicarbonate, water and no treatment 
assessed the proportion of ears still impacted 
after treatments. The proportions appear to be 
similar between the groups (Cerumol 16%, sodium 
bicarbonate 21%, water 18%, no treatment 26%), 
except for a slightly higher proportion remaining 
impacted in the ‘no treatment’ group. No p-values 
or baseline measures of the degree of occlusion 
were reported. The proportion of ears assessed 
as moderately clear were statistically significantly 
different between the Cerumol (15%) and the 
‘no treatment’ group (10%) only; p < 0.05. The 
proportion of ears assessed as completely clear was 
reported to be statistically significantly different 
between the Cerumol versus control group, the 
sodium bicarbonate versus control group and the 
water versus control group (Cerumol 9%, sodium 
bicarbonate 8%, water 8%, no treatment 2%) – all 
p < 0.05.
Measures of ease of wax removal
Keane and colleagues4 did not report these 
outcomes.
Measures of participant satisfaction
Keane and colleagues4 did not report these 
outcomes.
Measures of recurrence
Keane and colleagues4 did not report these 
outcomes.
Adverse events
No participants were reported to have any 
irritation or contact sensitivity from any of the 
treatments in the Keane and colleagues4 study.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Children
There were no studies in children that assessed the 
use of softeners alone with a delayed follow-up.
Mixed or unknown populations
One study54 was included that assessed the use of a 
softening agent after a follow-up period of 1 week 
in an unknown population. Fahmy and Whitefield54 
undertook two comparisons in secondary care (see 
Chapter 3, studies in secondary care settings, for 
primary care comparison). In one, a comparison of 
Exterol and glycerol was made and in the second a 
comparison of Exterol and Cerumol was made.
Measures of occlusion
In the study comparing Exterol with glycerol, 
Fahmy and Whitefield54 found that in 15% of ears 
in the Exterol group the earwax had dispersed at 
follow-up; however, no ears in the glycerol group 
were identified where the earwax had dispersed 
after treatment. No statistical significance testing 
was reported. Participants with earwax remaining 
then went on to receive syringing (see below). In 
this study at baseline some 90% of participants 
in both the Exterol and the glycerol group had 
total occlusion of the TM. The remaining 10% in 
each group were rated as having partial occlusion 
at baseline. There were no data reporting post-
treatment outcome in relation to pretreatment 
assessment in this study, however.
In the second study undertaken by Fahmy and 
Whitefield,54 comparing Exterol with Cerumol, 
the number of ears not requiring syringing was 
markedly greater (40%) with Exterol than with 
Cerumol (10%), p < 0.001. Participants with earwax 
remaining then went on to receive syringing (see 
below). In this study 46% of participants in the 
Exterol group were considered to have total or 
subtotal occlusion at baseline. The corresponding 
figure for the Cerumol group at baseline was 38%. 
The remaining 54% and 62% for each group, 
respectively, were rated as having partial occlusion 
at baseline. There were no data reporting post-
treatment outcome in relation to the pretreatment 
outcome in this study.
Measures of ease of wax removal
In the first Fahmy and Whitefield54 study 
comparing Exterol with glycerol, the proportion 
of ears that were subsequently syringed easily 
were 85% in the Exterol group and 50% in the 
glycerol group. No statistical significance testing 
was reported. The number of ears that were 
syringed with difficulty was higher in the glycerol 
group (50%) than the Exterol group (15%), but 
no statistical significance testing was undertaken. 
The study reports that when the number of ears 
not requiring syringing (above) was added to the 
number syringed easily, Exterol was statistically 
significantly superior to the control group; 
p < 0.001.
In the Fahmy and Whitefield54 study comparing 
Exterol with Cerumol, the number of ears syringed 
easily were greater in the Exterol group (90%) than 
the Cerumol group (42%) (p-value not stated) and 
hence the number of ears syringed with difficulty 
was greatest in the Cerumol group (58% Cerumol 
versus 10% Exterol; p-value not stated). The 
authors report that when the number of ears not 
requiring syringing (see above) was added to the 
number syringed easily, Exterol was statistically 
significantly superior to Cerumol; p < 0.001.
Measures of participant satisfaction
Fahmy and Whitefield54 did not report these 
outcomes in either of their studies in secondary 
care.
Measures of recurrence
Fahmy and Whitefield54 did not report these 
outcomes in either of their studies in secondary 
care.
Adverse events
Fahmy and Whitefield54 did not report AEs.
Softeners and irrigation studies
Adults
There were no studies in adult populations that 
assessed the use of softeners and irrigation with a 
delayed follow-up.
Children
There were no studies in children that assessed 
the use of softeners and irrigation with a delayed 
follow-up.
Mixed or unknown populations
One study,60 that assessed the use of a softening 
agent and irrigation over a delayed period of 
time in an unknown population, was included. 
This study compared sodium bicarbonate, olive 
oil, Cerumol, Waxsol, TP and dioctyl with a same 
participant control (of no treatment in one ear) 
over a 3-day period.
Measures of occlusion
Fraser60 did not report these outcomes.Assessment of clinical effectiveness
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Measures of ease of wax removal
Ease of syringing was tested between each of 
the interventions and their corresponding same 
participant control in the Fraser60 study and then 
differences (between intervention and control) 
were tested across the interventions. No baseline 
values for the degree of earwax were presented 
in this study. Cerumol, olive oil and Waxsol 
showed a positive difference in ease of syringing 
rating than their respective controls, suggesting 
that the treatment ear was syringed more easily. 
TP and dioctyl showed a negative difference 
suggesting that the control ear was syringed more 
easily. Sodium bicarbonate was reported to be 
equivalent to the control. In addition, when the 
mean differences (between each intervention 
and same participant control) were compared 
across interventions, the study author reports that 
Cerumol differed statistically significantly from 
sodium bicarbonate (p < 0.05), but that all other 
comparisons were not statistically significant. 
When the mean rank of the differences (between 
each intervention and same participant control) 
were compared across interventions, Cerumol was 
statistically significantly better than dioctyl and TP 
(p < 0.05).
Similar patterns were seen in the frequency of 
syringing successes and failures with Cerumol, olive 
oil and Waxsol rated better than controls, and TP 
and dioctyl rated worse than controls. However, 
it should also be pointed out that a number of 
participants in each of these groups were scored 
equal to control on the frequency of syringing 
success and failure.
Measures of participant satisfaction
Fraser60 did not report these outcomes.
Measures of recurrence
Fraser60 did not report these outcomes.
Adverse events
Frequency of otitis externa (inflammation of the 
external meatus) was reported by Fraser.60 There 
were 12 ears (4%) that had otitis externa: in three 
ears it was reported to be bilateral and probably 
not due to the study; of the remaining six ears, 
three ears had received sodium bicarbonate, two 
Waxsol and one TP.
Additional studies
Along with the above studies in secondary care 
(Table 10), two additional studies were included 
which do not fit into the categories of softeners 
alone or softeners and syringing, owing to their 
interventions. The first (Pothier and colleagues56) 
compared two different de-waxing techniques: 
endoscopic otoendoscope de-waxing and 
microscopic de-waxing. The second (Saloranta and 
colleagues58) treated participants who had earwax 
removed by syringing at an initial evaluation 
with either a skin oil or no treatment, to evaluate 
recurrence over a 12-month period.
De-waxing techniques
Pothier and colleagues56 compared two different 
de-waxing techniques; endoscopic otoendoscope 
de-waxing and microscopic de-waxing. On a visual 
analogue scale (VAS) of 0–100 the difficulty of de-
waxing was rated as less difficult in the endoscopic 
group (score 9) than in the microscopic group 
(score 20); p = 0.005. This corresponds to the 
difference in time taken to perform the de-waxing, 
which was also statistically significantly different 
between the two groups, where the endoscopic 
de-waxing took less time (1.8 versus 3.3 minutes; 
p = 0.001). Endoscopic de-waxing was also rated 
by participants (on a scale of 0–100) as causing less 
discomfort (score 5 versus 25) and less pain (score 
3.5 versus 10) than the microscopic de-waxing 
procedure respectively (p-values for statistical 
significance = 0.002 and 0.075, respectively). At 
baseline 40% of participants in the endoscopic 
de-waxing arm and 52% of participants in the 
microscopic de-waxing arm had complete occlusion 
of the TM but this difference was not statistically 
significantly different; p = 0.69.
No complications were reported during de-
waxing; however, one participant from each group 
sustained minor bleeding from ear canals. Five 
participants from the endoscopic group required 
conversion to microscopic de-waxing (three 
were successfully de-waxed, two were sent home 
with cerumenolytics) and two participants in the 
microscopic group were converted to endoscopic 
de-waxing (one was successfully de-waxed, one was 
sent home with cerumenolytics).
Prevention of recurrence
Saloranta and colleagues58 treated participants 
who had earwax removed by syringing at initial 
evaluation with either a skin oil (self-administered 
in those without learning difficulties) or no 
treatment, to evaluate recurrence over a 12-month 
period. Recurrence of impacted cerumen was seen 
in 23% of the Ceridal skin-oil-treated participants 
compared with 61% in those participants with no 
treatment (p < 0.05). The recurrence in treated ears 
was also statistically significantly less in the skin-DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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TABLE 10  Outcomes of treatments in secondary care
Immediate follow-up – adult population – softeners and irrigation as primary objective
Caballero and colleagues, 200555
Proportion of TM completely visualised
Chlorobutanol 
(n = 32)
Sodium carbonate 
(n = 29)
Saline  
(n = 28) p-value
21/32 (65.6%) 16/29 (55.2%) 12/28 (42.9%) p = 0.209
Immediate follow-up – child population – softeners and irrigation as primary objective
Dubow, 195957
Clearance: no. of cases (%)
Hydrogen peroxide 
(n = 20)
Mineral oil  
(n = 19)
TP  
(n = 20) p-value
7 (35%) 8 (42%) (14) 70% Not reported
Immediate follow-up – mixed populations – softeners and irrigation as primary objective
Chaput de Saintonge and Johnstone, 197359
TP (n = 32) Olive oil (n = 35) p-value
Amount of wax removed (n)
Complete 20 21 States ns, but p-value 
not reported Partial 12 10
Negligible 0 4
Volume of water used (n): (estimated by reviewer)
150 ml 7 1 Overall p < 0.05
TP needed smaller 
volumes of water 
than olive oil
300 ml 14 14
450 ml 4 6
600 ml 2 2
750 ml 0 2
900 ml 1 7
Delayed follow-up – adult population – softeners alone as primary objective
Keane and colleagues, 19954
Cerumol 
(n = 24)
Sodium 
bicarbonate 
(n = 25)
Water  
(n = 24)
Control 
(n = 38) p-value
Impacted, % (n, ears) 40.0 (16) 53.8 (21) 47.4 (18) 68.4 (26)
Moderately clear, % 
(n, ears)
37.5 (15) 25.6 (10) 31.6 (12) 26.3 (10) p < 0.05, Cerumol vs 
control
Completely clear, % 
(n, ears)
22.5 (9) 20.6 (8) 21.0 (8) 5.3 (2) p < 0.05, Cerumol vs 
control
p < 0.05, sodium 
bicarbonate vs 
control
p < 0.05, water vs 
control
continuedAssessment of clinical effectiveness
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Delayed follow-up – mixed populations – softeners alone as primary objective
Fahmy and Whitefield, 198254 (see Table 6 for results of study in primary care)
Study 1
Exterol  
(n = 20, ears n = 40)
Glycerol control  
(n = 20, ears n = 40)
p-value
Initially very 
hard wax
Initially hard 
wax
Initially very 
hard wax
Initially hard 
wax
Wax dispersed 
without syringing, 
ears
– 6 – – Not stated
Syringed easily, ears 15 14 2 18 Not stated
Syringed with 
difficulty, ears
5 – 14 6 Not stated
Study 2
Exterol (n = 25, ears n = 50) Cerumol (n = 25, ears n = 50)
p-value
Initially v 
hard
Initially 
hard
Initially 
soft
Initially v 
hard
Initially 
hard
Initially 
soft
Wax dispersed 
without syringing, 
ears
4 14 2 – – 5 p < 0.001
Syringed easily, ears 6 18 3 – 10 9
Syringed with 
difficulty, ears
2 1 – 8 17 1
Delayed follow-up – mixed populations – softeners and irrigation as primary objective
Fraser, 197060 (n = ears)
Ease of syringing
Sum scores
Difference  
(mean rank) Test ears Control ears
Cerumol (24 ears) 92 122 +30a (+11.9)b
Olive oil (25 ears) 116 140 +24 (+3.4)
Waxsol (26 ears) 110 128 +18 (+2.8)
Sodium bicarbonate 
(124 ears)
Control 0 (–3.5)
TP (24 ears) 118 107 –11 (–9.0)
Dioctyl (25 ears) 119 107 –12 (–9.1)
A positive difference indicates that the test were easier to syringe than the control ears.
a  Cerumol differed significantly from sodium bicarbonate (p < 0.05); all other comparisons were not significant.
b  When mean ranks were compared, Cerumol was significantly better than dioctyl and TP (p < 0.05).
Frequency of syringing successes and failures
Product better  
(n participants)
Scores equal  
(n participants)
Control better  
(n participants)
Cerumol (24 ears) 15 5 4
Olive oil (25 ears) 10 6 9
Waxsol (26 ears) 11 6 9
TP (24 ears) 7 7 10
Dioctyl (25 ears) 8 5 12
TABLE 10  Outcomes of treatments in secondary care (continued)DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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No. of ears in which very forceful syringing failed
Test ears Control ears
Cerumol (24 ears) 1 5
Olive oil (25 ears) 2 4
Waxsol (26 ears) 3 5
TP (24 ears) 5 3
Dioctyl (25 ears) 5 2
Appearance of wax removed by syringing
Percentage of lumps
Percentage partially 
broken up
Percentage completely 
broken up
Cerumol (24 ears) 46 37 17
Olive oil (25 ears) 40 44 16
Waxsol (26 ears) 15 46 39
Sodium bicarbonate (124 ears) 33 43 24
TP (24 ears) 42 25 33
Dioctyl (25 ears) 36 44 20
De-waxing techniques
Pothier and colleagues, 200656
Endoscopic otoendoscope  
de-waxing (n = 50)
Microscopic de-waxing  
(n = 50) p-value
Discomfort – median 
score on VAS 
(0–100)
5 25 p = 0.002
Pain – median score 
on VAS (0–100)
3.5 10 p = 0.075
Difficulty in de-
waxing – median 
score on VAS 
(0–100)
9 20 p = 0.005
Time taken to 
perform de-waxing 
(minutes)
1.8 3.3 p = 0.001
Prevention of recurrence after removal of cerumen
Saloranta and colleagues, 200558
Ceridal skin-oil (n = 13) No treatment (n = 18) p-value
Recurrence of 
cerumen impaction
3 (23%) 11 (61%) p < 0.05
Recurrence in 
treated ears
3/16 (19%) 15/29 (52%) p < 0.05
ns, not significant; TP, triethanolamine polypeptide; VAS, visual analogue scale.
TABLE 10  Outcomes of treatments in secondary care (continued)Assessment of clinical effectiveness
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TABLE 11  Characteristics of studies of self-care
Study Interventions Participants Outcomes
Author: Coppin and 
colleagues, 200863
Country: UK
Number of centres: Seven 
primary care practices
Design: RCT
Setting: Self-care/primary 
care
Follow-up: 1–2 weeks for 
comparison of interventions; 
within 6 weeks for 
assessment of further 
treatment AEs, rates and 
reasons for non-participation 
or non-compliance
1. Sodium bicarbonate for ≥ 2 
days (dose not reported) 
and self-irrigation (n = 118)
2. Sodium bicarbonate 
for ≥ 2 days (dose not 
reported) and irrigation by 
practice nurse (n = 119)
Target population: Adults 
consulting a GP or practice 
nurse with symptoms of 
occluding earwax (itching, 
sensation of blockage, 
reduced hearing) consenting 
to inclusion in study
Baseline characteristics:
Age, mean years (SD):
1. 57 (14)
2. 55 (16)
Gender M/F:
1. 66:34
2. 63:37
Primary outcomes:
Reported symptoms and 
wax clearance
Secondary outcomes:
Further treatment required 
and acceptability of 
treatment
Author: Harris 196864
Country: Ireland
Design: RCT
Number of centres: One
Setting: Self-care/primary 
care
Follow-up: 1 day
1. TP (enough ear drops 
to fill the ear and left 
in overnight) plus self-
irrigation with warm water 
(maximum of 12 squirts) 
the morning after (n = 24)
2. Control: No softener, self-
irrigation with warm water 
(maximum of 12 squirts) in 
the morning only (n = 21)
Target population: All 
participants attending 
surgery and complaining 
of symptoms directly 
attributable to ceruminosis
Baseline characteristics:
Age and gender not 
reported
Primary outcomes: (Not 
stated as primary or 
secondary)
Wax clearance
Meati clearance
Colour cerumen
Symptoms
AEs
AEs, adverse events; F, female; M, male; RCT, randomised controlled trial; SD, standard deviation; TP, triethanolamine 
polypeptide.
oil-treated group (19%) than the non-treated group 
(52%); p < 0.005. The study also reports that there 
were no AEs observed in either group.
Studies of self-care
Two RCTs63,64 investigated the use of self-irrigation 
after participants had been assessed for earwax 
in primary care. One63 compared self-irrigation 
to nurse irrigation in adult participants who had 
been given sodium bicarbonate to use for at least 
2 days. The follow-up was 1–2 weeks later for the 
comparison of interventions. A later follow-up 
(within 6 weeks) was undertaken to assess the need 
for further treatment and for the assessment of 
AEs and adherence to treatment. The other study64 
randomised participants to either TP overnight 
and self-irrigation in the morning, or just self-
irrigation in the morning. Both studies used 
soft bulb irrigators and followed up participants 
subsequent to the irrigation attempts. Table 11 
shows the characteristics of the two self-care 
studies.
The quality of the included RCT of self-irrigation63 
(Table 12) compared with nurse irrigation was 
assessed as having reasonable quality. The method 
of generating the randomisation sequence 
and the concealment of allocation were rated 
as being adequate. These factors limit the risk 
from selection bias. Blinding of the participants 
and care-providers was not possible due to the 
nature of the intervention; however, the outcome 
assessors could have been blinded to the treatment 
allocation and this was therefore judged as 
inadequate. Withdrawals were reported but there 
appeared to be additional numbers missing in the 
analysis of many of the outcomes and there was no 
discussion of the application of an ITT principle 
to the analysis of data. The RCT of self-irrigation 
with or without a previous softener64 was assessed 
to be of low methodological quality. Details of the 
randomisation schedule and allocation were not 
adequately described and it is also unclear whether 
the outcome assessors were blinded to treatment 
allocation.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
43
TABLE 12  Quality of included RCT of self-care
Study
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Coppin, 200863 Ad Ad Rep Un In N/A N/A Ad In Par
Harris, 196864 Un Un Un Par Un Un Un In In Ad
Ad, adequate; In; inadequate; ITT, intention to treat; Par, partial; Rep, reported; Un, unknown; N/A, not applicable. (See 
Appendix 1.)
Results of studies in self-care 
settings
The results of studies in self-care are reported in 
Table 13.
Measures of occlusion
In the study by Coppin and colleagues,63 at 
baseline 63% of participants in the self-irrigation 
group had a completely occluded right ear and 
67% a completely occluded left ear. In the nurse 
irrigation group these proportions were similar 
(62% with completely occluded right ear and 
69% with a completely occluded left ear). After 
treatment the degree of obstruction was rated on 
a 4-point scale (0 = no or minimal wax with TM 
fully visible; 1 = minor amount of wax with TM 
essentially visible; 2 = moderate amount of wax 
with TM partially obscured; 3 = complete occlusion 
of TM) by a treatment nurse. Based on this nurse-
evaluated score, wax ‘clearance’ (a combined 
score of 0 and 1) was seen in 48% of those in the 
self-irrigation group compared with 63% in the 
nurse-irrigation group; p = 0.03. There were no 
baseline data of the degree of obstruction using 
this particular scale hence no data on the post-
treatment outcome in relation to the pretreatment 
outcome were presented. This score was reported 
to have been used in a pilot study by the report 
authors, and a reference is provided, although it is 
also not clear if this was a fully validated measure.
The proportion assessed as not requiring further 
clearance in the Coppin and colleagues63 study 
was higher in the nurse-irrigation group (69%) 
compared with those in the self-irrigation group 
(51%); p < 0.01. This assessment was undertaken by 
a GP or a nurse who may or may not have carried 
out the pretreatment assessment (28% were by the 
same nurse).
Harris64 reported the number of participants with 
complete clearance versus partial or incomplete 
clearance of earwax, with statistically significantly 
higher proportions of participants seen with 
completely cleared ears in the TP softened group 
(p < 0.005). Of those with completely obscured TM 
at baseline (n = 14 per treatment group) in the TP 
softening group, eight participants were completely 
cleared after treatment. In the self-irrigation only 
group no participants were completely cleared 
after treatment. Of those with partially obscured 
TM at baseline (n = 10) in the TP softening group, 
all 10 were reported to be cleared at follow-up. In 
the self-irrigation-alone group, seven participants 
had partially obscured TM at baseline and just 
one was cleared at follow-up (Table 13). Subsequent 
to follow-up, six TP participants had softened 
wax cleared in primary care with gentle syringing 
and 19 participants in the control group had wax 
cleared with normal syringing after examination at 
the surgery.
Measures of ease of wax removal
Coppin and colleagues63 and Harris64 did not assess 
these measures.
Measures of participant satisfaction
On a self-reported symptom score that ranged 
from 0 (no symptoms) to 6 (severe symptoms) 
which had previously shown high internal reliability 
in a pilot study, the mean change in score from 
baseline in the Coppin and colleagues63 study was 
better in those participants in the nurse-irrigation 
group than the self-irrigation group [difference 
–0.45 (95% CI –0.11 to –0.79; p = 0.01)].
In the Coppin and colleagues study,63 satisfaction 
with treatment was assessed on a 7-point scale 
that had previously been used in a pilot study. Assessment of clinical effectiveness
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TABLE 13  Outcomes of studies with a self-care setting
Coppin and colleagues, 2008:63 self-irrigation vs nurse irrigation
Sodium 
bicarbonate + self-
irrigation (n = 118)
Sodium 
bicarbonate + nurse 
irrigation (n = 119)
Difference groups 
(95% CI); p-value
Wax clearance (obstruction score 0 
or 1), n (%)
50/104 (48) 64/102 (63) 15% (1% to 28%); 
p = 0.03
Requires no further clearance 
(based on normal clinical practice), 
n (%)
51/100 (51) 66/95 (69) 18% (5% to 32%); 
p < 0.01
Mean (SD) change in symptom 
score from baseline
–0.81 (1.44) –1.26 (1.15) –0.45 (–0.11 to 
–0.79); p = 0.01
Satisfied with treatment, n (%) 
(agreed slightly or more)
78/110 (71) 105/106 (99) 28% (19% to 29%); 
p < 0.001
Use same treatment again, n (%) 
(agreed slightly or more)
82/110 (75) 106/106 (100) 25% (17% to 25%); 
p < 0.001
Treatment convenient, n (%) 
(agreed slightly or more)
84/110 (76) 95/105 (90) 14% (4% to 24%); 
p < 0.01
Harris, 1968:64 softeners and self-irrigation vs self-irrigation alone
Clearance
TP (n = 24) Control (n = 21) p-value
Completely cleared 18 1 p < 0.005
Partially or not cleared 6 20
State of meati
Completely 
obscured
Partially 
obscured
Completely 
obscured
Partially 
obscured
Before treatment
14 10 14 7 ns
After treatment
Meati cleared 8 10 0 1
Meati not cleared 6 0 14 6
CI, confidence interval; ns, not significant; SD, standard deviation; TP, triethanolamine polypeptide.
TABLE 14  Treatment discomfort and AEs from studies with a self-care setting
Coppin and colleagues, 200863
Sodium 
bicarbonate + self-
irrigation (n = 118)
Sodium 
bicarbonate + nurse 
irrigation (n = 119)
Difference groups 
(95% CI); p-value
Treatment discomfort (slight or 
more), n (%)
43/100 (39) 35/108 (32) 7% (–6% to 19%); 
p = 0.30
Treatment dizziness (slight or 
more), n (%)
14/100 (13) 14/108 (13) 0% (–9% to 9%); p = 0.96
Infection, n (%) 1/97 (1) 1/93 (1) 0% (–3% to 3%); p = 1.00
Perforation, n (%) 1/97 (1) 1/94 (1) 0% (–3% to 3%); p = 1.00
Signs of trauma, n (%) 1/97 (1) 1/94 (1) 0% (–3% to 3%); p = 1.00
CI, confidence interval.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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The proportion of participants who rated their 
satisfaction with treatment as satisfied slightly or 
more was higher in the nurse-irrigation group 
than the self-irrigation group, a difference of 28% 
(95% CI 19% to 29%); p < 0.001. It was unclear 
whether this scale was a fully validated measure of 
satisfaction with treatment.
Harris64 did not report satisfaction as an outcome.
Measures of recurrence
Neither Coppin and colleagues63 or Harris64 
assessed these measures.
Adverse events
There were no statistically significant differences 
between the two groups in the rating of treatment 
discomfort [difference of 7% (95% CI –6% to 
19%)] in the Coppin and colleagues63 study (Table 
14). There were also no statistically significant 
differences between rates of dizziness, infection, 
perforation or signs of trauma (differences between 
groups for each type = 0%). One participant in the 
nurse-irrigation group had bilateral otitis externa. 
Of the two participants that had perforations (one 
in each group), one had old scarring on the TM 
and one had pre-existing cholesteatoma (unclear 
which group each belonged to). In the Harris64 
study, AEs were reported as one participant in the 
TP arm suffering erythema around the external 
auditory meatus. No other AEs were reported.
Studies in other care 
settings
One RCT62 was undertaken in a corporate 
research clinic in adult volunteers with excessive 
or impacted cerumen on examination (Table 15). 
The study compared TP, Murine and placebo with 
saline, and follow-up was immediate. One CCT61 
was undertaken in a military research unit in a 
population of adult entrants to the Royal Air Force 
who had impacted cerumen (Table 15). The study 
compared sodium bicarbonate, Cerumol, hydrogen 
peroxide, olive oil and ‘no treatment’ control. 
Follow-up was also immediate. Both studies also 
followed the softening agents with an irrigation 
procedure before assessing the outcomes.
The quality of reporting and methodology of the 
included studies was generally poor (Tables 16 and 
17). In the RCT the randomisation schedule and 
the concealment of allocation were unknown, which 
TABLE 15  Characteristics of studies in other care settings
Corporate research unit: adult population with immediate follow-up
Author: Roland and 
colleagues, 200462
Country: USA
Number of centres: One
Design: RCT
Setting: Corporate 
research clinic
Follow-up: Immediate
1. TP: Dose not reported 
(n = 24)
2. Murine: Dose not reported 
(n = 26)
3. Placebo: Dose not reported 
(n = 24)
Target population: ≥ 18-year-old 
company employees, volunteering 
with excessive or impacted 
cerumen, required to have mild, 
moderate or complete cerumen 
occlusion
Baseline characteristics:
Age, mean years (range): 45 (22–66) 
overall (no individual group details)
Gender M/F 51:23 (M/F ratio): 
(2.2:1)
Main outcome: Post-
treatment level of 
occlusion
Other outcome: 
Otological signs and 
symptoms
Military research unit: adult population with immediate follow-up
Author: Hinchcliffe, 195561
Country: UK
Number of centres: One
Design: CCT
Setting: Military
Follow-up: Immediate
1. Sodium bicarbonate BPC: 5 
drops (n = 37 ears)
2. Cerumol: 5 drops (n = 37 
ears)
3. Hydrogen peroxide BPC: 5 
drops (n = 37 ears)
4. Olive oil BP: 5 drops (n = 37 
ears)
5. Control: No treatment 
(n = 37 ears)
Target population: Adult entrants to 
the Royal Air Force in the 1950s, 
found to have hard wax obscuring 
the meatus in one or both ears on 
entrant examination
Baseline characteristics:
Age: Not reported
Gender: Not reported
No. of occasions 
wax meatus was 
not cleared within 
specified 5 minutes
No. of cases with 
symptoms of 
discomfort
BP, British Pharmaceutical grade; BPC, British Pharmaceutical Codex; CCT, controlled clinical trial; F, female; M, male; 
RCT, randomised controlled trial; TP, triethanolamine polypeptide.Assessment of clinical effectiveness
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TABLE 16  Quality of RCT in other care setting
Study
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Roland, 200462 Un Un In Ad Ad Par Ad Ad In Ad
Ad, adequate; In; inadequate; ITT, intention to treat; Par, partial; Rep, reported; Un, unknown; N/A, not applicable. (See 
Appendix 1.)
TABLE 17  Quality of CCT in other care setting
Study 
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Hinchcliffe, 195561 Un Ad Par In In Un Un
Ad, adequate; In; inadequate; ITT, intention to treat; Par, partial; Rep, reported; Un, unknown; N/A, not applicable. (See 
Appendix 1.)
may lead to an increased risk of selection bias. 
Blinding of outcome assessors and the participant 
were judged to be adequate, with blinding of the 
caregiver judged as partially met. The number 
of withdrawals was discussed, but there was no 
discussion on an analysis based on the ITT 
principle. The CCT was judged to meet the criteria 
only partially for blinding of outcome assessors, 
but the reporting of outcomes and any withdrawals 
values was inadequate. These studies are at a high 
risk of bias, which may affect the direction of any 
effects shown. Caution is therefore required when 
interpreting the results.
Results of studies in other care 
settings
The results of studies in other care settings are 
reported in Table 18.
Measures of occlusion
Participants in the RCT by Roland and colleagues62 
were assessed for the degree of occlusion after 
treatment and syringing. The proportion of 
participants classified as having no occlusion was 
highest in the placebo group (41.7%). In the TP 
group the proportion with no occlusion was 29.2% 
and in the Murine group this was 15.4%. The 
proportion of participants classified as having mild, 
moderate or complete occlusion were subsequently 
lower in the placebo group and higher in the TP 
and Murine groups. While these data suggest 
that the placebo group had better outcomes 
than the TP and Murine groups, there were no 
statistically significant effects shown (p = 0.06). The 
change from baseline in the degree of occlusion 
was presented in a figure and estimated by a 
reviewer. This suggests that there was resolution 
of the earwax in 30% of the TP arm, 16% in the 
Murine arm and 42% in the placebo arm, but 
the differences were not tested statistically. The 
proportion rated as having an improvement in 
the amount the earwax was also higher in the 
placebo group (8% TP, 7% Murine, 22% placebo), 
and the proportion rated as having no change or 
a worsening of earwax was lower in the placebo 
group (62% TP, 77% Murine, 38% placebo), 
although again this was not tested for statistical 
significance. The degree of occlusion seen at 
baseline was not presented per intervention group, DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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but the level of occlusion across all participants was 
presented.
Measures of ease of wax removal
In the Hinchcliffe CCT61 the outcome assessed 
was the number of occasions the wax meatus was 
not cleared within a prespecified 5 minutes. In all 
groups the proportions not cleared in the time 
frame were generally low (sodium bicarbonate 16%, 
Cerumol 19%, hydrogen peroxide 11%, olive oil 
5% and control 24%), although the control arm 
appeared to have more participants ‘not cleared’ 
than the other comparisons. The study reports that 
olive oil was statistically significantly better than 
no treatment at all, but no p-value was reported to 
support this.
Measures of participant satisfaction
These outcome measures were not assessed 
by Roland and colleagues62 or Hinchcliffe and 
colleagues.61
Measures of recurrence
These outcome measures were not assessed 
by Roland and colleagues62 or Hinchcliffe and 
colleagues.61
Adverse events
In the Roland and colleagues62 RCT, rates of 
related AEs were low in all groups. One participant 
in the TP group and two in the Murine group had 
ear pruritis. One participant in the placebo group 
had ear discomfort and one participant in the TP 
group had contact dermatitis. There was only one 
AE classed as unrelated by the study authors, this 
was a case of vertigo seen in the TP group.
In the Hinchcliffe61 CCT AEs were only reported as 
numbers, no details of specific AEs were reported. 
All treatments except the control were associated 
with some AEs; these appeared to be higher in 
the Cerumol treatment arm (n = 22) than in the 
other treatments (sodium bicarbonate n = 4; 
hydrogen peroxide n = 6; olive oil n = 4), but no 
statistical significance testing was undertaken. The 
study author reports that symptoms of discomfort 
occurred significantly more often for Cerumol than 
for any other preparation, but no further data were 
reported to support this.
Outcomes of the above two studies are shown in 
Table 18.
TABLE 18  Outcomes of studies in other care settings
Roland and colleagues, 200462
Degree of occlusion
TP (n = 24) Murine (n = 26) Placebo (n = 24) p-value
None, n (%) 7 (29.2) 4 (15.4) 10 (41.7) TP vs placebo 
p = 0.37
Mild, moderate or 
complete occlusion
17 (71) 22 (85) 14 (58) Murine vs placebo 
p = 0.06
Change from baseline in occlusion (estimated by reviewer)
Resolved: 30% Resolved: 16% Resolved: 42% Not tested
Improved: 8% Improved: 7% Improved: 22%
No change/worse: 62% No change/worse: 77% No change/worse: 38%
Hinchcliffe, 195561 (n = ears)
Sodium 
bicarbonate 
(n = 37)
Cerumol 
(n = 37)
Hydrogen 
peroxide 
(n = 37)
Olive oil 
(n = 37)
Control 
(n = 37)
p-value
No. of occasions wax 
meatus was not cleared 
within specified  
5 minutes
6 (16%) 7 (19%) 4 (11%) 2 (5%) 9 (24%)
TP, triethanolamine polypeptide.Assessment of clinical effectiveness
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Summary of results of the 
systematic review of clinical 
effectiveness
Quantity, quality and nature of 
evidence
•  Twenty-six clinical trials conducted in primary 
care (14 studies), secondary care (eight studies) 
or other care settings (four studies), met the 
inclusion criteria for the review. Of these 
studies, there were 22 RCTs and four CCTs.
•  The evidence on the clinical effectiveness of 
the different methods of earwax removal was 
diverse in terms of the people, interventions, 
comparators and outcomes assessed. Many of 
the studies suffered from limitations associated 
with the completeness of reporting of methods 
and results. For those where information was 
presented, they were generally considered to 
be of poor quality, with many studies providing 
only partial or inadequate consideration of 
potential biases. Many of the differences and 
inadequacies may reflect the long period 
during which the research findings have 
emerged (1950–2007), with changes to clinical 
practice and developments in the principles for 
the conduct of research evident.
•  A range of interventions have been used in 
the studies involving 16 different softeners 
with or without irrigation in various different 
comparisons. Most comparisons are of 
different oil-based softeners against water-
based softeners. Doses are not always reported 
and timing of the intervention and follow-up 
assessment varies across the studies.
•  Participants in the trials also varied across 
the studies, in terms of age, sex and extent of 
earwax problem. In some cases few details of 
baseline characteristics are given in the study 
reports, so interpretation of results is difficult.
•  A range of outcome measures were reported 
across the studies often with limited 
information on the definition of these 
outcomes, making it difficult to assess their 
validity and objectivity, and how consistently 
they were applied. For example, measures of 
earwax removal might be reported in terms 
of clearance or visualisation of TM (described 
as complete, partial or negligible) or in terms 
of impaction or occlusion (described as none, 
mild, moderate or severe). Ease of earwax 
removal was reported in terms of number 
of attempts or the amount of liquid needed 
to achieve some degree of success. As a 
consequence, a pragmatic approach was taken 
to classify outcomes under these categories 
despite no evidence that these are directly 
comparable between studies.
•  Some studies reported measures of participant 
satisfaction, but these were not always assessed 
with valid measures. Measures of recurrence 
were rarely reported as most studies were of a 
short time frame. AEs were rarely reported.
•  Data analysis conducted in the trials was also 
variable with several studies not reporting the 
analytic approach used or results of statistical 
tests.
•  Due to these methodological issues, 
summarising the results of included studies 
was difficult and meta-analysis impossible. As 
such, care should be taken in interpreting the 
findings of the studies.
Results
•  Considering the studies that report statistical 
significant differences in outcomes measuring 
clearance of earwax (Tables 19 and 20) and 
ignoring any variations in methodological 
quality, results assessing the extent and ease of 
clearance of wax show that Cerumol, sodium 
bicarbonate, olive oil and water are all more 
effective than no treatment at removal of 
earwax; Cerumol is better than dioctyl, TP 
and sodium bicarbonate for ease of subsequent 
irrigation; TP is better than olive oil in the 
volume of water used in syringing; Audax 
is better than Earex for ease of removal by 
subsequent irrigation; Exterol and Otocerol are 
better than Cerumol in terms of the number of 
people requiring irrigation after treatment with 
softeners.
•  Other comparisons show that wet irrigation is 
better than dry irrigation for ease of removal; 
sodium bicarbonate drops followed by nurse 
irrigation is more effective than sodium 
bicarbonate drops followed by self-irrigation; 
softening with TP and self-irrigation is more 
effective than self-irrigation only; endoscopic 
de-waxing is better than microscopic de-
waxing; recurrence of earwax and impacted 
earwax is less in ears that are treated with skin 
oil than those not treated.
•  Patient satisfaction was assessed in five studies 
through several different measures. Over 
85% of people in two studies found the use of 
dioctyl-medo, oil-based softeners, Waxsol and 
Cerumol tolerable. In two other studies the 
effectiveness of softeners as judged by patients 
ranged from 29% for Earex to between 42% 
and 93% for Audax and 100% for Cerumol. DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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TABLE 19  Summary of results on measures of occlusion by interventions
Comparison Study Measure(s)a Statistical significance
Audax
1.  Audax
2. Earex
1. Lyndon and colleagues 
199245
Degree of impaction: None, 
mild, moderate or severe
Not statistically significant 
(no p-value reported)
Cerumol
1. Cerumol
2. Exterol
1. Fahmy and Whitefield 
198254 (study 2)
Wax dispersal without 
syringing
Statistically significant in 
favour of Exterol (p < 0.001)
2. Fahmy and Whitefield 
198254 (study 3)
Wax dispersal without 
syringing
Statistically significant in 
favour of Exterol (p < 0.001)
1. Cerumol
2. No treatment
1. Keane and colleagues 
19954
Clearance: Impacted, 
moderately clear or completely 
clear
Statistically significant in 
favour of Cerumol for 
completely clear (p = 0.05)
Murine
1. Murine
2. Placebo
1. Roland and colleagues 
200462
Occlusion: None or ‘mild-
moderate-complete’
Not statistically significant 
(p = 0.06)
TP
1. DS
2. TP
1. Singer and colleagues 
200049
TM visualisation: Complete or 
incomplete
Not statistically significant
1. TP
2. Olive oil
1. Chaput de Saintonge and 
Johnstone 197359
Amount of wax removed: 
Complete, partial or negligible
Not statistically significant 
(no p-value reported)
1. TP
2. Murine
1. Roland and colleagues 
200462
Occlusion: None or ‘mild-
moderate-complete’
Not statistically significant 
(p = 0.37)
Sodium bicarbonate preparations
1.  Aqueous sodium 
bicarbonate
2.  Aqueous acetic acid
1. Carr and Smith  
200152
Mean change in degree of 
cerumen
Not statistically significant 
(no p-value reported)
1. Sodium bicarbonate
2. No treatment
1. Keane and colleagues 
19954
Clearance: Impacted, 
moderately clear or completely 
clear
Statistically significant in 
favour of sodium bicarbonate 
for completely clear (p = 0.05)
Olive oil
1. Olive oil
2. No treatment
1. Hinchcliffe  
195561
No of times wax meatus not 
cleared within 5 minutes
Statistically significant in 
favour of olive oil (no p-value 
reported)
Water
1. Water
2. No treatment
1. Keane and colleagues 
19954
Clearance: Impacted, 
moderately clear or completely 
clear
Statistically significant 
in favour of water for 
completely clear (p = 0.05)
TM, tympanic membrane; TP, triethanolamine polypeptide.
a  A number of included studies did not report measures of occlusion as an outcome and a number of other studies did 
not report any data analyses.Assessment of clinical effectiveness
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TABLE 20  Summary of results on measures of ease of wax removal by interventions
Comparison Study Measure(s)a Statistical significance
Audax
1.  Audax
2. Earex
1. Lyndon and colleagues 
199245
Ease of syringing: not required, 
easy, difficult or impossible
Statistically significant in 
favour of Audax (p < 0.005)
Cerumol
1. Cerumol
2. Dioctyl capsules
1. Fraser  
197060
Ease of syringing Mean ranks comparison 
statistically significant in 
favour of Cerumol (p < 0.05)
1. Cerumol
2. Sodium bicarbonate
1. Fraser  
197060
Ease of syringing Statistically significant in 
favour of Cerumol (p < 0.05)
1. Cerumol
2. TP
1. Fraser  
197060
Ease of syringing Mean ranks comparison 
statistically significant in 
favour of Cerumol (p < 0.05)
1. Cerumol
2. Waxsol
2. Fraser  
197060
Ease of syringing Not statistically significant 
(no p-value reported)
1. Cerumol
2. Otocerol
1. Jaffe and Grimshaw  
197850
Number of people needing 
syringing
Statistically significant in 
favour of Otocerol (p = 0.05)
TP
1. TP
2. Olive oil
1. Chaput de Saintonge and 
Johnstone  
197359 
Ease of syringing: volume of 
water used for syringing
Statistically significant in 
favour of TP (p = 0.05)
Sodium bicarbonate preparations
1. Sodium bicarbonate
2. Olive oil
1. Fraser  
197060
Ease of syringing Not statistically significant 
(no p-value reported)
Water
1. Water
2. Self-administered oil
1. Eekhof and colleagues 
200153
Mean number of syringing 
attempts
Not statistically significant 
(p = 0.18)
Olive oil
1. Olive oil
2. No treatment
1. Hinchcliffe  
195561
No. of times wax meatus not 
cleared within 5 minutes
Statistically significant in 
favour of olive oil (no p-value 
reported)
Dioctyl-medo
1. Dioctyl-medo
2. Oil
2. Fraser  
197060
Ease of syringing Not statistically significant 
(no p-value reported)
TP, triethanolamine polypeptide.
a  A number of included studies did not report measures of ease of wax removal as an outcome, and a number of other 
studies did not report any data analyses.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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TABLE 21  Summary of research in progress
Contact name Title Funding body
Dr K Schroeder Olive oil vs ear syringing for the removal of earwax in primary 
care: pragmatic randomised trial
Scientific Foundation Board, 
Royal College of GPs, UK
Mr S Gillett Microsuction vs instruments for de-waxing: a randomised 
controlled trial
Royal United Hospital Bath 
NHS Trust, UK
Dr M Caballero Chlorobutanol, potassium carbonate, and irrigation in cerumen 
removal 
Hospital Clinic of Barcelona, 
Spain
Mr S MacKeith The use of wax softeners (cerumenolytics) before de-waxing: a 
randomised clinical study
NHS R&D Support Funding, UK
Dr C Hand The treatment of symptomatic earwax in primary care None
In another study, people undergoing nurse 
irrigation were more satisfied than those self-
irrigating their ears (difference 28%).
•  Adverse events appear to be minor, limited in 
extent and mainly related to irrigation. None 
of the studies reported perforation of the TM 
or serious infections. In the majority of studies 
fewer than 10% of people suffered any AE. 
Minor pain (0–21%) and irritation/itching of 
the ear (4–15%) were the main AEs.
Conclusion
Despite the relative benefits of certain softeners in 
aiding the extent and ease of earwax clearance, it 
is not possible to say that any one type of softener 
is superior in clearing earwax with or without 
subsequent irrigation on the evidence available. 
Separate studies have found significant benefits 
from wet syringing compared with dry syringing, 
from nurse irrigation rather than self-irrigation, 
and from endoscopic than microscopic de-waxing.
Research in progress
We identified a total of five ongoing trials from 
our searches (Table 21). Schroeder and colleagues 
aimed to evaluate olive oil as a softening agent, 
comparing the usual care of self-administered olive 
oil for 5 days prior to irrigation versus 3 weeks. 
The primary outcome of the trial was ear canal 
clearance and the trial was set to finish in 2006.
Gillett and colleagues aimed to investigate the 
differences in discomfort and/or complications 
between microsuction and the use of instruments. 
The trial was set to finish in July 2008, although no 
subsequent publication has been identified at the 
time of writing.
The third study by Caballero and colleagues was set 
in a hospital clinic in Spain and aimed to compare 
Otocerum® ear drops, Taponoto® ear drops and 
placebo. This is reported to be a phase IV trial, 
non-randomised, double-blind and parallel-
assignment trial. The primary outcome was the 
proportion with a completely visualised TM, with 
either the treatments alone or with irrigation 
if needed. The study was expected to finish in 
October 2008 and no publication has so far been 
identified.
Two other controlled trials were identified from 
searches of the National Research Register. A 
study by MacKeith and colleagues was sited at the 
Bristol Royal Infirmary and aimed to evaluate 
wax softening agents used immediately prior 
to de-waxing by microsuction. The outcome 
was the impact of softening agents on the pain 
or discomfort of the procedure. The trial was 
anticipated to end in June 2007 and the trial status 
is shown as completed.
The second study, by Hand and the Suffolk and 
Norfolk Research and Development Consortium 
(SAND), aimed to compare preparations for the 
treatment of symptomatic earwax. No further 
details are provided and the trial was set to end in 
January 2007.
No publication of the trial data for any of the five 
studies has been found so far.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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A
 dverse outcomes that are reported to be 
 associated with the removal of earwax, 
especially from ear irrigation, are well documented 
in the descriptive literature of the condition66–68 
and also in studies reporting litigation and 
compensation claims that are related to earwax 
removal.34,69,70 These include more serious adverse 
events (SAEs), which can be broadly grouped into 
ear infections (otitis externa, otitis media); damage 
to the ear (external auditory canal, perforation 
of TM), various levels of discomfort and noises 
(pain, vertigo, fullness of ear and tinnitus), 
and both temporary and permanent hearing 
impairment.6,67,70 Some literature also suggests that 
people with diabetes may have an increased risk of 
suffering from malignant otitis externa as a result 
of irrigation. This is an infection of the external 
auditory canal and deep periauricular tissues, and 
may progress into skull base osteomyelitis with 
cranial nerve paralysis, and, in rare cases, may 
result in death.71,72
However, despite the perception that there is a 
potential risk from earwax removal there were 
very few serious adverse outcomes reported in the 
RCTs that were identified in the systematic review 
of clinical effectiveness above (see Chapter 3). This 
may be due to factors relating to the study design, 
including small sample sizes and, in many cases, 
the short duration of follow-up. As such, a wider 
search of the literature was undertaken to identify 
any additional studies.
Searching
A targeted search of the literature was undertaken 
to identify additional studies reporting AEs 
associated with the removal of earwax, to assess 
the safety of earwax removal and to inform the 
economic modelling of the problem. The search 
was not restricted by study design. The following 
section complements the clinical effectiveness 
section, reporting overall results from both the 
RCTs identified, and any relevant observational 
studies. No systematic critique of the studies 
was undertaken; however, key methodological 
limitations of the studies are discussed in the 
relevant sections below. In addition, only AEs that 
the study authors attributed to the interventions 
were included. The studies were assessed on an 
ITT basis.
Adverse events from drops 
alone
Four RCTs4,44,50,52 were identified that included 
AEs from using drops alone with no irrigation. 
These RCTs are all critically assessed and data 
extracted in the clinical effectiveness section above 
(see Chapter 3). Two of these RCTs, by Carr and 
Smith52 and Keane and colleagues,4 did not find 
any AEs. The other two RCTs are shown in Table 22. 
One observational study by Midani and colleagues73 
was identified and data is also summarised in 
Table 22. This was an open-label study of Sofenz 
cerumenolytic solution in 109 participants with 
excessive and impacted cerumen. A total of 58 AEs 
were reported, but only 16 were reported to be 
directly related to the treatment.
There were major differences in all of the studies in 
terms of population, drops used, care setting and 
methodologies used. Therefore, no formal meta-
analysis of this data was attempted. However, an 
estimated probability for individually defined AEs 
from relevant studies was generated for illustration. 
An overall probability of an AE occurring was 
also calculated from the studies that included 
AEs as outcomes. Caution is required therefore 
in the interpretation of this data. The ranges 
of AEs reported for each condition and overall 
proportion for all AEs from the studies and the one 
observational study are reported in Table 22.
The overall number of AEs was 43 out of a total 
study population of 407 participants from the 
RCTs and observational study. The probability 
of minor AEs occurring was 10.57%. It is worth 
noting, however, that the probability of AEs may 
be variable depending on the type of drops used. 
The Cerumol arm of the Jaffe and colleagues 
RCT,74 for example, accounts for 13 AEs, whereas 
the arm using Otocerol accounts for a further 
eight AEs out of the total of 43. However, due to 
Chapter 4  
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TABLE 22  Percentage of adverse outcomes due to ear drops alone
Adverse outcome
Overall probability of AEs 
in study population (%)
Range of AEs 
across studies (%) References
Defined AEs from studies
Giddiness 0.94 – Jaffe and Grimshaw50
Pain 2.83 – Jaffe and Grimshaw50
Itchiness/pruritus 2.51 2.00–2.75 Dummer and colleagues,44 Midani and 
colleagues73
Skin irritation/erythema  9.43 4.00–17.92 Jaffe and Grimshaw,50 Midani and 
colleagues,73 Dummer and colleagues44
Oedema 3.67 – Midani and colleagues73
Buzzing 2.00 – Dummer and colleagues44
Other ear disorders 4.59 – Midani and colleagues73
All studies that assessed AEs
10.57 0–17.92% Jaffe and Grimshaw,50 Carr and Smith,52 
Keane and colleaguesa,4 Dummer and 
colleagues,44 Midani and colleagues73
AEs, adverse events.
a  Control arm with no treatment not included.
the heterogeneity of the studies it is not possible 
to draw any reliable conclusions about which drops 
are likely to cause more adverse outcomes than 
others. Based on data available it would seem that 
AEs from drops are relatively rare and tend to be of 
a mild nature.
Adverse events for drops 
and irrigation
An assumption was made that the reporting of AEs 
from drops and irrigation would be split into major 
AEs (those events that would be more likely to 
require additional treatment or resource use), and 
minor AEs (those that were likely to be transient 
and would not require additional treatment).
Major adverse events from 
drops and irrigation
Sixteen RCTs that included AEs as outcomes were 
identified. Three of these RCTs did not explicitly 
state what AEs had occurred and so it was not 
possible to assess whether the AEs were major 
or minor in nature, and so they are discussed 
separately, below. One other study, by Burgess43 was 
excluded because only the number of ears syringed 
were reported and it was not possible to tell how 
many participants were involved in the trial. 
Therefore, 12 RCTs were included.
In addition, two observational studies were 
identified. The first study was a retrospective 
analysis of 2400 patient records from a tinnitus 
clinic in the USA, who had experienced severe 
tinnitus. Eleven participants reported that their 
tinnitus started as a result of cerumen removal. 
However, it was not clear how many of the 2400 
participants with severe tinnitus had actually 
received ear irrigation, and there was no clear 
association between the two events, and so the 
study was excluded.75 The other study76 was a 
large prospective observational study (952 ears 
in 622 subjects) of people attending an ENT 
clinic in Nigeria, who were using drops to soften 
earwax and then undergoing irrigation of the 
ear with a Propulse II irrigation system. The only 
adverse outcomes reported were one participant 
with vertigo and another with a TM perforation. 
No minor AEs were reported. The study was 
undertaken in a different care setting to the UK, 
and the majority of participants were children, 
therefore this may limit the generalisability of the 
studies results. However, the equipment used and 
the ‘wet’ phenotype of cerumen is similar to both 
countries and populations and, as such, the study 
was included.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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As described, the individual RCTs and the one 
observational study results were used to produce a 
probability for individually defined AEs. An overall 
probability of major AEs from drops and irrigation 
was also generated from all studies that included 
AEs as outcomes. Caution is recommended in 
the interpretation of these data. The RCTs were 
also heterogeneous, with reports from a variety of 
settings and using several different types of drops 
and irrigation techniques as active treatments and 
controls. Furthermore, the external validity of 
the Nigerian observational study to a UK context 
requires caution in its interpretation. The ranges of 
AEs reported for all major AE from the studies are 
reported in Table 23.
There were nine occurrences of AEs in a total 
study population of 1515 participants. The overall 
probability of major adverse outcome was therefore 
0.59%. Six of the nine AEs came from the Fraser 
and colleagues study60 (all otitis externa) involving 
124 participants. If this study was excluded then 
the incidence of AEs would drop to 0.22%. This 
would be close to the Sharp and colleagues’6 
estimation a 0.1% incidence of major complications 
based on their otolaryngological unit in Scotland. 
No incidence of tinnitus, otitis media and hearing 
loss were reported in any of the included studies. 
It would seem that major AEs occur relatively 
infrequently, but, given the heterogeneous nature 
of the studies included, this result should be 
interpreted with caution.
Minor adverse events from 
drops and irrigation
The same 12 RCTs that were identified for the 
major AEs section above were all included in this 
section. No observational studies were identified 
reporting rates of minor AEs from the literature 
search. As mentioned above an estimate of the 
probabilities of minor AEs from drops and ear 
irrigation were generated. These need to be treated 
as illustrative only. The ranges of AEs reported for 
each condition and overall proportion for all AEs 
from the studies are reported in Table 24.
There were 128 occurrences of AEs from a total 
study population of 893. Overall, the incidence 
of minor AEs was 14.33% from all the included 
studies. The Coppin and colleagues’ study reported 
108 out of the 128 incidences of AEs.63 The higher 
incidence of AEs in this study, especially for 
discomfort and dizziness suggest a more sensitive 
inclusion of AEs than the other studies.63 One of 
TABLE 23  Proportion of major adverse outcomes due to drops and ear irrigation
Adverse outcome 
Overall probability of AEs 
in study population (%)
Range of AEs 
across studies (%) References
Defined AEs from studies
Tinnitus 0 – No incidence in included studies
Vertigo 0.16 – Ogunleye and Awobem76
Perforated ear drum 0.16 – Ogunleye and Awobem76
Otitis media 0 – No incidence in included studies
Otitis externa  1.94 0.85–4.84 Coppin and colleagues,63 Fraser60
Permanent hearing loss 0 – No incidence in included studies
Temporary hearing loss 0 – No incidence in included studies
All studies that assessed AEs
0.59 0–4.84 Ogunleye and Awobem,76 Coppin 
and colleagues,63 Meehan and 
colleagues,46 Whatley and colleagues,47 
Singer and colleagues,49 Pavlidis and 
Pickering,42 Amjad and Scheer,51 
Lyndon and colleagues,45 Saloranta and 
colleaguesa,58 Roland and colleagues,62 
Fraser,60 Dubow,57 Harris64
AEs, adverse events.
a  Control arm with no treatment not included.Adverse events
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TABLE 24  Proportion of minor adverse outcomes due to drops and ear irrigation
Adverse outcome
Overall probability of AEs 
in study population (%)
Range of AEs 
across studies (%) References
Defined AEs from studies
Pain 20.83 0  Meehan and colleagues46
Itchiness/pruritus 3.01 1.69–4.05 Roland and colleagues,62 Dubow57
Skin irritation/dermatitis 1.94 1.35–2.78 Roland and colleagues,62 Lyndon and 
colleagues,45 Harris64
Dizziness  11.03 3.85–11.81 Pavlidis and Pickering,42 Coppin and 
colleagues63
Discomfort 25.40 1.35–32.91 Roland and colleagues,62 Coppin and 
colleagues63
Ear bleed 1.09 – Whatley and colleagues47
Ear trauma 0.84 – Coppin and colleagues63
All studies that assessed AEs
14.33 0–32.91 Coppin and colleagues,63, Meehan 
and colleagues,46 Whatley and 
colleagues,47 Singer and colleagues,49 
Pavlidis and Pickering,42 Amjad and 
Scheer,51 Lyndon and colleagues,45 
Saloranta and colleaguesa,58 Roland 
and colleagues,62 Fraser,60 Dubow,57 
Harris64
AEs, adverse events.
a  Control arm with no treatment not included.
the arms in the trial was a self-syringing group and 
this may also explain the higher number of AEs 
in the study. If this study was excluded then the 
probability of minor AEs would fall to 3.05% for 
the remaining included studies.
Three further RCTs41,48,61 reported an overall rate 
of AEs but did not define the adverse outcomes 
that had occurred therefore it was not possible to 
determine whether they were major or minor AEs. 
One of these studies, by Hinchcliffe and colleagues, 
reported only the number of ears treated and 
as it was not possible to determine how many 
participants there were in this trial it was excluded. 
There was a total 257 participants in the two 
remaining RCTs.41,48 There were an estimated 21 
AEs (the studies reported AEs only as a percentage 
of each arm with or without AE). This gave an 
overall probability of 8.17% for the occurrence 
of AEs. Another study76 in Nigeria using drops 
to soften earwax, and then irrigation of the ear, 
reported that there were no minor AEs.
The incidence of minor AEs is relatively common 
compared to the major AEs, but it is unclear how 
long many of these AEs last. It is likely, however, 
by their very nature, that they will be relatively 
transient and have little or no impact on resource 
use.
Conclusion
The evidence from the included RCTs and the 
two observational studies suggest that using both 
drops and ear irrigation are safe techniques for 
the removal earwax, with the number of SAEs 
being low. However, some studies may have been 
more sensitive at including AE data than others, 
and in many the length of follow-up was not 
suitable for capturing AEs. These factors and the 
methodological issues noted above (and in Chapter 
3) suggest that care is required before interpreting 
earwax removal techniques as safe procedures. 
The probabilities of more SAEs obtained from this 
simple aggregation technique were not thought 
to be reliable enough to put into the economic 
model. The minor incidence rates were felt unlikely 
to have a major impact on either health-related 
quality of life (HRQoL) or resource use and so were 
also not used.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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T
he aim of this section is to evaluate the cost-
effectiveness of methods of earwax removal. A 
systematic review of the literature was conducted 
to identify economic evaluations on the use of 
softeners with or without irrigation and other 
methods of earwax removal. An economic model 
was then developed to compare different strategies 
to achieve earwax removal. This section will report 
the results of the systematic review, the rationale 
and the components of the economic evaluation, 
including the structure of the model, the sources of 
data on costs and benefits, assumptions underlying 
the model, and results of the analysis.
Systematic review
A systematic review of the literature was undertaken 
to identify economic evaluations considering 
the treatment of earwax. The methods for the 
systematic review are described in Chapter 2. The 
details of the inclusion and exclusion criteria are 
shown in Appendix 1 and the search strategies are 
shown in Appendix 2.
No cost-effectiveness studies were identified that 
met the inclusion criteria for the review.
Southampton Health 
Technology Assessments 
Centre (SHTAC) economic 
analysis
A modelled economic evaluation was undertaken to 
estimate the comparative cost-effectiveness of three 
alternative treatment strategies for earwax removal 
in adults, without any known contraindications to 
the use of softeners or irrigation.
Rationale for the model 
structure
With no nationally accepted guidelines for the 
management of symptomatic earwax in the UK 
(see Chapter 1, Current service provision and 
description of interventions), it was recognised 
that current practice would vary. Reflecting 
such variations in the economic model would be 
difficult, if not impossible. As a consequence a 
simplified model structure was developed using 
information from available practice guidelines, 
other published evidence and expert advice from 
clinicians and other health professionals. The 
model was developed from the NHS perspective, 
with each alternative treatment option involving 
primary care practitioners in diagnosing the 
condition and recommending subsequent 
treatment options.
Three options were considered in the economic 
model with the intention of reflecting current 
practice for the population under consideration 
and possible alternatives. The options considered 
in the model following presentation at primary 
care are (1) use of softening drops (softeners) for a 
week with return to the primary care practice for 
ear irrigation if no spontaneous earwax clearance 
occurs (current standard practice); (2) use of 
softeners for a week followed by self-irrigation 
and return to primary care if unsuccessful for 
professional irrigation; and (3) ‘no treatment’. 
The ‘no treatment’ or ‘do nothing’ option was 
included in the model as a universal comparator. 
It represents a hypothetical situation when no 
treatment is available or offered to the patient 
or the patient decides not to undergo treatment. 
Some anecdotal evidence suggests that some 
primary care practices no longer offer professional 
irrigation, with the suggestion that the condition 
will resolve itself. Details of the treatment strategies 
are provided in Chapter 5 (Model structure).
Population included in the model
The target population includes adults aged 
35–44 years with earwax, who are eligible for any of 
the evaluated treatment alternatives. Patients who 
have a known contraindication for irrigation (such 
as current or pre-existing otitis media, vertigo, 
recurrent ear infection, history of ruptured TM, 
permanent hearing loss, acute illness or fever) 
are considered outside the scope of this economic 
evaluation. Although excessive earwax is more 
prevalent in older age groups, the 35–44 age 
group was selected as this was the group for whom 
evidence of effectiveness was available.
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Perspective of the economic evaluation
As already stated, the perspective of the cost-
effectiveness analysis is predominately that of 
the NHS; however, the out-of-pocket expenses 
on the OTC medications and equipment are 
also included. The out-of-pocket expenditures 
include softeners for all patients undergoing active 
treatments, bulb irrigators for patients choosing 
self-irrigation, and painkillers and antibiotics 
for those patients who had a SAE associated with 
irrigation. These cost items were added to the 
total cost of health-care resources associated with 
the treatment of earwax. However, out-of-pocket 
expenses are relatively small in comparison with 
the cost of resources used at primary and secondary 
care in the treatment of earwax.
Outcomes
Results of the model are reported as incremental 
costs and incremental benefits in terms of 
successful removal of earwax and additional 
quality-adjusted life-years (QALYs), and the 
incremental cost-effectiveness ratio (ICER) 
calculated with respect to ‘no treatment’.
Methods of the economic 
evaluation
Model structure
This section describes in detail the clinical 
pathways associated with each active treatment 
alternative introduced in Chapter 5 (SHTAC 
economic analysis) above. Figure 1 presents the 
structure of the model.
In the base-case scenario it was assumed that 
patients in each of the active treatments follow a 
GP’s advice to apply softeners for 1 week. The use 
of softeners has two advantages: first, the softeners 
assist any subsequent irrigation by softening 
earwax and, second, they facilitate a spontaneous 
earwax clearance in some patients, after which 
no irrigation is required. Use of softeners is 
considered to be the first line of treatment followed 
by irrigation as the second line of treatment. 
Finally, if the earwax is still not removed after 
three rounds of applying softeners and syringing, 
patients may be referred to secondary care for 
removal of earwax by a specialist otolaryngologist 
(OTL). In the first active treatment alternative 
(current or standard practice), patients presenting 
at primary care for earwax treatment are initially 
assessed by a GP (assumption used in the base-case 
analysis) or a nurse (a scenario analysis); they are 
advised to use olive oil or sodium bicarbonate for a 
week and if spontaneous earwax clearance does not 
occur then return to the practice for irrigation. The 
irrigation is administered by a practice nurse using 
an electric irrigator.
Alternatively, in the second active treatment option, 
patients may be advised to apply softeners for a 
week, and if spontaneous earwax clearance has not 
occurred they should proceed with self-irrigation 
using a bulb irrigator, which is available from 
chemists. Patients for whom self-irrigation does not 
result in earwax removal return to primary care 
for a second irrigation. Unlike the first irrigation, 
the second and third irrigations are administered 
professionally by a practice nurse using an electric 
irrigator. The second (and the third, if required) 
irrigation attempts do not require prior assessment 
by a GP.
The base-case scenario includes both active 
treatment alternatives, as well as a conventional ‘no 
treatment’ comparator.
There are no data to estimate the proportion 
of patients given each of the treatment options; 
therefore for the purpose of an economic 
evaluation the treatment strategies listed above 
represent the decision choices available for GPs and 
their patients.
Assumptions used in the model
The economic evaluation does not differentiate 
between patients who present with one or both 
ears occluded. Although this is a simplifying 
assumption, there were no reliable data that would 
allow differentiation of the outcomes with respect 
to unilateral or bilateral presentation of earwax.
While there is a non-zero probability of 
experiencing spontaneous earwax clearance 
associated with the first application of softeners, 
it is not the case for severely impacted and 
hardened earwax. In such instances, spontaneous 
earwax clearance assisted by softeners is unlikely 
to occur. Severely occluding and/or hardened 
earwax may not even be successfully removed 
at the first irrigation attempt at primary care 
and will require a second, and sometimes third, 
round of using softeners followed by irrigation 
in primary care. In such instances it is assumed 
that the use of drops merely facilitates the next 
professionally administered irrigation attempt, and 
is not associated with the probability of achieving a 
spontaneous earwax clearance.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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If the first irrigation attempt was unsuccessful, the 
probability of a successful earwax removal at the 
second and the third irrigation attempt at primary 
care would not depend on whether the first 
irrigation was administered by a practice nurse or 
the patients themselves.
Most patients achieve the desired outcome (earwax 
removal) without a SAE associated with irrigation. 
It is assumed that the use of softeners alone as well 
as the ‘do nothing’ option are not associated with 
a SAE. In the base-case scenario the probability of 
a SAE is assumed to be the same regardless of the 
mode of irrigation (self-irrigation or administered 
by a practice nurse) and whether irrigation is 
undertaken for the first, second or the third time.
The published clinical evidence used to populate 
the model4,63 does not report an incidence of SAEs. 
However, the occurrence of a SAE was viewed as a 
clinically important factor, which can also affect the 
results of an economic evaluation. By including the 
likelihood of a SAE in the model we have effectively 
reduced the benefits that occur following successful 
removal of earwax.4,63
As there are no published estimates of the 
incidence of SAEs associated with irrigation, 
an expert OTL’s opinion was obtained. The 
probability estimate of having a SAE as a result 
of irrigation was based on the observed rate of 
presentation to secondary care for treatment of a 
TM puncture/rupture or a serious ear infection. 
The corresponding assumption used in the model 
is that all the SAE patients are referred and treated 
at secondary care. However, it is possible that some 
patients with a TM puncture/rupture or a serious 
ear infection are monitored and treated by their 
GPs. If this is the case the estimate used in the 
model is an underestimate.
The patients who had a SAE associated with 
irrigation (typically a TM perforation or an 
infection) experience pain and discomfort. 
However, following the experts’ advice it was 
assumed that after 1 week the pain subsides and in 
2 weeks most patients experience a spontaneous 
healing of a TM or resolution of a serious ear 
infection.
As discussed in Chapter 3, irrigation is a fairly 
safe procedure, with only a small proportion of 
patients experiencing minor complications such 
as superficial erythema and dizziness. Minor 
complications are assumed to be short-lasting 
and not significant enough to be associated with a 
measurable decrease in HRQoL or an additional 
use of health-care resources. Therefore, the minor 
complications are not included in the modelled 
economic evaluation. There is paucity of evidence 
on the incidence of more serious and possibly 
lasting complications such as tinnitus. These are 
not included in the modelled economic evaluation.
Apart from the temporary loss of hearing in the 
affected ear(s), there are a few other symptoms 
such as aural fullness, vertigo, itching and tinnitus 
that affect HRQoL of patients being treated 
for earwax problems. However, there are no 
published estimates of utility values associated with 
symptoms other than loss of hearing. Therefore, 
the estimated loss of utility for the model is limited 
to the loss of hearing that was applied to all 
patients until the earwax is cleared. In addition, 
utility decrements are applied to patients who 
experienced a SAE that involves both loss of 
hearing and pain.
Model type and characteristics
We developed an economic model of treatment 
alternatives for a single event of earwax removal. 
A deterministic decision tree (Figure 1) analysis 
was conducted, focusing on binary outcomes 
representing earwax that was removed or not 
removed, with results expressed as incremental cost 
per patient with earwax safely removed. Analysis 
also incorporated loss of utility associated with 
temporary loss of hearing due to occlusion, and for 
pain and loss of hearing due to a SAE, with results 
presented as incremental cost per QALY. The base-
case analysis was conducted in a population aged 
35–44 years, with the corresponding age-adjusted 
utility value of 0.91 (Kind and colleagues77).
Results of the deterministic decision-analytical 
model in terms of QALYs were extrapolated 
to a lifetime horizon (45 years) using an excel 
spreadsheet. The major assumption in these 
calculations was that, according to clinical experts, 
the recurrence rate of earwax is 0.35, which is 
close to one episode occurring every 3 years or 
15 single presentations over the assumed time 
horizon. The age-specific utility values were used 
for the estimated effects (QALYs)77 as the cohort, 
aged 35 years at the baseline, was progressing 
through the different age categories. Both costs 
and outcomes were discounted using a 3.5% 
discounting rate. The calculations also take the UK 
age-adjusted annual mortality rate into account. 
Although the assumption of no treatment over this Economic analysis
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period of time is unlikely to be realistic, the no 
treatment alternative is included in the analysis for 
the purpose of maintaining consistency across all 
stages of an economic analysis. Table 25 presents 
characteristics of the decision-tree model and the 
lifetime extrapolation.
Assessment of uncertainty (sensitivity 
analysis)
A deterministic sensitivity analysis was used to 
address particular areas of uncertainty in the 
model. We investigated the uncertainties around 
the probability estimates that were expected, a 
priori, to have a disproportionate impact on the 
study results.
Scenario analysis was used to address the 
uncertainty associated with some aspects of the 
chosen structure of the model.
Parameter uncertainty is addressed using 
probabilistic sensitivity analysis (PSA). Probability 
distributions are assigned to the point estimates 
used in the base-case analysis. The point estimates 
for treatment effects are reported in Tables 26 
and 27.
The purpose of this analysis was to test the 
robustness of the cost-effectiveness results to 
variation in structural assumptions and parameter 
inputs.
Data sources used in the model
This section of the report describes the inputs 
to the model, provides justification for their use, 
details their respective sources and explains their 
role in the model. The data used in the model have 
been collected from a variety of sources, chosen 
on the basis of appropriateness to the UK and the 
quality of the data as assessed by the reviewers and 
in consultation with clinical experts.
Clinical effectiveness data
As can be seen in Chapter 3, there is limited 
clinical effectiveness data available for the model. 
Two studies can be used: one study of the use of 
softeners alone by Keane and colleagues,4 which 
involved a ‘no treatment’ comparator, and one 
study by Coppin and colleagues,63 which compared 
self-irrigation with irrigation in primary care 
and estimated patient-relevant outcomes. Other 
estimates are from clinical evidence and experts’ 
advice, which suggests that earwax is eventually 
resolved in the majority of patients. Therefore, 
in the base-case analysis both active treatment 
arms are associated with a very high probability 
of successful earwax removal. Table 26 presents 
TABLE 25  Characteristics of the modelled economic evaluation
Type of the model
Treatment alternatives/
pathways Outcome Time horizon Discounting
Deterministic 
decision tree
No treatment
Softeners followed by self-irrigation
Softeners followed by irrigation 
administered by a practice nurse
Binary outcome 
‘earwax removed’ 
(yes/no)
7 weeksa Not applicable
Deterministic 
decision tree
No treatment
Softeners followed by self-irrigation
Softeners followed by irrigation 
administered by a practice nurse
QALY 7 weeksa Not applicable
excel model 
with interactive 
inputs from the 
deterministic 
decision treeb
No treatment
Softeners followed by self-irrigation
Softeners followed by irrigation 
administered by a practice nurse
QALY Lifetime (until the 
baseline cohort 
of 35-year-olds 
reaches the age 
of 80)
3.5% applied to 
both costs and 
outcomes
QALY(s), quality-adjusted life-years; SAE, serious adverse event.
a  Seven weeks is a minimally acceptable time horizon to allow time for up to three presentations at primary care 
for irrigation, which, including the first week of using softeners, takes 4 weeks, and may be followed by 2 weeks of 
monitoring a SAE and at least 1 week to include the outcomes of a hospital admission of the patients for whom a SAE 
was not resolved.
b  The base-case calculations were repeated four times using the age-adjusted utility values77 to obtain age-adjusted 
estimates of QALYs for each of the treatment alternatives.Economic analysis
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TABLE 26  Estimates of clinical effectiveness used in the base-case analysis
Treatment alternatives 
including ‘no treatment’ 
option
Probability of earwax 
removed (range used 
in the sensitivity 
analysis)a Source Comments
No treatment (spontaneous 
earwax removal)
0.05 (0.035–0.065) bKeane and 
colleagues, 19954
The outcomes were assessed on an 
ordinal scale with three categories: 
‘impacted’, ‘moderately clear’ and 
‘completely clear’. The model outcome 
‘earwax removed’ corresponds to the 
‘completely clear’ (of wax) outcome in 
Keane and colleagues4
Use of softeners preceding 
irrigation at primary care
0.20 (0.14–0.26) bKeane and 
colleagues, 19954
Softeners followed by self-
irrigation
0.48 (0.34–0.62)  Coppin and 
colleagues, 
200763
The outcomes were initially assessed 
on an ordinal 4-point scale assessing the 
degree of obstruction of the membrane 
(see Chapter 3, Research in progress). 
Coppin and colleagues63 reported a 
binary outcome of the degree of wax 
clearance. The model outcome ‘earwax 
removed’ corresponds to the combined 
scores of 0 (no or minimum wax with 
TM fully visible) and 1 (minor amount of 
wax with TM essentially visible)
Softeners followed by 
irrigation administered by 
nurse at primary care
0.62c (0.43–0.81) Coppin and 
colleagues, 
200763
Second irrigation – at primary 
care
0.805 (0.69–0.91) Linear 
extrapolation
Third irrigation – at primary 
care
0.99 (0.95–1.0) Expert advice Remaining patients assumed to undergo 
de-waxing in secondary care
Successful de-waxing at 
secondary care without SAE
0.97 (0.8–1.0) Pothier and 
colleagues, 
200656
SAE, serious adverse event; TM, tympanic membrane.
a  The range of estimates used in the sensitivity analysis was calculated by varying the point estimate by 30%.
b  The outcomes were originally reported with respect to number of impacted ears and were subsequently converted 
into the outcomes with respect to patients.
c  In total, 14% of patients in softeners and nurse irrigation arm were lost to follow-up in the Coppin and colleagues63 
study. It is reasonable to assume that patients did not present for the professionally administered irrigation because 
the earwax was resolved after application of softeners.
probability estimates of clinical effectiveness and 
Table 27 presents probabilities associated with a 
SAE used in the model.
Health states/utilities
A systematic literature search did not result in 
any published estimates of utility loss due to 
symptomatic earwax. As discussed in Chapter 5 
(Assumptions used in the model), reduction in 
the quality of life associated with the range of 
symptoms caused by impacted earwax is limited to 
the loss of hearing and, for the small proportion of 
patients experiencing SAE, to the loss of hearing 
and pain. A targeted literature search identified 
some published utility decrements associated 
with the loss of hearing due to reasons other than 
symptomatic earwax. Table 28 presents the results.
One study78 reports utility decrement of 0.006 
derived from patients with a range of conditions 
that result in mild to severe hearing loss 
[International Classification of Diseases, Ninth Edition, 
Clinical Modification (ICD-9-CM) diagnosis 
code 389], which can be used for an estimate of 
temporary hearing loss. The other study79 reports 
a utility gain associated with hearing improvement 
due to provision of a hearing aid. In this study 
the mean postintervention changes in European 
Quality of Life-5 Dimensions (EQ-5D) and Short 
Form-6 Dimensions (SF-6D) were similar, although 
the change in mean utility scores assessed by EQ-
5D was not statistically different from zero. The 
mean utility score assessed by Health Utilities 
Index (HUI)3 demonstrated a significantly 
higher improvement of 0.06. As there is only a 
limited understanding of the degree of hearing 
loss associated with symptomatic earwax, it is not 
certain whether the estimates of utility gain due to 
the provision of hearing aid is comparable with the 
utility gain associated with earwax removal.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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TABLE 27  Base-case analysis probabilities associated with a SAE
Event/treatment
Probability of event/
treatment (range used 
in sensitivity analysis) Source Comments
SAE associated with irrigation 
administered by nurse at 
primary care
0.0006 (0.0003–0.0009) Expert advice The base-case estimate is based on 11 SAEs 
observed in secondary care, servicing the 
population of 300,000a
The upper limit in the range is based on 18 
SAEs observed annually in secondary care, 
servicing a population of 280,000a
SAE associated with self-
irrigation 
0.0006 (0.0003–0.0009) Expert advice Assumed to be the same as the probability 
of SAE in primary care
Hospital admission for either 
myringoplasty or treatment of 
a serious infection
0.05 (0.035–0.065) Expert advice
Probability of partial 
permanent hearing loss if 
myringoplasty is only partially 
successful
0.25 (0.18–0.33) Expert advice
Proportion of patients with 
TM perforation in the total 
number of patients with SAE
0.333 (0.23–0.43) Expert advice There are two types of SAE: a TM 
perforation and a serious ear infection. 
These SAEs differ with respect to treatment 
pathways and costs
SAE(s), serious adverse event(s); TM, tympanic membrane.
a  The following assumptions were made in the calculation of the estimated rate of SAEs: the incidence of symptomatic 
earwax is 8%7 and 80% of the population with earwax require irrigation.
TABLE 28  Published utility decrements associated with the loss of hearing
Source
Characteristics 
of the population Method
Disutility value 
(standard 
error)
Degree of 
the hearing 
loss Comments
Sullivan and 
Ghushchyan, 
200678
N = 320;
USA patients with 
the ICD-9-CM 389 
conditiona
SF-12 
converted 
into EQ-5D
0.006 (0.0001) As defined by 
the ICD-9-
CM diagnosis 
code 389
The disutility estimate 
represents the marginal 
decrement in EQ-5D index 
scores after controlling for 
age, comorbidity, gender, race 
ethnicity income and education
Barton and 
colleagues, 
200479
N = 609
UK patients with 
mean age of 68.4 
who are eligible for a 
hearing aid
HUI3, SF-6D 
and EQ-5D
0.06,b 0.014,b 
0.005,b 
respectively
Not reported
EQ-5D, European Quality of Life-5 Dimensions; HUI, Health Utilities Index; ICD-9-CM, International Classification of 
Diseases, Ninth Edition, Clinical Modification; SF-12, Short Form-12 items; SF-6D, Short Form-6 Dimensions
a  The regression analysis with EQ-5D as a dependent variable was conducted on the much larger sample involving 
patients with the range of ICD-9-CM conditions.
b  Assessed by comparing utility score before and after fitting hearing aids.
Table 29 shows the utility values used in the model 
for each health state in the cohort of 35- to 44-year-
old patients presented at baseline with earwax. The 
age-specific population norm for the cohort of 35- 
to 44-year-old patients is 0.91.77 In the base-case 
analysis the disutility value of 0.006 for the loss of 
hearing and the disutility value of 0.012 for the 
duration of SAE were used as, according to expert 
opinion, these estimates correspond to the loss of 
quality of life associated with symptomatic earwax. 
It should be noted that the experts were informed 
of the disutility value when asked to estimate the 
impact of a SAE on utility; therefore, this value was 
not obtained independent of the 0.006 disutility. Economic analysis
64
TABLE 29  Utility values used for each health state in the model
Health state Utility Source Time interval to which utility applies
Earwax causing temporary loss 
of hearing
0.904 Sullivan and Ghushchyan, 
200678
From the baseline and until earwax is 
removed and hearing restored
Earwax removed/hearing 
restored
0.910 Kind and colleagues, 
199977
Applies at the point of a successful earwax 
removal and until the exit from the model
SAE (serious infection and TM 
perforation)
0.898 Expert advice Applies for 2 weeks from the SAE onset
Permanent slight loss of 
hearing as a result of TM 
perforation
0.904 Assumption Applies for life to the 25% of patients for 
whom myringoplasty was not completely 
successful
SAE, serious adverse event; TM, tympanic membrane.
TABLE 30  Health-care resource use associated with earwax treatment at primary care
Resource
Amount 
used
 Unit cost (£) 
(2006–7 prices) Source Cost (£)
Pharmaceuticals (not NHS cost borne by patients)
Softeners – olive oil 10 ml 0.73 NHS electronic drug tariffa 0.73
Equipment and consumables
Electric irrigator (Propulse III) 
used for irrigation at primary 
care
1 item 78.99 (excluding 
VAT)
www.medisave.co.uk/
instruments-ear-
syringe-c-240 241.html 
(price was valid until 
September 2008)
2 × 78.99/2000 = 0.08a
Cleansing tablets for electric 
irrigator (assuming the 
machine is cleaned after each 
application)
1 pack × 200 20 (including 
postage)
Expert advice (based on the 
actual primary care practice 
expenditures)
20/200 = 0.1
Cost of annual services of an 
irrigator
Annually 60 Expert advice  2 × 60/2000 = 0.06a
Disposable jet tips for an 
electric irrigator
1 pack  100 44.00  www.medisave.co.uk/
instruments-ear-
syringe-c-240 241.html
44/100 = 0.44
Otoscope (including bulbs) 1 item 319.00 Expert advice (assumed 4 
years of use)
319/4000 = 0.08a
Disposable tips for an otoscope  1 pack × 850 47.00 (including 
postage)
Expert advice 47/850 = 0.056
Head torch (including bulbs) 1 item 60 Expert advice (assumed to 
be replaced annually)
60/1000 = 0.06
Other disposable and non-
disposable equipment (e.g. 
Noots Tank, Propulse 
reservoir, Jobson-Horne probe, 
capes)
Various N/A Uppal and colleagues80 
(adjusted for 2006/07 
prices)
2.12
(A) Subtotal: equipment and consumables 3.00
Staff cost
GP consultation (primary 
assessment) 
5 minutes 2.90 per minute PSSRU,81 expert advice 14.50 
(B) GP consultation + 20% clinical staff overhead80 17.40
GP SAE – related consultation 
(referral to secondary care)
15 minutes 2.90 per minute PSSRU,81 expert advice 43.50DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Resource
Amount 
used
 Unit cost (£) 
(2006–7 prices) Source Cost (£)
(C) GP SAE – related consultation + 20% clinical staff overhead80 52.2
Practice nurse consultation 15 minutes 0.383 per minute PSSRU,81 expert advice 8.00
(D) Practice nurse consultation + 20% clinical staff overheads80 9.6
Subtotal
Direct clinical cost of GP initial assessment 17.40
Direct clinical cost of GP referral and follow-up (used in self-irrigation with SAE) 52.2 × 2 = 104.4
Direct clinical cost of nurse session (used in the second and third irrigation episode) 9.6
Direct clinical cost of earwax treatment without SAE 30.0 = [(A) + (B) + (D)]
Direct clinical cost of earwax treatment with SAE 134.4 = [(A) + (B) +  
(D) + 2 × (C)]
Total costs (direct, indirect and private patient costs)a
Cost of GP assessment 22.62
GP referral and follow-up only (used in self-irrigation-related SAE) 136.45b
Nurse session (used in the second and third irrigation) 12.48
Earwax treatment without SAE 39.70b
Earwax treatment with SAE (includes one GP referral one follow-up) 175.40b
N/A, not applicable; PSSRU, Personal Social Services Research Unit; SAE, serious adverse event;  VAT, value added tax.
a  The total cost includes direct and indirect costs. Indirect costs such as estates, domestics and non-clinical personnel 
are assumed to be 30% of direct cost.80
b  Includes the cost of softeners = £0.73 (paid by the patients).
TABLE 30  Health-care resource use associated with earwax treatment at primary care (continued)
The HUI3 value reported in the study of Barton 
and colleagues79 was used in the scenario analysis.
Assuming that the life expectancy of a person of 
35 years of age is 45 years, the disutility value 
of 0.006,78 if assessed using the time trade-off 
method, would correspond to a half year of life 
traded for the symptomatic earwax being removed. 
By implication the disutility value of 0.0679 would 
correspond to 5 years of life traded for living 
without symptomatic earwax.
Resource use and cost data
As the analysis reflects an NHS perspective, UK 
specific resource use and costing data have been 
used where available. Cost data were obtained from 
a number of primary and secondary sources.
Table 30 shows categories of health-care resource 
use, the amount used, the unit prices and the 
associated cost of earwax presentation at primary 
care.
The following assumptions were made in 
calculating the costs:
•  With respect to the cost of electric irrigator per 
patient (£0.08), the estimated annual number 
of patients presenting with earwax problems at 
the typical primary care practice was assumed 
to be about 1000. This was based on the mean 
number of three presentations per day. It was 
assumed that two electronic irrigators in use in 
the typical primary care practice (2 × £78.99) 
are replaced every 2 years during which time 
about 2000 patients are treated for earwax.
•  With respect to the cost of a nurse consultation 
(an ear irrigation session), the estimated 
average nurse time is an arithmetic mean 
between 10 minutes that are typically spent 
on irrigating one ear and 20 minutes spent 
on irrigating both ears. See Chapter 5 
(Assumptions used in the model), which 
outlines assumptions of the model.
Different cost components are used in the 
model depending on the treatment option and 
the patients’ progression along the alternative 
treatment pathways as depicted in the decision tree 
(Figure 1). The ‘no prescription’ option is associated Economic analysis
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only with the cost of an initial assessment 
conducted either by a GP (base-case analysis) or 
a nurse (scenario analysis). Treatment of patients 
who applied softeners following consultation at the 
primary care practice and achieved a spontaneous 
earwax removal is associated with the cost of 
initial assessment and the cost of softeners (e.g. 
£22.62 + £0.73 = £23.35). Those patients who 
achieve clearance following a single professional 
irrigation at primary care incur the cost of the 
initial assessment, the softener cost and the cost 
of the irrigation administered by a practice nurse 
(£39.70 = earwax treatment without SAE in Table 
30). Those patients suffering an AE incur, in 
addition to the above costs, a GP consultation in 
order to refer the patient to secondary care (OTL) 
and a follow-up consultation (£175.40 = earwax 
treatment with SAE in Table 30). Both consultations 
are assumed to take 15 minutes of GP time. The 
exact same costing process is followed for the 
second and third attempts at syringing in primary 
care, if required.
Table 31 shows the category of health-care 
resources associated with self-irrigation at home. 
Patients self-irrigating at home incur the cost of 
an initial consultation in primary care, the cost of 
softeners and a bulb irrigator. For those patients 
experiencing spontaneous clearing of earwax the 
costs include the cost of initial assessment and 
the cost of softeners only. Patients who are not 
TABLE 31  Health-care resources associated with self-irrigation at home
Resource
Amount 
used
Unit cost (£) 
(2006–7 prices) Source Cost (£)
GP consultation (primary assessment)
GP consultation including 
20% staff overheads and 30% 
indirect cost
5 minutes 2.90 per minute PSSRU, expert 
advice
22.62
Pharmaceuticals
Softeners – olive oil 10 ml 0.73 NHS electronic 
drug tariffa
0.73
Equipment
Bulb irrigator (25 ml) 1 itemb 5.99 Online costc 5.99
Total cost of earwax self-irrigation 22.62 + 0.73 + 5.99 = 29.34
a  Available at: www.ppa.org.uk/edt/September_2008/mindex.htm (last accessed on 28 May 2008).
b  With recurrent rate of earwax of 0.35 (expert advice), the shelf-life of a bulb irrigator should be about 3 years, to be 
used more than once, which may not be a realistic assumption. Therefore, the total cost of a bulb irrigator is included 
in the calculations.
c  http://shop.ypproducts.co.uk/acatalog/Enemas_Tubes.html (last accessed on 28 May 2008).
successful at self-irrigation are assumed to present 
at primary care for the second and, if necessary, 
third irrigation that is administered by a practice 
nurse. Subsequent costs are incurred as per the 
option for attending primary care for syringing.
Table 32 shows the health-care resources used for 
dewaxing and treating SAE in secondary care.
Patients presenting at secondary care for treatment-
related SAEs incur additional costs. As discussed 
above, two categories of SAE were included in the 
economic evaluation: TM perforation and serious 
infection. Following expert advice, all patients with 
SAEs experience pain and need to use painkillers 
for 1 week, incurring the associated cost. In 
addition, all patients with serious infection are 
prescribed antibiotics for 2 weeks, incurring the 
cost.
Treatment for SAEs by an OTL consists of initial 
and follow-up appointments, with a series of 
investigations (Table 32). Those treated on an 
outpatient basis require either two presentations 
for treatment of TM or four presentations for 
treatment of a serious infection. Those patients 
requiring hospital admission (5% of those referred 
to the OTL) for myringoplasty (surgical treatment 
of TM perforation) require on average either a day-
case admission or an overnight admission, while a 
serious ear infection requires, on average, a 2-day DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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TABLE 32  Health-care resources used in de-waxing and treating a SAE
Resource
Amount 
used
Unit cost (£) 
(2006–7 prices) Source Total cost (£) (comments)
Pharmaceuticals
Analgesics, paracetamol 
500 mg
32 tablets 0.69 NHS electronic 
drug tariffa
0.69 (applied to 100% of TM 
perforation patients assuming 1–2 
tablets, 3 times per day, for 7 days)
Antibiotics, ofloxacin 
200 mg
10 5.51 NHS electronic 
drug tariffa
5.51 (applied to 100% of serious 
infection patients)
Antibiotic/steroid ear drops 
–clioquinol 1%/flumetasone 
0.02%
7.5 ml 1.47 NHS electronic 
drug tariffa
1.47 (applied to 18% of SAE patients 
whom Hussain82 used in scenario 
analysis)
Investigations
The total cost of 
investigations, such as 
audiometry, ear swabs for 
culture and sensitivity
N/A N/A Uppal and 
colleagues80 
(adjusted for 
2006–7 prices)
42.40 (applied to 100% of SAE patients)
The total cost of a new and 
the follow-up appointments
Various N/A Uppal and 
colleagues80 
(adjusted for 
2006–7 prices)
170.7b (applied to 100% of SAE patients)
Myringoplasty = minor ear 
procedure without CC (day 
case CZ08Y) 
N/A 705 DHSc 705 (applied to 5% of SAE patients in 
the model who were referred to OTL)
Hospital admission 
for a serious infection 
treatment = intermediate 
ear procedure without CC
1377 DHSc 1377 (applied to 5% of SAE patients in 
the model patients who were referred 
to OTL)
Total cost of OTL treatment
De-waxing without a SAE 170.7
Treatment of serious infection without hospital admissiond 42.4 + (2 × 170.7) + 5.51 + 
(0.18 × 1.47) = 389.57
Treatment of serious infection with hospital admission 42.4 + (2 × 170.7) + 1377 + 5.51 + 
(0.18 × 1.47) = 1766.57
Treatment of TM perforation without surgeryd 42.4 + (4 × 170.7) + 0.69 = 725.89
Treatment of TM perforation with surgery 42.4 + (4 × 170.7) + 705 + 0.69 = 1430.89
CC, complications and comorbidities; N/A, not applicable; OTL, otolaryngologist; SAE, serious adverse event; TM, 
tympanic membrane.
a  Available at: www.ppa.org.uk/edt/September_2008/mindex.htm (last accessed on 28 May 2008).
b  This includes clinical staff cost, overheads, equipment and indirect costs.
c  National Schedule of Reference Costs 2006–7: NHS Trusts. Available via www.dh.gov.uk/en/Publicationsandstatistics/
Publications/PublicationsPolicyAndGuidance/DH_082571 (last accessed on 28 May 2008).
d  According to the experts, a TM perforation involves four presentations to secondary care, whereas a serious 
infection requires two presentations.
hospital admission (expert opinion). The total 
secondary care cost of treating a TM perforation 
without admission is higher than that for a serious 
infection. In contrast, if a patient is admitted 
to hospital the cost of treatment of a serious 
infection becomes more expensive than for a TM 
perforation.
Base-case results of a single 
presentation model
Results of the base-case deterministic decision 
analysis of alternative approaches to earwax 
removal are presented in Table 33. The results 
are reported in terms of incremental costs and 
incremental gains: a gain in likelihood of earwax 
being successfully removed and additional QALYs. Economic analysis
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TABLE 33  Base-case cost-effectiveness results comparing ‘no treatment’ alternative with softeners followed by self-irrigation and 
softeners followed by professional irrigation
Treatment 
alternative
Cost (£) 
(2006–7 
prices)
Probability of 
earwax being 
removed at the end 
of the seventh week
Incremental
cost per 
successfully 
treated patienta QALYs
Incremental cost 
per QALY
(ICER)a
No treatment 22.62 0.05 – 0.121727 –
Softeners followed 
by self-irrigation
37.28 0.999977 14.66 0.122327 24,433
Softeners followed 
by irrigation at 
primary care
42.38 0.999983 19.76 0.122342 32,130
ICER, incremental cost-effectiveness ratio; QALY(s), quality-adjusted life-year(s).
a  ICER are calculated with respect to the comparator – ‘no treatment’.
Table 33 shows results of the base-case analysis 
using a deterministic decision-analytic model with 
a 7-week time horizon. The ICER is calculated 
with respect to the conventional comparator ‘no 
treatment’.
In comparison with the ‘no treatment’ option, 
the additional cost of successful treatment of a 
patient with an earwax problem is £14.66 for the 
alternative beginning with the use of softeners 
and self-irrigation, and £19.76 for the alternative 
beginning with the use of softeners followed 
by irrigation at primary care. However, when 
two active treatment options are compared, the 
incremental cost of treating an additional patient 
with softeners followed by professional irrigation, 
as opposed to treating with a combination of 
softeners and self-irrigation, is about £850,000 
per successful earwax removal. With the additional 
QALY gain of only 0.000015, this gives an ICER of 
£340,000 per QALY. This is because the additional 
gain associated with the option of softeners 
followed by irrigation at primary care is small, 
at 0.000006, or 6 additional patients in every 
1,000,000 patients treated for earwax problems.
Both active treatment alternatives are associated 
with a very high probability of achieving an 
outcome (i.e. earwax removal), which, for all 
practical purposes, is not different from 1.0 (i.e. 
virtual certainty). Therefore, the above results 
can be interpreted within a cost-minimisation 
framework, which demonstrated that the same 
outcome can be achieved at a lesser cost if patients 
use softeners first, followed by self-irrigation, 
and present at primary care only if self-irrigation 
did not result in earwax removal. However, as 
further discussed in Chapter 7, the self-irrigation 
alternative may not be appropriate for every 
patient presenting at primary care with an earwax 
problem.
Although it was assumed in the base-case scenario 
that the probability of SAE in both active treatment 
alternatives is the same, there was no published 
clinical evidence to support this assumption. 
Neither was there consensus between the experts 
who provided feedback on the results of this study. 
Some clinical experts consider self-irrigation using 
a soft rubber bulb irrigator to be a completely 
safe alternative to the current practice involving 
professional irrigation. However, one expert 
advised that although a TM puncture is unlikely 
to occur when a soft rubber bulb irrigator is used, 
self-irrigation may not necessarily exclude the 
probability of having a SAE, such as displacing the 
ear drum and exerting traumatic pressure on the 
inner ear.
Two principal factors contributed to the base-case 
results: the difference in the estimated clinical 
effectiveness between the two active treatment 
options as reported by Coppin and colleagues63 
(0.42 versus 0.68) and a small incremental gain in 
terms of QALYs. This was not surprising, given that 
in the base-case analysis the size of the disutility 
associated with hearing loss was only 0.006.78 These 
and other parameter uncertainties are explored 
in the univariate and bivariate sensitivity analyses 
reported in Chapter 5 (Deterministic sensitivity 
analysis).
Lifetime extrapolation of 
results of a single presentation 
modelling
Table 34 shows the results of the lifetime 
extrapolation of the outcomes of the modelling of DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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TABLE 34  Lifetime cost-effectiveness results comparing softeners followed by self-irrigation and softeners followed by professional 
irrigation (in 2006–7 prices)
Treatment alternatives No treatment
Softeners followed by 
self-irrigation
Softeners followed by 
irrigation at primary care
Total discounted cost (£)a 178.85 294.84 335.17
Total discounted QALYsa 20.671636 20.676380 20.676500
Incremental cost (£)b – 115.99 156.32
Incremental effectb – 0.004744 0.004864
ICER (£/QALY)b £24,450 £32,136
ICER, incremental cost-effectiveness ratio; QALY(s), quality-adjusted life-year(s).
a  Both lifetime cost and QALY estimates were adjusted for all-cause mortality.
b  Calculated with respect to the comparator ‘no treatment’.
a single presentation with an earwax problem in 
2006–7 prices.
In comparison with no treatment, the difference 
in total discounted cost over 45 years is £116 for 
the treatment alternative involving self-irrigation 
and £156 for the treatment alternative involving 
professional irrigation. The corresponding 
discounted QALY gains are 0.004744 and 0.004864 
for self-irrigation and the professional irrigation 
treatment alternatives, respectively. This translates 
into the estimated ICER of about £24,450 per 
QALY for the treatment alternative involving self-
irrigation and £32,136 per QALY for the treatment 
alternative involving professional irrigation. The 
slight difference between base-case results and 
lifetime model results is due to rounding error in 
the very small effect differences between the three 
treatment pathways. When two active treatments 
are compared with each other the incremental cost 
of £40.30 and incremental QALY of 0.0001202 
resulted in the ICER of more than £335,000.
Deterministic sensitivity analysis
Table 35 shows the variables that were included in 
the sensitivity analyses.
1.  In the first sensitivity analysis the rate of AEs 
associated with irrigation administered by a 
practice nurse at primary care was kept at the 
same level as in the base-case analysis, while 
the rate of SAE associated with self-irrigation 
was increased until it reached the level at which 
the treatment alternative of softeners followed 
by irrigation at primary care became more cost-
effective in terms of QALYs.
2.  In the second sensitivity analysis both clinical 
effectiveness estimates associated with active 
treatments were altered, with the clinical 
effectiveness of self-irrigation decreasing 
and irrigation administered by a practice 
nurse increasing until the combination of the 
parameter values reached the level at which the 
alternative associated with self-irrigation was 
dominated by softeners followed by irrigation 
administered by a practice nurse at primary 
care.
3.  In the remaining sensitivity analyses the model 
parameters were varied as indicated in Table 35.
Table 36 shows results of the sensitivity analyses.
The threshold analysis indicated that the results 
of a base-case scenario (a single event model) are 
robust to the small variations in the probability of 
SAE associated with self-irrigation. The probability 
of a SAE associated with self-irrigation needs to be 
increased approximately 10 times from the base-
case value of 0.0006 to 0.00596 (while maintaining 
the probability of SAE associated with professional 
irrigation at the baseline level) before the 
treatment alternative associated with self-irrigation 
became dominated by the treatment alternative 
involving irrigation at primary care.
The threshold analysis indicated that the results are 
also robust with respect to the small variations in 
clinical effectiveness parameters (the probability of 
earwax removed). The cost of treatment involving 
self-irrigation remains less expensive, albeit 
fractionally less effective, until the probability of 
successful earwax removal using self-irrigation is 
decreased from 0.48 in the base case to 0.25 (ie. 
assumed to be two times less effective), while the 
probability of successful earwax removal using 
professional irrigation is increased from 0.62 
to 0.92. When both extreme values are used in Economic analysis
70
TABLE 35  Variables included in the sensitivity analyse
Variable(s)
Base-case point estimate (range 
tested in the sensitivity analysis) Type of analysis
1. Probability of SAE 
associated with self-
irrigation was varied
0.0006 (0.0006–0.059) Bivariate threshold analysis to identify the SAE value 
associated with softeners and self-irrigation being 
dominated by softeners and irrigation at primary care
2.Clinical effectiveness 
of self-syringing
0.48 (0.15–0.25)  Threshold analysis to identify the clinical effectiveness 
values associated with softeners and self-irrigation being 
dominated by softeners and irrigation at primary care
3. Clinical effectiveness 
of irrigation at 
primary care
0.62 (0.60–95) Threshold analysis to identify the clinical effectiveness 
values associated with softeners and self-irrigation being 
dominated by softeners and irrigation at primary care
4. Clinical effectiveness 
of softeners 
0.2 (0.01–0.5) Univariate analysis
5. Cost of self-irrigation 
(including softeners)
6.72 (2.00–9.00) Univariate analysis
SAE, serious adverse event.
the base-case analysis, the treatment alternative 
involving self-irrigation is dominated by the 
treatment alternative involving irrigation at 
primary care.
Results of the one-way sensitivity analysis indicated 
that the outcomes are sensitive to the variation 
in the rate of successful earwax removal from the 
use of softeners. When the clinical effectiveness 
of the use of softeners increased from 0.01 to 0.5 
the ICER decreased by about two times in both 
the active treatment arm in comparison to the 
‘no treatment’ alternative. The ICER comparing 
softeners followed by irrigation at primary care 
remained unacceptably high when compared 
with treatment associated with self-irrigation 
(ICER = £329,098 per QALY at the value of clinical 
effectiveness of softeners equal to 0.5).
Results of the one-way sensitivity analysis indicated 
that the outcomes are not very sensitive to the 
variation in the cost of self-irrigation. When the 
cost was varied from £2.00 to £9.00 the ICER 
comparing treatment involving self-irrigation to 
no treatment changed from around £19,000 per 
QALY to almost £28,500 per QALY compared 
with the base-case estimate of ICER £24,433 per 
QALY. The ICER comparing softeners followed by 
irrigation at primary care remained unacceptably 
high when compared to treatment associated with 
self-irrigation (ICER = £534,933 per QALY at the 
cost of self-irrigation of £2; ICER = £173,819 per 
QALY at the cost of self-irrigation of £9.00).
Scenario analyses
Two scenario analyses were undertaken. In the 
first it was no longer assumed that a GP conducts 
the first assessment of patients presenting with 
an earwax problem; instead, the patients from all 
treatment arms were assessed by a nurse. In the 
second scenario analysis, as discussed in Chapter 5 
(Health states/utilities) the estimate of a disutility 
value associated with the loss of hearing was taken 
from the study by Barton and colleagues,79 which 
used a HUI3 quality-of-life assessment tool.
By substituting a GP assessment cost with a 
nurse assessment cost, the total cost of earwax 
treatment without SAE at primary care decreased 
from £39.70 to £29.60. The latter estimate 
comprised the costs of softeners (£0.73) and initial 
assessment by a nurse (£12.48), followed by the 
cost of a professional irrigation session (£16.38). 
No changes in the GPs’ involvement in treating 
patients with SAE were assumed. Table 37 shows the 
results of this scenario analysis.
Reduction in the cost of assessment resulted 
in a reduction of the total cost of all treatment 
alternatives. However, the incremental costs in 
comparison with the ‘no treatment’ alternative have 
not changed significantly when translating into the 
ICER values, which are not substantially different 
from the base-case analysis results. When two active 
treatment options are compared, the estimated 
ICER is £462,670 per QALY, which is higher than 
the £340,000 per QALY in the base-case analysis. DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 38  Results of the scenario analysis assuming that the disutility associated with the loss of hearing is 0.06 rather than 0.006, as 
assumed in the base-case analysis
Treatment 
alternative
Cost (£) 
(2006–7 
prices)
Probability of earwax 
being removed at the 
end of the seventh 
week
Incremental cost 
per successfully 
treated patienta QALYs
Cost per QALY 
(ICER)a
No treatment 22.62 No change – 0.114769 –
Softeners followed 
by self-irrigation
37.28 No change No change 0.120768 2444
Softeners followed 
by irrigation at 
primary care
42.38 No change No change 0.120923 3211
ICER, incremental cost-effectiveness ratio; QALY(s), quality-adjusted life-year(s).
a  ICER is calculated with respect to the comparator – ‘no treatment’.
TABLE 37  Results of the scenario analysis of comparing ‘no treatment’ with two active treatment alternatives, while assuming the 
reduced cost of irrigation at primary care
Treatment 
alternative
Cost (£) 
(2006–7 
prices)
Probability of 
earwax being 
removed at the end 
of the seventh week
Incremental 
cost per 
successfully 
treated patienta QALYs
Incremental 
cost per QALY 
(ICER)a
No treatment 12.48 0.05 – 0.121727 –
Softeners followed 
by self-irrigation
27.53 0.999977 15.05 0.122327 25,083
Softeners followed 
by irrigation at 
primary care
34.70 0.999983 22.22 0.122342 36,130
ICER, incremental cost-effectiveness ratio; QALY(s), quality-adjusted life-year(s).
a  ICER is calculated with respect to the comparator – ‘no treatment’.
This is because the differences in cost between 
two active treatments increased from £5.10 in the 
base-case analysis to £7.17 in the scenario analysis, 
rendering the less expensive treatment strategy 
involving self-irrigation more cost-effective relative 
to strategy based solely on professional irrigation.
Table 38 shows the results of the second scenario 
analysis using the disutility values from Barton and 
colleagues.79
When the disutility associated with the loss 
of hearing is assumed to be 0.06 (Barton and 
colleagues)79 or 10 times higher than the disutility 
estimate assumed in the base-case analysis, 
the ICER gained is substantially reduced for 
either of the active treatment alternatives when 
compared with no treatment. When these options 
are compared with each other the ICER is about 
£32,910 per QALY. The large difference between 
the ICER estimates in the base case and the 
scenario analysis is explained by the nature of the 
measurement instruments. Barton and colleagues79 
commented that, unlike the EQ-5D, the HUI3 
explicitly asks about a person’s capability to hear, 
and therefore it is not surprising that people 
with impaired hearing have lower levels of utility 
according to the HUI3 than according to the 
EQ-5D and SF-6D. Other studies on the clinical 
effectiveness and cost-effectiveness of digital 
hearing aids have identified similar differences.83
Probabilistic sensitivity analysis
Table 39 reports the mean costs and outcomes from 
the PSA of results of a single presentation model. 
The PSA generated cost and QALY estimates for 
each active treatment alternative that were similar 
to those for the base-case analysis (see Table 33 for 
base-case analysis). Variables included in the PSA, 
distributions and parameters of distributions used 
can be seen in Appendix 7.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 39  Probabilistic sensitivity analysis (single presentation)
Treatment alternative Mean cost (£)  SD Mean effects (QALY) SD
No treatment 22.62 2.3 0.121727 0.000014
Softeners followed by self-
irrigation
37.20 2.6 0.122327 0.000011
Softeners followed by 
irrigation at primary care
42.30 3.6 0.122342 0.000009
SD, standard deviation; QALY, quality-adjusted life-year.
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FIGURE 2  Cost-effectiveness acceptability curves comparing no treatment, softeners followed by irrigation and softeners followed by 
self-irrigation.
Figure 2 shows the cost-effectiveness acceptability 
curves for all alternative treatments. The chart 
indicates the probability that a given treatment 
option is optimal compared with the alternatives. 
This suggests that a ‘no treatment’ option is a 
cost-effective option at lower threshold levels 
of willingness-to-pay for health outcomes 
(QALYs). At the threshold above £30,000 per 
QALY, the treatment involving self-irrigation 
becomes more likely an optimal option among 
the three alternative treatments. As the threshold 
is increased, softeners followed by irrigation 
at primary care is increasingly likely to be the 
optimal treatment alternative. At the threshold of 
about £330,000 per QALY both active treatment 
alternatives are equally likely to be optimal.
Summary of economic analysis
•  A systematic review of the literature found no 
existing economic evaluations that met the 
inclusion criteria of the review.
•  We developed a deterministic decision tree 
model from an NHS perspective to estimate 
comparative cost-effectiveness of treatment 
options for earwax following presentation at 
primary care. It focused on an adult population 
aged 35–44 years, with no contraindications to 
treatment options considered.
•  The decision tree model compares use of 
softeners for 1 week with return to the primary 
care practice for irrigation if no earwax 
clearance occurs (standard practice), use of 
softeners for 1 week followed by self-irrigation 
and return to primary care if unsuccessful for 
professional irrigation, and no treatment.
•  The structure and data inputs of the model 
were based on our systematic review of the 
literature on clinical effectiveness and cost-
effectiveness of treatment, systematic searches 
on HRQoL and AEs associated with earwax 
and hearing loss, other published literature for 
costs, and consultation with clinical experts.
•  Results from the decision tree model were 
extrapolated over different time horizons to 
give an estimate of lifetime cost-effectiveness of 
treatment alternatives.Economic analysis
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•  Base-case cost-effectiveness results suggest 
that the ICER for softeners followed by self-
irrigation is about £24,400, and for softeners 
followed by irrigation at primary care it is 
about £32,100, compared with no treatment.
•  The ICER is over £340,000 when comparing 
the two active treatments as the additional gain 
associated with professional irrigation is very 
small, but at an additional cost.
•  The lifetime model ICERs are virtually the 
same as the base-case ICERs due to a constant 
recurrence rate of wax used in all three 
treatment pathways. The slight difference 
in base case and lifetime ICERs is due to 
rounding errors in the small effectiveness gains 
between treatment pathways. If there had been 
evidence that treatment reduced the frequency 
or likelihood of recurrence then the lifetime 
model would have been more informative.
•  Sensitivity analyses show results are mostly 
robust although outcomes are sensitive to 
variation in the rate of successful earwax 
removal from the use of softeners.
•  Scenario analyses show that results are not 
sensitive to reduced cost of irrigation in 
primary care, but are sensitive to changes in 
disutility value associated with loss of hearing.
•  Caution should be taken in interpreting the 
results of the economic evaluation. The paucity 
of evidence on the safety, benefits and costs of 
the different strategies necessitated the use of 
different assumptions developed from available 
evidence and expert advice. Uncertainty about 
the structure and inputs in the model brings 
into question the reliability of the results. 
With the focus on a selected population 
group (people aged 35–44 years with no 
contraindications) and the evaluation of an 
intervention which may only have relevance to 
a specific patient group, the findings may have 
limited applicability to the general population. 
As a consequence, the results of the economic 
evaluation should be regarded as exploratory 
and should not be used as a basis for changing 
policy and practice.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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V
alue of information analysis was used to help 
identify future research priorities.84,85 Our 
first step was to calculate the population expected 
value of perfect information (PEVPI). This equates 
to the difference between the expected value of 
a decision based on perfect information and a 
decision based on currently available information. 
Calculating PEVPI provides a ‘preliminary screen’ 
with the purpose of eliminating research designs 
that have costs in excess of the PEVPI. In the event 
that no research designs were to pass this screening 
test further research investment would not be 
recommended.
For those research designs that do pass the initial 
screening test, the groups of parameters that may 
be investigated should be examined in terms of 
expected value of partial perfect information 
(EVPPI) for parameters. If the EVPPI exceeds the 
cost of the research design for a particular group 
of parameters, subsequent investment may be 
deemed worthwhile, whereas if the cost of a new 
study design exceeds the EVPPI then the additional 
research should not be undertaken. Both PEVPI 
and EVPPI are decision threshold specific, and 
will vary depending upon the health-care payer’s 
perspective of this threshold.
The analysis was conducted in the statistical 
package r. The decision tree model was replicated 
in r and code written to estimate the PEVPI and 
EVPPI. This acted as a technical validation of the 
original treeage model and facilitated reduced run 
times for the value of information analysis than 
could have been obtained with excel.
Figure 3 shows the PEVPI by decision threshold 
based on an annual population of 2 million67 and 
assuming that each patient is treated a mean of 
1.25 times to achieve clearance. When the decision 
threshold is low the technology is not expected 
to be cost-effective and additional information is 
unlikely to change the decision. The PEVPI reaches 
a maximum when the threshold is equal to the 
ICER of the treatment options (the ICER for self-
irrigation versus no treatment is £24k, whereas 
the ICER for GP irrigation versus self-irrigation is 
around £340k); that is where we are most uncertain 
about whether to adopt or reject the technology 
based on existing evidence. This analysis in Figure 3 
assumes a 10-year lifespan of the technology.
Figure 4 shows the PEVPI for a range of lifespan 
thresholds for the technology. These assume the 
technology will last for this period of time before a 
new technology comes along and replaces it. PEVPI 
is calculated as follows:
PEVPI EVPI
I
r
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t
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+ = ∑
( ) 1 1
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where T is the technology lifespan, r is the discount 
rate and I is the population incidence. The recent 
debate over the threshold to adopt for the lifespan 
of a technology is acknowledged,86 although a 10-
year lifespan would seem a reasonable proxy for 
the estimation of uncertainty given the historical 
longevity of the technology revealed in the clinical 
effectiveness review. An alternative would have 
been to conduct an empirical exercise or solicit 
expert opinion perhaps through a Bayesian 
process, both of which Phillips and colleagues85 
profess also have their weaknesses.
Figures 3 and 4 suggest that the decision problem 
passes the initial screening test for a common 
range of thresholds. Thus we proceed to calculate 
the EVPPI with the purpose of informing future 
research priorities and study designs.
Figure 5 shows the EVPPI conducted on selected 
groups of parameters. To reduce computational 
burden we followed the advice of Brennan and 
colleagues87 and used a higher number of runs in 
the inner loop (750) than the outer loop (500) for 
a total of 375,000 iterations per group of EVPPI 
parameters.
Choice of parameter groups was informed by 
potential study designs that could feasibly be 
conducted: utilities; primary care costs; secondary 
care costs; irrigation efficacy; softener efficacy; and 
frequency of AEs. The EVPPI is, again, a function 
of the choice of decision threshold.
Figure 6 shows the EVPPI in more detail around 
the generally accepted decision threshold adopted 
in the UK (i.e. between £20,000 and £30,000 
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per QALY). The figure illustrates that if future 
research is to be commissioned, it should prioritise 
improving the estimates of the costs of primary 
care and the efficacy of irrigation. These results 
are unsurprising as they are the principal drivers 
of the model. Secondary care costs are of far less 
importance as they are related to the management 
of AEs, which are deemed so rare as to have 
negligible impact on the analysis.
Whether this research should be undertaken 
depends upon the cost of the study into the groups 
of parameters and the exact threshold under 
which the decision is to be made. In this case it 
is likely that a prospective costing study or chart 
review for primary care costs and a clinical trial or 
observational study for irrigation efficacy would be 
required. If the threshold is £20,000 per QALY, it 
is unlikely that a clinical trial to inform irrigation 
efficacy could be undertaken, but a costing study 
could be performed within the EVPPI upper 
bound. However, if the adopted decision threshold 
is closer to the level of maximum uncertainty then 
investment in a clinical trial may be well founded. 
Investment in other groups of parameters is far less 
certain dependent upon the decision threshold.
A caveat is that the CIs around many of the 
parameters included in the model have been 
estimated, rather than informed by published 
evidence, and it is these estimates which inform 
the analysis. Furthermore, the analysis does not 
strongly suggest further research on utilities would 
be warranted, as the published utility estimate used 
in the model is accompanied by a low variability. 
Perhaps, in retrospect, if there is doubt as to the 
validity of this estimate in the UK, as attested by 
expert advice, then a Bayesian model could have 
been used in which a prior probability was used to 
identify current expectations.
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Statement of principal 
findings
Clinical effectiveness
Twenty-six clinical trials (22 RCTs and four CCTs) 
met the inclusion criteria of the review and 
were included for the assessment of the clinical 
effectiveness of methods for earwax removal. 
A range of interventions have been used in the 
studies, such as softeners with or without irrigation, 
in different populations and in different settings. 
Participants in the trials also varied across the 
studies in terms of age, sex and extent or severity 
of earwax. In some cases few details of baseline 
characteristics are given in the study reports, so 
interpretation of results was difficult. Outcomes 
also vary across studies often with limited 
information on the definitions used, making it 
difficult to assess their validity and objectivity, and 
how consistently they were applied. For example, 
measures of earwax removal might be reported 
in terms of clearance or visualisation of TM 
(described as complete, partial or negligible) or in 
terms of impaction or occlusion (described as none, 
mild, moderate or severe). Ease of earwax removal 
was reported in terms of number of attempts or the 
amount of liquid needed to achieve some degree of 
success. Methods of data analysis were also variable 
with several studies not reporting the analytic 
approach used or results of statistics tests. Due 
to these methodological issues, summarising the 
results of included studies was difficult and meta-
analysis was judged inappropriate.
Considering the studies that report statistical 
significance, results from these studies suggest 
that Cerumol, sodium bicarbonate, olive oil and 
water are all more effective than no treatment for 
removal of earwax; Cerumol is better than dioctyl, 
TP and sodium bicarbonate for ease of subsequent 
irrigation; TP is better than olive oil in the volume 
of water used for syringing; Audax is better than 
Earex for ease of removal by subsequent irrigation; 
Exterol and Otocerol are better than Cerumol 
in terms of the number of people requiring 
irrigation after treatment with softeners; wet 
irrigation is better than dry irrigation for ease 
of removal; sodium bicarbonate drops followed 
by nurse irrigation is more effective than sodium 
bicarbonate drops followed by self-irrigation; 
endoscopic de-waxing is better than microscopic 
de-waxing; and recurrence of earwax and impacted 
earwax is less likely in ears treated with skin oil 
than those not treated.
Patient satisfaction with the different treatment 
options was rarely assessed. Comparisons of 
different softeners, including dioctyl-medo, oil-
based softeners, Waxsol and Cerumol, showed 
that over 85% of people found them tolerable. 
When considering the effectiveness of different 
softeners, people’s responses ranged more widely, 
with 29% assessing Earex as effective compared 
with between 42% and 93% for Audax and 100% 
for Cerumol. Another comparison of nurse-
versus-self-irrigation found that people were 
more satisfied with nurse irrigation (difference 
28%). AEs were rare (usually < 10% of patients 
affected) and minor in nature. Most were limited 
to those associated with irrigation, such as minor 
pain (0–21%) and irritation/itching (4–15%). 
None of the studies reported perforation of the 
TM or infection. Although there was evidence 
assessing the comparative benefits of different 
interventions for removing earwax, it was of poor 
quality and equivocal. As a consequence it was not 
possible to identify a particular softener as being 
superior in clearing wax either with or without 
subsequent irrigation. Although separate studies 
have found benefits of wet syringing over dry 
syringing, from nurse-provided irrigation rather 
than self-irrigation and, endoscopic compared with 
microscopic de-waxing, the evidence was limited 
in nature and quality, so only tentative conclusions 
should be drawn.
Economic evaluation
Although we conducted a systematic review of 
the cost-effectiveness of the different methods 
for earwax removal, no economic evaluations 
were identified. As a consequence, a de novo 
economic model was developed to examine the 
cost-effectiveness of different alternative strategies, 
including softeners followed by irrigation in 
primary care (primary care option), softeners 
followed by self-irrigation (self-care option) and 
a ‘no treatment’ option. The results indicated 
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that the self-care option (£24,433 per QALY) is 
likely to be more cost-effective than the primary 
care option (£32,130 per QALY) when compared 
with the ‘no treatment’ option over a 7-week time 
horizon. When the two active treatment options 
were directly compared, the incremental cost of 
treating an additional patient with the primary 
care option as opposed to self-care option was 
£340,000 per QALY. When assessed over a lifetime 
horizon (45 years) the cost per QALY compared 
to the ‘no treatment’ option was £24,450 for the 
self-care option to £32,136 for the primary care 
option. Similarly, when comparing the two active 
treatments over a lifetime horizon, the resultant 
incremental cost per QALY was over £335,000 for 
the primary care option. A constant recurrence 
rate of wax was assumed for all three treatment 
pathways due to a lack of data to model an 
alternative assumption. Therefore, the lifetime 
results are merely an extrapolation of costs and 
outcomes from the base-case model out to a 45-
year period.
The results were fairly robust to a range of 
sensitivity and scenario analyses undertaken to 
explore parameter uncertainties of the modelled 
economic evaluation. Variations in measures of 
clinical effectiveness, rates of AE and costs resulted 
in cost per QALYs ranging between £15,000 
and £40,000 for the two options compared to no 
treatment, and between £170,000 and £535,000 
when the two active treatment options were 
compared. However, interpretation of these results 
should be undertaken with caution. Uncertainties 
as to current clinical practice and the paucity of 
clinical and economic evidence are considerable 
limitations to the economic evaluation. As a result 
the economic evaluation should be considered 
exploratory and not as a justification for any 
changes in practice.
Strengths and limitations of 
the assessment
The assessment has certain strengths:
•  It was independent of any vested interest.
•  The review brings together the evidence for 
the clinical effectiveness and cost-effectiveness 
of different methods of earwax removal using 
consistent methods of critical appraisal, 
presentation and transparency. In addition a 
de novo economic model has been developed, 
following recognised guidelines.
•  The evidence synthesis was guided by 
the principles for undertaking systematic 
reviews and economic evaluations. Prior to 
undertaking the assessment, the methods were 
set out in a research protocol (Appendix 1), 
and this was commented on by an advisory 
group. The protocol defined the research 
question, inclusion criteria, quality criteria, 
data extraction process and methods used 
to undertake the different stages of the 
assessment.
•  An advisory group has informed the review 
from its initiation, through the development 
of the research protocol and completion of the 
report.
•  Systematic searches were undertaken to identify 
data for the economic model, and main results 
were summarised and presented.
•  The quality of the clinical effectiveness studies 
was assessed using criteria recommended by 
the NHS CRD.
In contrast, the assessment was affected by certain 
limitations:
•  The studies identified by the systematic review 
of clinical effectiveness were published over 
a considerable period, from 1950 to 2007. 
Inevitably the nature of clinical trials in terms 
of their methods and their reporting in 
publications has changed significantly during 
this period. Of the trials included in this 
systematic review, those early published studies 
tended to provide very limited details of their 
methods and results. As a consequence, it was 
difficult to assess the quality of the studies 
and interpret their results appropriately. In 
addition, the technologies have continued 
to develop, with new softeners, methods of 
irrigation and changes in the nature of the 
service used to deliver the interventions. Again, 
this limits the comparability of the evidence.
•  Limited details are given in many of the 
studies of the participants involved in the 
studies, the dose and frequency of softeners 
used and the length of follow-up. All affect the 
generalisability of the findings.
•  The effectiveness of the different interventions 
for removing earwax was assessed through a 
range of different outcomes. While many of 
the outcomes assessed the extent and ease of 
clearance, the specific nature of the different 
outcomes varied considerably. The extent of 
clearance was assessed by outcomes such as 
amount of TM visualised, proportion achieving 
complete visualisation of the TM, degree of DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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wax removal, hearing, wax clearance, wax 
occlusion, degree of impaction, amount of wax 
removed, recurrence of cerumen impaction 
and further treatment required. Ease of 
removal of earwax was assessed through 
outcomes such as volume of water for syringing 
and syringefuls used, mean number of 
syringing attempts, mean time to syringe, ease 
of wax removal, ease of syringing, frequency of 
syringing, and time taken to de-wax. In many 
of the studies there was no clear description 
or definition of these outcome measures. 
Many are open to subjective measurement 
and interpretation. As a consequence, it was 
difficult to directly compare and synthesise 
the outcomes from the different studies. 
No studies assessed benefits of the different 
interventions on quality of life. Although a 
limited proportion of studies did examine 
different measures of patient satisfaction, these 
were limited to whether patients were satisfied 
with the intervention and if they found them 
effective and tolerable. Again, these outcomes 
were not clearly defined or described and open 
to subjective interpretation.
•  Some studies used a different unit of allocation 
to that used for the analysis (e.g. participants 
compared with ears). Although there are 
methods for handling the analysis of such data, 
it was unclear whether these were followed by 
the primary studies.
•  Although recurrence of earwax is thought to 
be a common problem for sufferers, it was 
not considered in the studies included in 
the systematic review. Recurrence may be a 
consequence of differences in the anatomical 
structure of different people’s ears, a result 
of damage that has been caused to the 
mechanism that allows earwax to be removed 
or to the use of medical devices (e.g. hearing 
aids). Inevitably people within this group will 
use a disproportionate amount of services and 
research should focus on identifying methods 
for diagnosing, treating and, if possible, 
preventing further problems. The economic 
evaluation assumed a recurrence rate of one 
event every 3 years. Inevitably this was a 
simplification and some people will incur a 
higher recurrence rate.
•  Follow-up with authors to clarify details of 
their methods and results was not routinely 
undertaken. Given that the majority of 
studies that lacked such information were 
those published nearly 60 years ago, it was 
considered of limited value to do so as authors 
would be difficult to trace and further details 
of studies are unlikely to be available. As 
technologies have developed and practice has 
changed, these early studies may have been 
of more limited relevance to current practice. 
Where there were uncertainties in key aspects 
in more recent publications, contact was 
attempted and was beneficial in some cases.
•  Synthesis of the studies included in the 
systematic review of clinical effectiveness was 
through narrative review. Due to the limitations 
of the literature, meta-analysis was not possible.
•  The limitations evident in the systematic review 
of clinical effectiveness and cost-effectiveness 
and in the evidence on the epidemiology 
and aetiology of earwax have impacted upon 
the development of the de novo economic 
evaluation. With studies either lacking detail 
of study characteristics or being heterogeneous 
in nature, the evidence base was limited. As 
a consequence, assumptions were used to 
develop the structure of the clinical pathway 
and to populate the different elements of the 
model (see Chapter 5, Assumptions used in 
the model). This has rendered the economic 
evaluation as exploratory, from which definitive 
recommendations for changing clinical practice 
should not be drawn.
•  The economic evaluation was developed from 
a NHS perspective, with patients having to 
attend primary care for assessment prior 
to decisions about subsequent treatment. 
Inevitably, some people will not attend primary 
care for assessment and/or treatment and 
will either suffer from the problem untreated 
or decide to self treat. These people are not 
included within the evaluation. The rationale 
for excluding these people was that the 
intention of providing evidence to decision-
makers as to possible future guidance to the 
NHS, and, as such, the research had to focus 
on aspects of current provision that could be 
affected by policy. This led to the exclusion of 
the evaluation of a service where advice from 
the NHS on self-syringing is provided without 
attendance at primary care practice (e.g. NHS 
Direct or through advice from pharmacists) 
or the effects of personal costs to the patient. 
Also, limited evidence was available as to the 
safety and effectiveness of self diagnosis and 
treatment.
•  With no definitive guidelines identified for 
the management of symptomatic earwax in 
the UK, the clinical pathway used to structure 
the economic evaluation was developed using 
assumptions based on available evidence and 
advice from clinical experts. As a consequence, Discussion
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it was uncertain if the clinical pathway used 
in the model was representative of current 
practice. For example, it was unclear who 
undertakes the first assessment within 
primary care, whether a practice nurse or a 
GP. Opinion appears to vary and it is likely 
that different primary care practices adopt 
different approaches. Also, the duration of the 
use of softeners was uncertain. Expert advice 
indicates that people use softeners for a week 
prior to self-based or primary-care-practice-
based irrigation. Others have suggested that 
the effectiveness of softeners may not depend 
on the duration of their use49 with spontaneous 
clearance achieved in a short period (e.g. 
20 minutes). Although alternatives have been 
examined through sensitivity and scenario 
analyses where possible, in some instances a 
pragmatic approach has been taken.
•  Similar concerns affect the parameter inputs 
used to populate the economic evaluation. 
No published evidence was found on the 
incidence of SAE associated with either 
professional irrigation or self-irrigation. As a 
consequence the base-case estimate was based 
on expert advice from an OTL. This may be 
an underestimate of the probability of SAE as 
it is based on the assumption that all patients 
are referred to secondary care. It is possible 
that some patients with SAE are first treated in 
primary care, and only those whose infection 
or TM perforation does not heal within the 
expected time are referred to secondary care. 
It was also assumed that the probability of 
SAE in both active treatment alternatives is 
the same regardless of the mode of irrigation 
(self-irrigation or administered by a primary 
care practice nurse) and whether irrigation is 
undertaken for the first, second or the third 
time, which may not correspond to actual 
clinical practice.
•  There were no published estimates of the 
loss of HRQoL associated with symptomatic 
earwax. The utility decrement of 0.006 
(standard error = 0.0001) was obtained from 
Sullivan and Ghushchyan.78 This was based on 
SF-12 quality-of-life estimates in the general 
US population, with the loss of hearing as 
defined by the ICD-9-CM diagnosis code 389. 
The original estimates were then converted 
into EQ-5D values. The estimates are not 
specific to patients presenting with earwax, 
although earwax is associated with temporary 
loss of hearing, as well as other symptoms. 
The utility decrement does not reflect minor 
complications, such as itching and tinnitus, and 
other minor symptoms, such as aural fullness 
and vertigo that affect HRQoL of patients with 
earwax problem. The direction of bias in the 
results of an economic evaluation associated 
with the use of utility decrement of 0.006 
based on the ICD-9-CM diagnosis code 389 
is unknown. An alternative utility estimate of 
0.0679 obtained in the population eligible for a 
hearing aid was used in the scenario analysis. 
The results indicated that the ICER estimates 
are sensitive to the choice of value of the utility 
gain.
•  The economic evaluation was conducted for a 
general population of adults aged 35–44 years 
without any known contraindications to 
irrigation, reflecting the participants in the 
primary studies of efficacy used to develop 
the economic evaluation. Although limited 
epidemiological data were available, it was 
felt that this group may not represent those 
in which the condition is most prevalent. As 
such, the results may not necessarily apply to 
other population groups, such as the elderly, 
children and people with disabilities. This is 
particularly important when considering the 
use of new technologies, such as self-irrigation, 
which require care in their use and adherence 
to instruction. It is likely that self-irrigation 
will only be relevant to a subgroup of the 
general population and therefore it should not 
necessarily be considered as an option for all 
groups.
Comparison with previous 
reviews
The findings of our evidence synthesis are 
generally in line with those of other systematic 
reviews in the area. We identified four previous 
reviews,1,29,37,74 each with slightly different 
methodologies and therefore different number 
of included studies. One review74 included nine 
RCTs, as well as seven in vitro studies and centred 
on commercially available products obtainable to 
facilitate ear syringing. All included RCTs were 
quality assessed and date of last searching was 
2002. Excluding the findings of the in vitro studies, 
the review found that no one product was superior 
to another.
A Cochrane Collaboration review updated in 
2009, which included nine RCTs, centred on the 
effectiveness of ear drops only.88 All included 
RCTs were quality assessed. Although most studies 
were judged not to be comparable and of poor DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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quality, two46,47of the nine included trials were 
meta-analysed. While the overall findings of the 
review were inconclusive, results from the meta 
analysis suggest TP is statistically superior to saline 
in preventing the need for syringing. A third 
review29 included 18 RCTs and concentrated on 
the effectiveness of topical preparations for the 
treatment of earwax. Trials were quality assessed 
and the date of last searching was January 2004. 
Preparations in this review were categorised into 
water-, oil- and non-water-based. Although the 
review undertook a meta-analysis, it also found 
that no one preparation was superior to another in 
either clearing earwax or facilitating syringing.
A more recent review37 included trials and 
systematic reviews,1,29 and considered treatments 
for both ear syringing and manual removal. 
The review carried out a grade evaluation of 
interventions for earwax on four of the included 
RCTs.4,42,56,62 Date of last searching was June 2007. 
Similarly to our conclusion, the overall conclusion 
of the review was that there was not enough 
evidence showing softeners alone to be effective or 
that one type of softener is superior to another.
Our review differed from these previous reviews, in 
that we assessed studies by setting, intention to use 
softening agent alone or as part of the irrigation 
procedure, followed by population and subgrouped 
into immediate or delayed follow-up. We assessed 
all methods of treatment, including self-syringing, 
all available preparation comparisons and each 
study was assessed for methodological quality. We 
did not feel that quantitative pooling of the data 
was appropriate. In the Hand and Harvey study,29 
data was combined. However, with such diverse 
outcomes and participant groups, we question 
whether this is appropriate. Furthermore, it is also 
questionable whether pooled data based on such 
poor quality studies provides reliable evidence 
about the effectiveness of these products.
Research recommendations
The systematic review of clinical effectiveness and 
cost-effectiveness and the development of the 
de novo economic evaluation have highlighted 
the paucity of good-quality evidence available to 
identify the most appropriate methods for the 
removal of earwax. This is a key concern given 
the prevalence of the condition, its implications 
for the use of health service resources and the 
apparent need to provide national guidance 
for practitioners. In addition, the potential for 
litigation has an influence on the provision of the 
service and unequivocal evidence is required to 
provide a safe, effective and efficient service. To 
provide clearer guidance, there will be a need for 
further research.
Much of the research identified in the systematic 
review has focused on the use of different drops to 
soften, dissipate or dissolve the wax, with limited 
attention being given to other facets, such as the 
method of mechanical removal, the role of the 
provider of the service, the effects of variations 
in practice and the importance of patient choice. 
Inevitably, it will be helpful to have clear evidence 
on the safety and effectiveness of the different 
drops and of the different methods for mechanical 
removal of earwax. However, a key concern that 
requires further research is how the different 
interventions are delivered and to which patient 
groups. Current practice, although thought to 
be variable nationally, tends to involve people 
attending primary care practices for diagnosis and 
treatment. Self-treatment with drops and then 
self-irrigation may offer a less costly alternative, 
with people only attending primary care practices 
if they are unable to clear the problem to their 
satisfaction. As a condition with a high recurrence 
rate, this would have the potential for reducing 
costs considerably. However, uncertainty remains 
as to whether self-irrigation is a safe and effective 
option that would be acceptable to patients and 
practitioners. By the nature of the process involved 
and concerns about litigation against the health 
service, it may be that the use of self-irrigation 
would be limited to a specific patient subgroup 
able to consent to its use and self treat. It would 
be helpful to identify this group and the safety, 
benefits and costs of the use of self-irrigation 
compared to current practice.
As such, it would be helpful to have an RCT 
to assess the clinical effectiveness and cost-
effectiveness of self-treatment through the 
provision of drops and use of a soft bulb irrigator 
compared with standard practice. With the 
variation in current practice within the UK, the 
trial should focus on the role of the practice nurse 
in assessing the condition, recommending drops 
and irrigating the ears within the comparator. 
Where appropriate, it should consider the 
possibility of using different drops for softening the 
earwax, different durations of the use of softeners 
and the particular methods for irrigation. However, 
these should be considered secondary to the use 
of self-treatment and the provision of the service. 
The patient groups included in the trial should be 
representative of those currently attending primary Discussion
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care, with a predominance of more elderly patients. 
Recurrence is common among people with earwax 
and this aspect will need to be encompassed 
with any evaluation. The outcomes to be used in 
the RCT will be important and will need to be 
objective, clearly defined and assessed by validated 
outcome assessors to improve comparability. 
They should include relief from patient reported 
symptoms, measures of clearance, quality of life 
and patient satisfaction and AE.
An economic evaluation will be a key part of 
any subsequent research. It is evident that the 
data that would normally underpin an economic 
evaluation are very limited. Further evidence is 
required on the epidemiology of the condition in 
terms of the prevalence of the condition, levels 
of recurrence and its natural history. It will be 
important to measure the patient’s quality of 
life using an appropriate and validated measure 
(e.g. EQ-5D or HUI3) focusing on people with 
symptomatic earwax rather than surrogates 
associated with hearing loss. AEs are thought to 
be important factors in providing the service and 
it will be important to collect data from any RCT. 
Given their apparent rarity and limited length 
of follow-up of most RCTs, there will need to be 
additional research to collect data on SAEs from 
primary and specialist care databases (e.g. serious 
infections and perforations of the TM). Accurate 
data on the costs of the different treatment options 
will be important to the evaluation and should be 
collected prospectively as part of any study.
While an RCT incorporating an economic 
evaluation provides the most robust form of 
evidence, it is possible that investment in other 
forms of study design would provide appropriate 
data to help develop the current evaluation and 
allow decisions concerning policy to the NHS. A 
value of information analysis assessed the value 
of further research on utilities, primary care costs, 
secondary costs, irrigation efficacy, softener efficacy 
and frequency of AEs. At a decision threshold of 
between £20,000 and £30,000 the EVPPI identified 
improvements in estimates of costs associated 
with primary care and the efficacy of methods 
of irrigation as the key inputs for improved 
information. As such, a prospective costing study 
or chart review of primary care costs may provide 
useful data to improve the current economic 
evaluation within the bounds of acceptable research 
costs. Improving data on the efficacy of different 
methods of irrigation is likely to require a clinical 
trial which would be more costly, but could provide 
information for other parameters.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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The systematic review has shown limited good-
quality evidence assessing the clinical effectiveness 
and cost-effectiveness of the different methods of 
earwax removal. As a consequence, it has proved 
difficult to differentiate between the different 
methods of earwax removal in terms of their 
effectiveness in clearing earwax, improving patient 
quality of life and satisfaction, or AEs. It appears 
that softeners do have some effect in helping to 
clear earwax in their own right or as a precursor 
to irrigation. However, which specific softeners 
are most effective remains unclear. There was 
limited consideration of the most effective method 
of irrigation or mechanical removal of earwax. 
Although irrigation was a key part of the treatment 
within many of the trials, the specific methods were 
not a focus of the analyses. Where the methods of 
irrigation or mechanical removal were assessed, 
the evidence was limited in quantity and/or 
methodological quality, so no clear guidance can be 
provided. The paucity of evidence on the benefits 
and costs of the different methods for the removal 
of earwax rendered the economic evaluation 
limited in its scope, and speculative, with many 
uncertainties remaining. Although it found 
self-treatment more cost-effective than primary 
care practice-based care, it focused on a limited 
population group (i.e. people 35–44 years with no 
contraindications) and was underpinned by several 
speculative assumptions (e.g. comparable clinical 
effectiveness). As such, the economic evaluation 
should be considered illustrative of the possible 
analysis that could be undertaken if a satisfactory 
evidence base were available. It does not provide 
evidence for recommendations that can be used to 
change clinical practice.
As a consequence, further research is required to 
identify the most effective method for the removal 
of earwax for different groups of people. The 
research should focus on those elements where 
uncertainty remains and that have the potential to 
impact on patients, the provision of the service and 
value for money. Although much of the research so 
far has looked at the role of softeners, perhaps the 
more important aspect for research is consideration 
of the method of mechanical removal and provision 
of the service. Traditionally, this has relied upon 
the patient attending the primary care practice for 
consultation, followed by the use of softeners and 
a further visit to have the earwax removed. Self-
treatment may provide an alternative option for 
a specific group of people who find it acceptable 
and are able to undertake the procedure. It would 
provide the opportunity for those people to treat 
themselves when required, with the possibility of 
removing some of the burden from the health 
service. For many people professional care from 
the health service will continue to provide the 
most appropriate method for the removal of 
earwax and research should assess the role of the 
practice nurse and other members of the nursing 
team in the provision of care. In both instances 
research should assess the clinical effectiveness 
and cost-effectiveness of the different approaches, 
focusing on efficacy, acceptability to patients and 
practitioners, possible AEs and costs. While a 
RCT incorporating an economic evaluation would 
provide the most robust method for assessing 
several aspects of the removal of earwax, a 
prospective study of the costs of the provision of 
care within primary care may provide a less costly 
option in the first instance.
Chapter 8  
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Systematic review
A systematic review will be undertaken in 
accordance with the NHS Centre for Reviews 
and Dissemination (CRD) guidelines,40 published 
guidelines on meta-analysis,89 and criteria for 
appraising economic evaluations.90,91
Literature searches
Literature will be identified from several sources 
including electronic databases, bibliographies 
of articles, grey literature and consultation with 
experts in the area. A comprehensive database of 
relevant published and unpublished articles will be 
constructed using the reference manager software 
package. The searches carried out will include:
1.  General health and biomedical databases, 
including MEDLINE, EMBASE, Science 
Citation Index and BIOSIS.
2.  Specialist electronic databases: DARE and The 
Cochrane Library.
3.  Grey literature and conference proceedings.
4.  Contact with individual experts and those with 
an interest in the field.
5.  Checking of reference lists.
6.  Research in progress: National Research 
Register (historical), UKCRN, Current 
Controlled Trials (CCT) and ClinicalTrials.gov.
All databases will be searched from their inception 
to the current date. In the first instance searches 
will be conducted in all languages, with non-
English language articles set to one side in a 
separate foreign language reference database. 
Thereafter, an assessment of the volume of non-
English language literature will be made and, 
translation and time restrictions permitting, these 
will be included in the review. Letters will be sent 
to experts to ask if they know of any relevant 
published or unpublished studies that we have not 
identified.
Study inclusion
Studies will be selected for inclusion in the review 
in a two-stage process using the predefined 
and explicit selection criteria outlined in Table 
1 below. The full literature search results will 
be screened independently by two reviewers to 
identify all citations that may meet the inclusion 
Appendix 1  
Protocol methods
criteria. Full manuscripts of all selected citations 
will be retrieved and assessed by two independent 
reviewers against the inclusion criteria. These 
criteria will be piloted on a sample of papers. 
Any disagreements over study inclusion will be 
resolved by consensus or if necessary by arbitration 
involving a third reviewer.
Planned inclusion/exclusion criteria
The planned inclusion/exclusion criteria for the 
systematic review are shown in Table 1.
Data extraction
The extraction of studies’ characteristics, methods 
and findings will be conducted by one reviewer and 
checked by a second reviewer using a predesigned 
and piloted data extraction form to avoid any 
errors. Any disagreements between reviewers 
will be resolved by consensus or, if necessary, by 
arbitration by a third reviewer.
Quality assessment
The methodological quality of all included studies 
will be appraised using a formal quality assessment 
criteria recommended by CRD40 (see below) and 
criteria for appraising economic evaluations.90,91 
Study quality will be assessed by one reviewer and 
checked by a second reviewer. Any disagreements 
between reviewers will be resolved by consensus 
or if necessary by arbitration involving a third 
reviewer.
Data synthesis
The results of included studies will be tabulated 
and summarised in a narrative review. The 
methods of data synthesis will be determined 
by the nature of the studies identified through 
searches and included in the review. Quantitative 
synthesis of results will be considered if there are 
several high-quality studies of the same design, but 
specific details are not possible until the data has 
been obtained. Sources of heterogeneity will be 
investigated using appropriate methods.
Economic evaluation
Cost-effectiveness will be assessed through a two-
stage process. First, a systematic review of cost-
effectiveness studies (full economic evaluations) 
will be undertaken to address the question of the Appendix 1
94
TABLE 1  Inclusion criteria for systematic reviews
Interventions All methods of earwax removal or softening, including:
•  Drops
•  Almond oil
•  Olive oil
•  Sodium bicarbonate drops
•  Cerumol
•  Exterol
•  Molcer
•  Otex
•  Waxsol
•  Irrigation (e.g. syringing, electronic irrigators)
•  Mechanical removal other than irrigation (e.g. suction, probes and forceps)
•  Other methods
•  Combinations of above methods
[Note: Interventions specify methods of removal and softening. Although it does not outline 
methods of visualisation (e.g. microscope, endoscope and head light loop) these will be 
identified in data extraction as they will be important elements of removal.]
Population Adults and children presenting with build-up of earwax requiring removal
Outcomes Measures of hearing
Adequacy of clearance of wax (e.g. visualisation of tympanic membrane)
Quality of life
Time to recurrence or further treatment
Adverse events (AEs)
Measures of costs and cost-effectiveness (e.g. cost per quality-adjusted life-year)
(Note: Studies must report summary statistics or present sufficient raw data to allow these to 
be calculated.)
Study design Randomised controlled trials
Controlled clinical trials
Cohort studies (AEs)
Costing studies, cost-effectiveness evaluations (including modelling studies)
(Note: Where there is evidence from different types of study design for a specific intervention, 
only those studies with the most rigorous designs will be included and data extracted.)
AEs, adverse events.
cost-effectiveness of different methods for earwax 
removal in the different patient groups. The 
methods for the review will be analogous to those 
presented for the review of clinical effectiveness 
and results will be presented using a narrative 
synthesis. Quality assessment of cost-effectiveness 
studies will be conducted using a checklist 
adapted from those developed by Drummond and 
colleagues90 and Philips and colleagues.91
Second, if no economic evaluation relevant to 
the UK setting is identified, construction of a 
de novo economic model will be considered 
where appropriate, with the aim of establishing 
the relative cost-effectiveness of the different 
interventions for removing earwax. The structure 
of the model will reflect current treatment 
pathways employed by clinicians and other health 
professionals for the removal of earwax. Any 
proposed alternatives to current practice identified 
in the literature or through consultation with 
practicing clinicians and other health professionals 
will also be considered. The structural validity of 
the model will be checked through consultation 
with clinicians and other health professionals in 
the UK who are experienced in earwax removal. 
The model will be either a decision tree or a 
Markov process model, although its design will 
be determined, in part, by the data available to 
populate it. Health states will likely comprise: 
occlusion, complete clearance and adverse events 
(AEs) (e.g. perforation leading to long-term DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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hearing loss). It is expected that the model will be 
populated with the data from the systematic review 
of clinical effectiveness and cost-effectiveness, 
and from other routinely collected data sources 
[e.g. unit costs from the Personal Social Services 
Research Unit (PSSRU)]. If data are not identified 
from these sources, we will consider performing 
additional targeted searches and/or consultation 
with experts on all model inputs to provide 
appropriate data. The model will be from the 
perspective of the NHS and will include, where 
possible, all costs and consequences related to the 
NHS perspective and all patient-related benefits.
The base-case model will aim to focus on adults 
who are eligible for the entire range of treatment 
alternatives for earwax removal, although the 
model will aim to assess those interventions 
shown to be effective in the systematic review of 
clinical effectiveness. Subject to data availability, 
alternative versions of the model may be developed 
to examine subgroups that may respond differently 
to treatment. Possible subgroups will be identified 
through consultation with clinical advisors and 
through the evidence from the systematic review. 
Each alternative treatment pathway is likely to be 
quantified in terms of the success of treatment, 
symptom recurrence, serious AEs suffered, the 
resource cost of treatment and impact on patients’ 
quality of life. Costs will be presented in a base 
year and discounting of costs and benefits will be 
performed. Incremental costs and benefits will 
then be measured for alternative treatments. If 
possible, the outcome measure from the economic 
evaluation will be cost per quality-adjusted life-year 
(QALY).
The model’s underlying assumptions will be 
assessed through sensitivity analyses and threshold 
analysis for a range of parameters at which 
reasonable cost-effectiveness levels could be 
achieved. Probabilistic sensitivity analysis, whereby 
parameters are varied within reported ranges and 
distributions, will be undertaken to determine the 
impact of uncertainty upon the model.
Value of information analysis will be undertaken 
where possible to help identify future research 
priorities quantified by the value of reducing 
decision uncertainty (and its consequences in terms 
of the opportunity costs), which could be derived 
from additional research investment on earwax 
removal technologies.84,85 It is intended that this 
approach will systematically appraise which future 
research would be most valuable and also assist in 
identifying appropriate research designs.92
The model will be constructed in treeage pro 2007 
or Microsoft excel and will be made as transparent 
as possible in order that it can be readily updated 
when new data emerge. The modelling work will 
follow guidelines for good practice as reported by 
Philips and colleagues.91 Building a model is an 
iterative process and quality control checks will 
be included at several points during the process 
to ensure that appropriate structure and data are 
applied. This is necessary to ensure that the results 
can be relied upon to inform decision-makers 
regarding the cost-effectiveness of the intervention. 
There are several steps to this formal process:
•  A comparison of the model results with those 
from any other relevant models identified from 
our systematic review. Any differences between 
the results will be explored and, if necessary, 
appropriate modifications made to the model.
•  Model results will be analysed to ensure they 
accurately reflect the inputs used in the model. 
This ensures that the data used to populate the 
model are being applied at the correct times 
and locations. Extreme parameter values can 
be used to test whether the model behaves as 
expected.
•  The model will be critically appraised by a 
second health economist/modeller. This will 
allow the approach to be validated and permits 
any areas of disagreement to be resolved prior 
to generation of model results.
These three steps help ensure that all aspects of 
potential error in the model – a lack of internal 
validity, a lack of external validity and any 
omissions or biases from an individual health 
economist – are addressed.
Types and sources of information for economic 
evaluation
Epidemiology  Information on the epidemiology 
of hearing impairment including the incidence, 
prevalence and prognosis of the condition will be 
identified from the literature and supplemented if 
necessary with clinical expertise.
Treatment efficacy and safety  Efficacy and safety data 
will be extracted from the clinical studies identified 
in our systematic review of clinical effectiveness. If 
there is a paucity of data on parameters, clinicians 
may need to be consulted in order to obtain 
estimates of, or variability around, the parameters 
included in the model. The outcomes are likely 
to be assessed in terms of symptom relief, AEs 
suffered and symptom recurrence.Appendix 1
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Quality of life  In order to calculate cost per QALY 
the estimates of utility decrements for patients 
who suffer symptoms of hearing impairment and 
AEs typically associated with wax removal will 
be sought. Ideally utility weights for common 
adverse effects will be obtained from patient-based 
estimates (or, potentially, ‘guardian-based’ estimates 
in the case of children). These decrements may be 
reported in literature and preference will be given 
to the utility weights expressed in age- and sex-
specific EQ-5D population norms for the UK.77 
Separate targeted searches will be undertaken to 
try and identify relevant data. If necessary, however, 
they will be obtained from alternative sources such 
as clinical opinion through contact with clinicians.
Cost and resource use measurement  The pattern of 
resource use and their associated costs may be 
identified from published or official sources. If 
necessary these data will be supplemented by 
contact with clinicians and NHS trust finance 
departments. Major resource components will 
include treatment costs in terms of primary and/
or secondary care visits (including staff costs, 
equipment and overheads), treatment of AEs and 
follow-up visits. All drug costs will be obtained 
from the British National Formulary (BNF) online. 
Inpatient days and outpatient visits costs will also 
be obtained from NHS reference costs. Unit costs 
for home visits by GPs or district nurses will be 
obtained from published data.93
Quality assessment criteria
Quality criteria for assessment of experimental studies
1. Was the assignment to the treatment groups really random?
2. Was the treatment allocation concealed?
3. Were the groups similar at baseline in terms of prognostic factors?
4. Were the eligibility criteria specified?
5. Were outcome assessors blinded to the treatment allocation?
6. Was the care-provider blinded?
7. Was the patient blinded?
8. Were the point estimates and measure of variability presented for the primary outcome 
measure?
9. Did the analyses include an ITT analysis?
Some instructions for using a checklist for RCTs
Quality item Coding Explanation
1. Was the assignment to the treatment groups really random?
Random sequence generation Adequate
Partial
Inadequate
Unknown
Adequate: Random numbers table or computer and 
central office or coded packages
Partial: Envelopes (sealed) without further description 
or serially numbered opaque, sealed envelopes
Inadequate: Alternation, case record number, birth date, 
or similar procedures
Unknown: Just the term ‘randomised’ or ‘randomly 
allocated’, etc.
2. Was the treatment allocation concealed?
Concealment of randomisation
The person(s) who decide on eligibility should 
not be able to know or be able to predict 
with reasonable accuracy to which treatment 
group a patient will be allocated. In trials that 
use good placebos this should normally be the 
case; however, different modes or timing of 
drug administration in combination with the 
use of small block sizes of known size may 
present opportunities for clinicians who are also 
involved in the inclusion procedure to make
Adequate
Inadequate
Unknown
Adequate: When a paper convinces you that 
allocation cannot be predicted (separate persons, 
placebo really indistinguishable, clever use of block 
sizes (large or variable). Adequate approaches 
might include centralised or pharmacy-controlled 
randomisation, serially numbered identical containers, 
on-site computer-based system with a randomisation 
sequence that is not readable until allocation, and 
other approaches with robust methods to prevent 
foreknowledge of the allocation sequence to clinicians 
and patientsDOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Quality item Coding Explanation
accurate guesses and selectively exclude 
eligible patients in the light of their most likely 
treatment allocation; in centres with very low 
inclusion frequencies combined with very brief 
follow-up times this my also present a potential 
problem because the outcome of the previous 
patient may serve as a predictor of the next 
likely allocation
Inadequate: This option is often difficult. You have to 
visualise the procedure and think how people might 
be able to circumvent it. Inadequate approaches might 
include use of alternation, case record numbers, birth 
dates or week days, open random numbers lists, serially 
numbered envelopes (even sealed opaque envelopes can 
be subject to manipulation) and any other measures that 
cannot prevent foreknowledge of group allocation
Unknown: No details in text; disagreements or lack of 
clarity should be discussed in the review team
3. Were the groups similar at baseline regarding the prognostic factors?
Baseline characteristics
Main aim is to enable the reviewer to see which 
patients were actually recruited. It enables one 
to get a rough idea on prognostic comparability. 
A real check on comparability requires 
multivariable stratification (seldom shown)
Reported
Unknown
Consult the list of prognostic factors or baseline 
characteristics (not included in this appendix). Reviewer 
decides
4. Were the eligibility criteria specified?
Prestratification
Consult the list of prognostic factors or baseline 
characteristics (not included in this appendix)
Adequate
Partial
Inadequate
Unknown
Single-centre study
Adequate: Prestratification on at least one factor from 
the list or no prestratification if the number of patients 
exceeds a prespecified number
Partial: Leave judgement to reviewer
Inadequate: Stratification on a factor(s) not on our list or 
no stratification, whereas the number of patients is less 
than the prespecified number
Unknown: No details in text and no way to deduce the 
procedure from the tables
Multicentre study
Adequate: Must prestratify on centre. Within each 
centre the criteria for single-centre studies also apply
Partial: Impossible option
Inadequate: No prestratification on centre or violating 
the criteria for single-centre studies (see above)
Unknown: No details in text and no way to deduce the 
procedure from the tables
5. Were outcome assessors blinded to the treatment allocation?
Blinding of assessors
The assessor may be the patient (self report), 
the clinician (clinical scale, blood pressure) 
or, ideally, a third person or a panel. Very 
important in judgement of cause of death but 
unimportant in judgement of death
Adequate
Inadequate
Unknown
Adequate: Independent person or panel or (self) 
assessments in watertight double-blind conditions
Inadequate: Clinician is assessor in trial on drugs with 
clear side effects or a different influence on laboratory 
results, ECGs, etc.
Unknown: No statements on procedures and not 
deducible
6. Was the care-provider blinded?
Blinding of caregivers
Look out for good placebos (see, hear, taste, 
feel, smell), tricky unmasking side effects 
accounting for the subjectivity of the outcome 
measurements and the accessibility of co-
interventions by the caregivers
Adequate
Partial
Inadequate
Unknown
Adequate: Placebo described as ‘indistinguishable’ and 
procedures watertight (use your imagination with the 
‘cheat’ in mind; e.g. statement that sensitive/unmasking 
laboratory results were kept separate from ward 
personnel)Appendix 1
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Quality item Coding Explanation
Partial: Just ‘double-blind’ in text and no further 
description of procedures or nature of the placebo
Inadequate: Wrong placebo (e.g. fructose in trial on 
ascorbic acid)
Unknown: No details in text
Co-interventions
Register when they may have an impact on any 
of the outcome phenomena. Consult the list of 
cointerventions (not included in this appendix).
Adequate
Partial
Inadequate
Unknown
Adequate: Percentages of all relevant interventions in all 
groups
Partial: One or more interventions omitted or omission 
of percentages in each group
Inadequate: Not deducible
Unknown: No statements
7. Was the patient blinded?
Blinding of patients
This item is hard to define. Just the statement 
‘double-blind’ in the paper is really insufficient 
if the procedure to accomplish this is not 
described or reasonably deducible by the 
reviewer. Good placebos (see, hear, taste, 
feel, smell), tricky unmasking side effects 
accounting for the subjectivity of the outcome 
measurements and the accessibility of co-
interventions by the patient are required
Adequate
Partial
Inadequate
Unknown
Adequate: Placebo described as ‘indistinguishable’ and 
procedures watertight
Partial: Just ‘double-blind’ in text and no further 
description of procedures or nature of the placebo
Inadequate: Wrong placebo
Unknown: No details in text
Compliance
Dosing errors and timing errors
Adequate
Partial
Inadequate
Unknown
Adequate: Medication Event Monitoring System (MEMS 
or eDEM)
Partial: Blood samples, urine samples (use of indicator 
substances)
Inadequate: Pill count or self report
Unknown: Not mentioned
Check on blinding
Questionnaire for patients, caregivers, assessors 
and analysis of the results; the (early) timing is 
critical because the treatment effect may be the 
cause of unblinding, in which case it may be used 
as an outcome measure
Reported
Unknown
Reviewer decides
8. Were the point estimates and measure of variability presented for the primary outcome measure?
Results for the primary outcome measure Adequate
Partial
Inadequate
Unknown
Adequate: Mean outcome in each group together with 
mean difference and its standard error (SE) or standard 
deviation (SD) or any CI around it or the possibility to 
calculate those from the paper. Survival curve with log-
rank test and patient numbers at later time points
Partial: Partially reported
Inadequate: No SE or SD, or SD without N (SE = SD/N)
Unknown: Very unlikelyDOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Quality item Coding Explanation
9. Did the analysis include an intention-to-treat (ITT) analysis?
ITT
Early dropout can make this very difficult. 
Strictest requirement is sensitivity analysis 
including early dropouts
Adequate
Inadequate
Reviewers should not just look for the term ITT but 
assure themselves that the calculations were according 
to the ITT principle
Dealing with missing values
The percentage missing values on potential 
confounders and outcome measurements 
(seldom given) is a rough estimate of a trial’s 
quality. One can carry them forward, perform 
sensitivity analysis assuming the worst- and 
best-case scenarios, use statistical imputation 
techniques, etc. Note that the default option 
(deletion) assumes that the value is randomly 
missing, which seems seldom justified
Adequate
Partial
Inadequate
Unknown
Adequate: Percentage of missing values and distribution 
over the groups and procedure of handling this stated
Partial: Some statement on numbers or percentages
Inadequate: Wrong procedure (a matter of great debate)
Unknown: No mentioning at all of missing and not 
deducible from tables
Loss to follow-up
This item examines both numbers and reasons; 
typically an item that needs checking in the 
methods section and the marginal totals in 
the tables. Note that it may differ for different 
outcome phenomena or time points. Some 
reasons may be reasons given by the patient 
when asked and may not be the true reason. 
There is no satisfactory solution for this
Adequate
Partial
Inadequate
Unknown
Adequate: Number randomised must be stated. 
Number(s) lost to follow-up (dropped out) stated or 
deducible (from tables) for each group and reasons 
summarised for each group
Partial: Numbers, but not the reasons (or vice versa)
Inadequate: Numbers randomised not stated or not 
specified for each group
Unknown: No details in textDOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Appendix 2  
Literature searches and flow 
chart of included studies
T
he following databases were searched for 
published studies and recently completed 
and ongoing research. Searches were updated in 
December 2008.
1.  General health and biomedical databases, 
including MEDLINE, EMBASE, Science 
Citation Index and BIOSIS.
2.  Specialist electronic databases: DARE and the 
Cochrane library.
3.  Grey literature and conference proceedings.
4.  Contact with individual experts and those with 
an interest in the field.
5.  Checking of reference lists.
6.  Research in progress: National Research 
Register (historical), UK Clinical Research 
Network (CRN), Current Controlled Trials 
(CCT) and ClinicalTrials.gov.
Clinical effectiveness searches
The following strategies were used to search 
MEDLINE (OVID), 1966–2008. These were 
translated to search the other databases listed 
above.
1.  cerumen/(578)
2.  cerum*.tw. (531)
3.  (ear* and wax*).tw. (581)
4.  earwax*.tw. (60)
5.  or/1–4 (1280)
6.  randomized controlled trial.pt. (248764)
7.  controlled clinical trial.pt. (76414)
8.  randomized.ab. (160990)
9.  placebo.ab. (103272)
10. clinical trials as topic.sh. (135286)
11. randomly.ab. (117274)
12. trial.ti. (71485)
13. exp Cohort Studies/(648803)
14. cohort.tw. (102947)
15. or/6–14 (1169187)
16. 5 and 15 (114)
17. humans.sh. (10090140)
18. 16 and 17 (105)
19. from 18 keep 1–105 (105)
Figure 7, shows the identification of studies for 
inclusion in the systematic review of clinical 
effectiveness.
Foreign language publications
Two foreign language publications were identified 
on searches and are listed below. From their 
English language abstracts it would appear that 
neither of these had a comparator group, and 
would therefore not meet the inclusion criteria of 
our review. However, we were unable to fully screen 
these for inclusion.
1.  Cassano P, Mora E, Damiani V, Passali 
FM, Passali D. Valutazione dell’efficacia 
cerumenolitica di Audispray. Otorinolaringol 
2002;52:131–5.
2.  Cavallazzi GM, Bottero A. Impiego clinico 
di un nuovo ceruminolitico: considerazioni 
preliminary. Riv Orl Aud Fon 1988;8:197–200.Appendix 2
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Identified on searching
(after duplicates removed)
n = 202
Excluded
n = 158
Excluded
n = 19
Full copies retrieved and
papers inspected
n = 45
Included studies n = 26
RCTs n = 22
CCTs n = 4
Titles and abstracts
inspected
FIGURE 7  Flow chart of identification of studies for inclusion in the systematic review of clinical effectiveness. CCTs, controlled clinical 
trials; RCTs randomised controlled trials.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Appendix 3  
Data extraction forms: primary care setting
Meehan and colleagues46
Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: Meehan and 
colleagues:46 Abstract
Year: 2002
Country: USA
Study design: Double-blind 
RCT
Number of centres: One
Setting: Emergency care
Funding: None reported
1. DS (Colace): 1 ml
2. TP (Cerumenex): 1 ml
3. NS: 1 ml
Duration of treatment: 15 
minutes
Other interventions used: 
Irrigation with 50 ml 
of saline if TM was still 
occluded after treatment, 
repeated once if needed
Number of participants: 48
DS: n = 15
TP: n = 17
Saline: n = 16
Sample attrition/dropout: None 
reported, but numbers of 
participants in secondary outcomes 
are lower
Inclusion criteria for study entry: 
Cooperative participants aged 
1–18 presenting to a paediatric 
emergency department, with 
complete or partial TM occlusion
Exclusion criteria for study entry: 
None reported
Primary outcomes: Amount 
of TM visualised
Secondary outcomes: AEs
Method of assessing 
outcomes: Grades of TM 
occlusion – complete, 
partial or clear
Length of follow-up: 
Immediate
Baseline characteristics of participants
All DS (n = 15) TP (n = 17) Saline (n = 16) p-value
Gender M/F 24 : 24     No p-values reported
Mean age 4.6
Median age 3.5
TM occlusion – complete 11 11 9
TM occlusion – partial 4 6 7
Results
Primary outcomes
TM occlusion DS (n = 15) TP (n = 17) Saline (n = 16) p-value
Complete
Partial
Clear
5
8
2
5
5
7
5
9
2
No p-values reported
Comments: after solvent (intervention) only
Secondary outcomes
DS (n = 15) TP (n = 17) Saline (n = 16) p-value
TM occlusion after one 
irrigation:
n = 13 n = 15 n = 15 No p-values reported
Complete 4 4 4
Partial 6 3 5
Clear 3 8 6Appendix 3
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TM occlusion after two 
irrigations:
n = 12 n = 15 n = 15 No p-values reported
Complete 3 4 3
Partial 4 3 4
Clear 5 8 8
Comments: The most common AE was pain with irrigation overall (10/48)
Methodological comments
Allocation to treatment groups: RCT – no other details reported
Blinding: Study states double-blind evaluation, but no details reported
Comparability of treatment groups: no details reported
Method of data analysis: The abstract reports a trend for the efficacy of Cerumenex without irrigation and that adding 
irrigation improves the effectiveness of Colace, while a second irrigation does not improve outcomes. No data analysis or 
p-values are reported to support this
Sample size/power calculation: None reported
Attrition/dropout: None reported, but numbers of participants reported in secondary outcomes are lower
General comments
Generalisability: No breakdown of baseline characteristics for the three groups is provided, population consists of American 
children attending a university paediatric emergency department
Outcome measures: It is unclear how valid or objective the measure was, or how consistent the assessments were.
Intercentre variability: N/A
Conflict of interests: None reported
AEs, adverse events; DS, docusate sodium; F, female; M, male; N/A, not applicable; NS, normal saline; RCT, randomised 
controlled trial; TM, tympanic membrane; TP, triethanolamine polypeptide.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Inadequate
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Inadequate
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Partial
7. Was the patient blinded? Partial
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate 
10. Were withdrawals and dropouts completely described? Inadequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Whatley and colleagues47
Extracted by: EL Checked by: PH
Reference and design Intervention Participants Outcome measures
Author: Whatley and 
colleagues47
Year: 2003
Country: USA
Study design: RCT
Number of centres: Two
Setting: Children’s 
hospital emergency 
department or large 
general paediatric clinic 
in same town
Funding: Not stated
1. DS (docusate): 1 ml
2. TP (triethanolamine 
polypeptide): 1 ml
3. Saline control: 1 ml
Duration of treatment: 
Between 15 and 30 
minutes depending on 
number of irrigations
Other interventions used: 
In all groups, if, after 
15-minutes, the TM was 
not completely visualised, 
the ear was irrigated with 
50 ml of tepid tap water 
(85–95°F). If still not 
clear another irrigation 
was undertaken
A 60-ml syringe with a 
18-gauge angiocatheter 
precut to 1.5 cm in 
lengths was used for 
irrigation
Number of participants: 96 assessed 
for eligibility, 3 refused to 
participate, 93 randomised
1. DS: 35
2. TP: 30
3. Control: 28
Sample attrition/dropout: DS one 
discontinued study, one excluded 
from analysis (protocol violation).
Inclusion criteria for study entry: 
Aged 6 months to 5 years with 
complete or partial cerumen 
obstruction of the TM (assessed 
by 1 of 4 investigators)
Exclusion criteria for study entry:
Otitis externa
Myringotomy tubes presently or 
placed within the last 2 years
Suspected perforation of TM
Severe healing loss in 1 or both 
ears
Known allergy to study agents
Prior complication from irrigation
Primary outcomes: Proportion 
achieving complete 
visualisation of the TM
Secondary outcomes: Adverse 
events
Method of assessing outcomes: 
Wax (based on colour 
and consistency) was 
characterised as soft, hard or 
mixed
Complete obstruction defined 
as inability to visualise any 
of the TM, partial ability to 
visualise part of the TM but 
not all membrane landmarks, 
including light reflex, ossicles 
and mobility. To determine 
interobserver variability each 
investigator examined the 
same 26 ears prior to study 
initiation. A kappa value of 
0.72 was obtained
Length of follow-up: Immediate
Baseline characteristics of participants
DS (n = 34) TP (n = 30) Saline (n = 28) p-value
Mean (SD) age, months 36.4 (19.1) 30.9 (15.2) 36.7 (19.5) p = 0.38
Gender, M/F (%) 14:20 (41:59) 13:17 (43:57) 15:13 (54:46) p = 0.59
Race, n (%)
African American 26 (76)
8 (24)
0
15 (50)
14 (47)
1 (3)
19 (68)
8 (29)
1 (3)
p = 0.16, between all 
groups
White
Other
Wax, n (%)
Hard 11 (32) 12 (40) 7 (25) p = 0.57, between all 
groups Soft 11 (32) 12 (40) 11 (39)
Mixed 12 (35) 6 (20) 10 (36)
Complete obstruction 
at enrolment, n (%)
31 (91) 24 (80) 22 (79) p = 0.33
Results: Mean age (SD) in months for all participants 34.7 (18.1) gender for all (%) M 42 : F 50 (36 : 58)
Primary outcomes  DS (n = 34) TP (n = 30) Saline (n = 28) p-value
Clear TM after agent, 
n (%)
4 (12) 4 (13) 1 (4) p-value not 
reported
Clear TM after first 
irrigation, n (%)
13 (38) 12 (40) 12 (43)
Clear TM after second 
irrigation, n (%)
18 (53) 13 (43) 19 (68) Between the 3 
groups, p = nsAppendix 3
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Comments: Potential confounders, including study site, different investigators and type of wax were analysed. The 
difference in the success rate between sites was not statistically significant (p = 0.64), nor was the difference between 
investigators (p = 0.58). The only trend was that the success rate for soft wax (68%) was higher than for mixed (50%) or 
hard (43%); p = 0.13.
Secondary outcomes DS (n = 34) TP (n = 30) Saline (n = 28) p-value
Comments: AEs – one patient had a small amount of ear canal bleeding after irrigation, but was able to complete the study 
(not reported which intervention group the participant was in).
Methodological comments
Allocation to treatment groups: A computerised, random-number program was used. Syringes were placed in consecutively 
numbered envelopes by a hospital pharmacist. Each enrolled participants was then assigned the next numbered envelope
Blinding: States double-blind, pharmacist loaded and sealed the syringes into envelopes, but not clear if any distinguishing 
factors between syringes or when the code was broken. Treatments were a different colour and any residues after 
drainage could enable investigators to determine which treatment a participant had received
Comparability of treatment groups: No statistically significant differences in baseline characteristics. Compared with the 
paediatric clinic, a higher proportion of patients enrolled in the emergency department received TP (42% vs 15%) and 
fewer patients received saline (22% vs 45%). Visually race appears to be dissimilar; however, differences are shown as 
statistically not significant
Method of data analysis: Categorical variables analysed using a chi-squared test or a Fisher’s exact test. Continuous 
variables analysed using ANOVA. p < 0.05 was considered statistically significant. sas statistical software version 8.02 
(SAS Institute, Cary, NC) was used
Sample size/power calculation: A sample size of 90 was estimated to achieve 80% power to detect a 40 percentage-point 
difference between the treatment groups ( = 0.05; χ2 with d = 2). A 40 percentage-point difference was considered to be 
significant, based on previous studies
Attrition/dropout: In the docusate group 1 patient discontinued (due to the ear being irrigated before an agent was placed) 
and one was excluded
General comments
Generalisability: Population was young children, predominantly of African American race (64%). Convenient sample, only 
assessed when an investigator was available
Outcome measures: Inter-rater reliability assessed and reasonable
Intercentre variability: No significant differences noted by investigators. There was an imbalance of the TP and normal saline 
treatment groups between the 2 sites, with a higher percentage of participants enrolled in the emergency department 
TP group (42% vs 15%) and fewer participants in the normal saline group (22% vs 45%). Participants in the DS treatment 
group at each site were evenly distributed (36% vs 39%). The differences in success rates between sites was not significant 
(p = 0.64) nor the differences between investigators (p = 0.58)
Conflict of interests: None noted
AEs, adverse events;  ANOVA, analysis of variance; F, female; M, male; RCT, randomised controlled trial; SD, standard 
deviation; TM, tympanic membrane.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Adequate
2. Was the treatment allocation concealed? Adequate 
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Partial 
6. Was the care-provider blinded? Partial 
7. Was the patient blinded? Partial 
8. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate 
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Adequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, not reported, unclear.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: Singer and 
colleagues, 49
Year: 2000
Country: USA
Study design: Double-
blind RCT
Number of centres: One
Setting: Emergency 
department
Funding: None reported
1. DS (Colace): 1 ml in 
liquid form
2. TP (Cerumenex): 1 ml in 
liquid form
Duration of treatment: 
10–15 minutes
Other interventions used: 
If membrane was still 
obscured, ear irrigated 
with 50 ml of lukewarm 
normal saline solution. 
Repeated for a second time 
if TM was still obscured 
(50-ml syringe with 
18-gauge angiocatheter 
at tip)
Number of participants: 50 (1 
ear only per patient)
1. DS: 27
2. TP: 23
Sample attrition/dropout: None 
reported
Inclusion criteria for study entry: 
≥ 1 year, medially required 
visualisation of ear canal (i.e. 
earache, hearing loss, fever) 
and ear canal partially or 
totally occluded by cerumen
Exclusion criteria for study 
entry: Known or suspected 
TM perforation, overt ear 
infection, uncooperative or 
allergy to solvent agents.
Primary outcomes: Proportion of 
ears in which membrane totally 
visible with or without irrigation 
or irrigation with 100 ml irrigant.
Secondary outcomes: Presence of 
AE
Method of assessing outcomes: 
Partially or totally obscured TM 
not stated but an interobserver 
agreement on patients 
independent patient set was good, 
p = 0.79 (reference given)
AE: Participants/parents were 
asked to indicate AEs during 
procedure
Length of follow-up: Immediate
Baseline characteristics of participants
DS (n = 27) TP (n = 23) p-value
Mean age years (SD) 38.7 (30.7) 46.1 (29.1) No p-values reported
Gender M/F (%) 16 (59), 11 (41) 16 (70), 7 (30)
Children ≤ 5 years (%) 9 (33) 4 (17)
Completely occluded 
ears
21 (78) 18 (78)
Results: 13% of participants ≤ 5 years old
Primary outcome: 
n (%) DS (n = 27) TP (n = 23)
Percentage 
difference, 
DS – TP (95% CI) p-value
Completely visualised 
ears after solvent only
5 (19) 2 (9) 9.8  
(–8.8 to 28.5)
No p-values
reported
Completely visualised 
ears after solvent with 
or without irrigation
22 (82) 8 (35) 46.7  
(22.3 to 71.1)
TM visualisation, number (%)a
Complete Incomplete Complete Incomplete p-value
After solvent only 5 (19) 22 (81) 2 (9) 21 (91) No p-values reported
First 50-ml ear 
irrigation
10 (45) 12 (55) 2 (10) 19 (90)
Second 50-ml ear 
irrigation
7 (58) 5 (42) 4 (21) 15 (79)
Comments:
a  Subsets of same data as above.
Secondary 
outcomes DS (n = 27) TP (n = 23)
Percentage 
difference, 
DS – TP (95% CI) p-value
AEs (i.e. pain, vertigo, 
nausea or hearing loss)
0 (0) 0 (0) 0 (–7.8 to –7.8) No p-values 
reported
Comments: 
Singer and colleagues49Appendix 3
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Methodological comments
Allocation to treatment groups: Assignment was generated by computerised random numbers program. A series of opaque 
consecutively numbered syringes were prepared by hospital pharmacy, unconnected to the emergency department or 
enrolment process
Blinding: States double-blind, but as solutions differ in colour (Colace = pink, Cerumenex = yellow) solvent likely to have 
become obvious when used
Comparability of treatment groups: Groups are reported to be similar in age, sex and proportion of completely obscured 
TMs, but no r-values given. However, the mean age of the Colace group was lower, most likely because it included more 
than double the amount of children
Method of data analysis: spss version 8.0 was used for statistical analysis and demographics were compared using chi-
squared test, t-tests for continuous variables. No p- or r-values are reported. Outcomes are presented as point and 
interval estimates with the difference in proportions and 95% CI for the difference. Post hoc subgroup analysis based on 
participants’ age was performed. It is uncertain if the study was powered for a subgroup analysis and authors provide no 
data. Data not extracted
Sample size/power calculation: 80% power to detect differences between groups in main outcome chi-squared test, α = 0.05), 
assuming after application of control solvent 40% of membranes completely visualised
Attrition/dropout: No dropouts are reported and all 50 participants finished treatment
General comments
Generalisability: American cooperative paediatric and adult patients
Outcome measures: Unclear how valid, objective or consistently applied the outcome measures were. Interobserver 
agreement was from an independent patient set
Intercentre variability: N/A
Conflict of interests: None reported
AE(s), adverse event(s); CI, confidence interval; F, female; M, male; N/A, not applicable, RCT, radomised controlled trial; 
SD, standard deviation; TM, tympanic membrane.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Adequate
2. Was the treatment allocation concealed? Adequate
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Inadequate
7. Was the patient blinded? Partial
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Adequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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General Practitioner Research Group41
Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: General Practitioner 
Research Group41
Year: 1965
Country: UK
Study design: Double-blind 
RCT
Number of centres: 14
Setting: Primary care
Funding: None reported
1. Dioctyl-medo ear drops: 
Gelatine capsules with 5% of 
dioctyl sodium sulphosuccinate 
in a maize oil base
2. Control: Oil-based alone
Duration of treatment: Half an 
hour before ear syringing
Other interventions used: Syringing 
(standardised method of 
syringing, only metal type of 
ear syringe was used and size 
recorded)
Number of participants: 
150
1. Dioctyl-medo: 77
2. Control: 73
Sample attrition/
dropout: None 
reported
Inclusion criteria for 
study entry: None 
reported
Exclusion criteria for 
study entry: None 
reported
Primary outcomes: Volume 
of water for syringing and 
syringefuls used
Secondary outcomes: Ease of 
wax removal
Character of syringed wax
Method of assessing outcomes:
Removal: 1 = easy or difficult, 
2 = partial or failed
Earwax: 1 = liquid, 
2 = shredded, 3 = hard lumps
Length of follow-up: 
Immediate
Baseline characteristics of participants
Age, maximum incidence All (n = 150) p-value
Males 31–50 years
Females 51–70 years
Gender M/F 1.3 : 1
Results: 32% of participants were new cases, 53% without syringing for over 12 months
Primary outcomes
Dioctyl (n = 77) Control (n = 73) p-value
No. of syringefuls used
No of 
cases
Total 
quantity 
(ml)
Mean 
per 
case
No of 
cases
Total 
quantity 
(ml)
Mean 
per case
No analysis 
conducted
0.25–1 35 2123 60 26 1732 65
1.25–2 13 1718 130.5 17 2329 136
2.5–4 12 2243 187.5 17 3487 207
5–15 6 2045 341 4 2613 653
Totals 66 8129 122 64 10,181 165.5
Note: Difference in mean caused by one participant in control group requiring 15 syringefuls of water to remove the wax. 
After exclusion of this case virtually no differences between groups in respect of this factor.
Comments: Maximum incidence for males in 31–51 year group, for females 51–70 year group. Syringes hold 2, 3 or 4 oz of 
water (57, 85 or 112 ml) and exact analyses was made in respect of each size syringe and number of syringefuls.
Secondary outcomes
Removal, n (%) Dioctyl (n = 77) Control (n = 73) p-value
Easy  54 (70) 42 (57)
Difficult 17 (22) 23 (32)
Partial 3 (4) 6 (8)
Failed 2 (3) 2 (3)
Comments: partial or failed removal combined was 8% for the dioctyl-medo group and 11% for the control group. Study 
reports differences, but no evidence of any statistical analysis.Appendix 3
110
Character of wax, n (%) Dioctyl (n = 77) Control (n = 73) p-value
Liquid 14 (19) 10 (14)
Shredded 34 (46) 28 (40)
Hard lumps 26 (35) 32 (46)
Failed 3 2
Not recorded 0 1
Comments: AEs were negligible and mostly related to syringing. 91% of dioctyl participants vs 89% control had no side 
effects. 92% of dioctyl participants vs 86% control found procedure tolerable.
Methodological comments
Allocation to treatment groups: Choice treatment by random selection. On ‘breaking the code’ it was found that 77 
participants received dioctyl-medo and 73 participants were in the control group. No other details reported
Blinding: Authors report double-blind trial. Doctor administers drops, assessments and syringing, but no other details 
reported
Comparability of treatment groups: Distribution of participants between groups is reported to be ‘even’ in respect of age and 
sex, but only gender ration is reported
Method of data analysis: Not reported
Sample size/power calculation: Not reported
Attrition/dropout: Not reported
General comments
Generalisability: UK primary care practice patients, no details on severity of occlusions
Outcome measures: Outcome measures open to subjective interpretation. Comparative results between the 2 preparations 
are reported to be unaffected by sex, age or duration of wax, but no description analysis given. Results slightly better in 
males, younger participants and cases of shortest duration. No statistical data to support this.
Intercentre variability: Standardised syringing procedure reported, but no other details given.
Conflict of interests: None reported
AEs, adverse events; F, female; M, male; RCT, randomised controlled trial.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Unknown
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Partial
7. Was the patient blinded? Partial
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Inadequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Pavlidis and Pickering42
Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: Pavlidis and 
Pickering42
Year: 2005
Country: Australia
Study design: RCT
Number of centres: One
Setting: Primary care
Funding: General Practice 
Education & Training, 
and General Registrars 
Association Registrar 
Scholarship & Research 
Fund funded consumables
1. Warm tap water and 
syringing (25-ml Luer-
Lok syringe)
2. Dry syringing (25-ml 
Luer-Lok syringe)
Duration of treatment:
1. 15 minutesa
2. Immediatea
Other interventions used: 
Auroscopic ear canal 
inspection for all patients 
after each syringing 
attempt
Patients with wax in 
both ears: a coin toss 
determined treatment for 
the left ear, with right ear 
receiving alternative
Number of participants: 26, 39 ears
1. n = 22 ears
2. n = 17 ears
Sample attrition/dropout: None reported
Inclusion criteria for study entry: ≥ 18 
years old, with earwax partially or 
totally occluding one or both ears that 
GP would normally syringe
Exclusion criteria for study entry:
Actual or suspected TM perforation
Previous ear surgery
Current otitis media or otitis externa
Swimming during previous 3 days
Ear drops during previous 3 days
Unable to lie down for 15 minutes
Unable to consent
Outcomes:
Mean number of 
syringing attempts
Mean time to syringing 
(minutes)
AEs
Method of assessing 
outcomes:
Syringing – 25 ml 
of water for each 
syringing attempt until 
visibly clear
Length of follow-up: 
Immediate
Baseline characteristics of participants
Wet syringing (ears = 22) Dry syringing (ears = 17) p-value
Gender M/F (%) 15 (68), 7 (32) 11 (65), 6 (35)
Age, mean years (SD) 63 (8) 65 (20) nsb
Mean duration of 
symptoms, days (SD)
300 (421) 249 (353) nsb
Comments: Patients aged between 37 and 90 years.
Results
Outcomes Wet syringing (ears = 22) Dry syringing (ears = 17) p-value
Mean no. of attempts 
(SD)
7.5 (7.3) 25.4 (39.4) p = 0.043 (in favour of 
wet syringing)
Mean time to syringe ear, 
minutesa
6.5 15.4 nsb
Comments: 1 patient had both ears syringed and experienced dizziness (not vertigo). No other AEs were noted and all 
TMs were intact at end of syringing.
a  It is stated that the number of syringing attempts is unusually high due to the small volume of the syringe used (25 ml), 
with GP being reported as normally using larger metal ear syringes (> 120 ml).
b  For non-significant results no p-value is given.Appendix 3
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Methodological comments
Allocation to treatment groups: Patients were randomised by the toss of a coin, but for those with wax in both ears the coin 
toss always determined the treatment for the left ear. Authors acknowledged that randomisation procedure could have led 
to selection bias
Blinding: Open, non-blinded trial
Comparability of treatment groups: Differences between groups for age and mean duration of symptoms reported as non-
significant
Method of data analysis: Unpaired, two-tailed t-tests to compare group differences
Sample size/power calculation: Not reported. It is stated that the study was not powered to detect major complications 
(approximately 1 in 1000 ears syringed)
Attrition/dropout: Not reported
General comments
Generalisability: UK adult patients with earwax partially or totally occluding one or both ears, which would normally be 
syringed by their GP
Outcome measures: Unknown how valid or objective the outcome measures were. All patients had their ears syringed by 
one of the research group to maintain technique consistency. It is stated that most patients preferred 15-minute water 
treatment to using softening preparation for some days at home prior to syringing, but no data are reported to support 
this
Intercentre variability: N/A
Conflict of interests: None reported. General Practice Education & Training, and General Registrars Association Registrar 
Scholarship & Research Fund funded consumables
AEs, adverse events; F, female; M, male; N/A, not applicable; RCT, randomised controlled trial; SD, standard deviation; 
TM, tympanic membrane.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Partial
2. Was the treatment allocation concealed? Inadequate
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Inadequate
6. Was the care-provider blinded? Inadequate
7. Was the patient blinded? Inadequate
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Inadequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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General Practitioner Research Group48
Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: General Practitioner 
Research Group48
Year: 1967
Country: UK
Study design: Double-blind 
RCT
Number of centres: 10
Setting: Primary care
Funding: None reported
1. Waxsol (dioctyl sodium 
sulphosuccinate): 6–7 
drops nightly*
2. Cerumol (p-
dichlorobenzene and 
benzocaine): 6–7 drops 
nightly*
Duration of treatment: 2 nights 
(10 minutes per treatment)
Other interventions used: 
Syringing
*Inserted with dropper 
by participants, following 
standardised instructions. 
If both ears are affected, 
procedure is repeated in the 
other ear
Number of participants: 107
1. Waxsol: 47
2. Cerumol: 60
Sample attrition/dropout: None 
reported
Inclusion criteria for study entry: 
All cases of earwax
Exclusion criteria for study entry: 
Minor degrees of wax easily 
removed without softening 
agent
Outcomes:
Volume of water for 
syringing
Ease of wax removal
Character of wax
AEs
Method of assessing 
outcomes:
Water volumes calculated 
from the number or 
fraction of syringefuls 
required
Removal of wax: easy, 
difficult, partial or failed
Character of wax: liquid, 
shredded or hard lumps
Length of follow-up: 
Immediate
Baseline characteristics of participants
All (n = 107) p-value
Age, %
10–30 years
31–50 years
51–70 years
71 years and over
27
34
31
8
No p-values reported
Elapsed time since last syringing, %
≥ 12 months
10–12 months
7–9 months
4–6 months
1–3 months
New cases
32
17
5
5
1
41
Wax in left ear, %
Wax in right ear, %
Wax in both ears, %
31
23
46
Results
Outcomes: Waxsol (n = 47) Cerumol (n = 60)
p-value Volume of water, fl oz
No. of 
participants
Total 
volume
No. of 
particpants
Total 
volume
0.5 0 0 1 0.5 No p-values reported
1 6 6.0 2 2.0
2 13 26.0 4 8.0
2.5 1 2.5 1 2.5
3 3 9.0 5 15.0
4 3 12.0 8 32.0Appendix 3
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5 0 0 1 5.0
6 6 36.0 4 24.0
7 2 14.0 2 14.0
8 3 24.0 12 96.0
9 0 0 2 18.0
10 1 10.0 2 20.0
12 6 72.0 8 96.0
14 1 14.0 2 28.0
16 2 32.0 2 32.0
18 0 0 1 18.0
24 0 0 1 24.0
26 0 0 1 26.0
40 0 0 1 40.0
Totals 47 257.5 60 501.0
Mean volume per 
participant
5.5 fl oz (156 ml) 8.4 fl oz (240 ml) Not reported
No. of participants (%) No. of participants (%) p-value
≤ 56 ml (2 fl oz) 19 (40) 7 (12) p < 0.05a
> 56 ml 28 (60) 53 (88)
Proportion of participants 
needing 14–112 ml (%)
55 35 p < 0.05a
Comments: 
a  Reported to be significant at 5% level in favour of Waxsol for cases ≤ 2 fl oz (56 ml), remaining ‘in favour’ of Waxsol at 
4 fl oz (112 ml).
Ease of wax removal, no. of participants (%)
Waxsol (n = 47) Cerumol (n = 60) p-value
Easily removed 39 (83) 48 (80) No p-values reported
Removed with difficulty 6 (13) 9 (15)
Partly removed 1 (2) 1 (2)
Failed 1 (2) 2 (3)
Character of wax, % of participants
Liquid 17 17 No p-values reported
Shredded 46 35
Hard lumps 37 24
Comments: Failed participant in Waxsol group – further syringing after a week cleared wax. Failed two participants 
in Cerumol group – one participant had wax removed after olive oil instillation and several attempts at syringing and 
instrumental means; the information for the other participant was not recorded.
Waxsol (n = 47) Cerumol (n = 60) p-value
AEs, % of participants 7 5 No p-values reported
Treatment found tolerable, 
% of participants
89 95
Comments:
a  No details reported.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Methodological comments
Allocation to treatment groups: Choice treatment by random selection. On ‘breaking the code’ it was found that 47 
participants received Waxsol and 60 participants received Cerumol. No other details reported
Blinding: Authors report double-blind trial, but no details reported
Comparability of treatment groups: No split for baseline characteristics of groups provided. Treatment groups are reported 
as reasonably matched, with the exception of a higher proportion of participants without prior treatment in the Cerumol 
group, but no data provided
Method of data analysis: Some statistical significant differences commented on, but minimal details reported and analysis 
based on post hoc division based on volume water
Sample size/power calculation: No details reported
Attrition/dropout: No details reported
General comments
Generalisability: UK Primary Care Practice patients, no details on severity of occlusions
Outcome measures: Unclear how valid, objective and consistently applied the measures were
Intercentre variability: Standardised instructions to patients reported, but no details given about possible variation in 
syringing procedure
Conflict of interests: None reported
AEs, adverse events; RCT, randomised controlled trial.
Quality criteria for assessment of RCTs (NHS CRD) 
Item Judgementa
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Inadequate
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Partial
7. Was the patient blinded? Partial
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Inadequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.Appendix 3
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Amjad and Scheer51
Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: Amjad and 
Scheer51
Year: 1975
Country: USA
Study design: Double-blind 
RCT
Number of centres: Not 
stated
Setting: Primary care
Funding: None reported
1. 1 dose of TP (triethanolamine 
polypeptide) oleate condensate
2. 1 dose of carbamide peroxide
Duration of treatment: Each 
affected ear was treated with 
1 application of drops, which 
were left in the ear canal for 30 
minutes
Other interventions used: Irrigation 
with lukewarm water after 
treatment
Number of participants: 80
1. TP: n = 40
2. Control: n = 40
Sample attrition/dropout: 
None reported
Inclusion criteria for study 
entry: Hard or impacted 
earwax
Exclusion criteria for study 
entry: None reported
Primary outcomes: Degrees of 
wax removal
Secondary outcomes: AE 
(subjective and observations 
of objective side effects)
Method of assessing outcomes:
Excellent (removal of all wax), 
good (removal of most wax), 
fair (removal of some wax) 
and poor (removal of little or 
no wax)
Degree of obstruction: 
complete or partial
Length of follow-up: Immediate
Baseline characteristics of participants
Pretreatment wax, number of ears
TP (n = 40) Carbamide peroxide (n = 40) p-value
Impacted 19 18 No p-values 
reported Hard 16 16
Loose 1 3
Soft 4  3 
Complete obstruction 36 32
Partial obstruction 4 8
Results
Primary outcomes
Efficacy of treatment, 
n (%)
TP (n = 40) Carbamide peroxide (n = 40) p-value
Excellent  27 (68) 2 (5) No p-value 
reported
Good 8 (20) 5 (12)
Fair 2 (5) 4 (10)
Poor 3 (7) 29 (73)
Effective (‘excellent’ plus 
‘good’)
35 (88) 7 (17)
Comments:
Secondary outcomes
TP (n = 40) Carbamide peroxide n = 40 p-value
AE 0 0 No p-value 
reportedDOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Efficacy to 
pretreatment wax
No. E + G F P E + G% No. E+G F P E + G% p-value
Impacted 19 16 1 2 84 18 2 0 16 11 No p-value 
reported Hard 16 14 1 1 88 16 3 2 11 19
Loose 1 1 0 0 100 3 1 0 2 33
Soft 4 4 0 0 100 3 1 2 0 33
Complete obstruction 36 31 2 3 86 32 4 3 25 13
Partial obstruction 4 4 0 0 100 8 3 1 4 38
Comments: No., number of ears; E + G, effective (‘excellent’ plus ‘good’); F, Fair; P, Poor.
Methodological comments
Allocation to treatment groups: 80 participants were randomly divided into equal intervention and control group
Blinding: Study states double-blind evaluation, but no details reported
Comparability of treatment groups: No details reported. Pretreatment wax appears similar
Method of data analysis: None reported. Only descriptive/frequency data presented
Sample size/power calculation: None reported
Attrition/dropout: None reported
General comments
Generalisability: No baseline characteristics provided, American population
Outcome measures: It is unclear how valid or objective the measure was, or how consistent the assessments were; study 
states that no comparison between treatments was intended, as carbamide peroxide needs multiple instillations
Intercentre variability: N/A – it appears to be a one-centre study
Conflict of interests: Cerumenex distributed by Purdue Frederick Co., New York, NY
AEs, adverse events; N/A, not applicable; RCT, randomised controlled trial.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Inadequate
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Inadequate
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Partial
7. Was the patient blinded? Partial
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Inadequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknownAppendix 3
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Dummer and colleagues44
Extracted by: EL Checked by: PH
Reference and design Intervention Participants Outcome measures
Author: Dummer and 
colleagues44
Year: 1992
Country: UK
Study design: RCT
Number of centres: One
Setting: Primary care
Funding: Supported by 
Napp Laboratories Ltd
1. Audax ear drops, night and 
morning for 3 days*
2. Cerumol ear drops, night 
and morning for 3 days*
Duration of treatment: 3 days
Other interventions used: None 
reported
*Drops for 3 days and 
assessed on 4th day in 
methods, drops for 4 days 
after which reassessment 
took place in summary
Number of participants: 50
Audax: 27
Cerumol: 23
Sample attrition/dropout: 
None reported
Inclusion criteria for study 
entry: Aged between 19 
and 90 years, presenting 
with impacted or hardened 
earwax
Exclusion criteria for 
study entry: Those with 
inflammation or the 
external auditory meatus, 
seborrhoeic dermatitis 
and eczema affecting the 
external ear, a perforated 
TM, a pre-existing ear 
infection requiring 
treatment with systemic 
antibiotics, known salicylate 
sensitivity, instrumentation 
of the ears (hearing aids), 
regular swimmers
Primary outcomes: (Not defined as 
primary or secondary.) Outcomes 
included: amount, colour and 
consistency of wax, symptoms, 
hearing, global impression of 
treatment efficacy (patient and 
investigator) and tolerability
Method of assessing outcomes: 
Amount of wax – considerable 
block to meatus, considerable but 
no blockage, medium, scanty
Colour – black, brown, yellow, 
pale
Consistency – concrete hard, 
firm, soft, runny
Symptoms – none, deafness, 
blockage, pain, discharge, 
irritation
Objective hearing – normal 
whispered voice test, abnormal 
whispered voice test, Rinne test 
abnormal, Weber test abnormal
Length of follow-up: Median 
number of days between visits 1 
and 2 was 4 days (range 3–7 days)
Baseline characteristics of participants
Audax (n = 27) Cerumol (n = 23) p-value
Mean age, years 51 55
Gender, M/F, n 18/9 14/9
Results: primary outcomes
Amount of wax
Audax (n = 27, ears = 54) Cerumol (n = 23, ears = 46) p-value
Increased 0 0 Not reported across groups
No change 24 (44%) 22 (48%)
Decreased 28 (52%) 24 (52%)
Missing data 2 (4%) 0
Colour of wax
Darkened 0 0 States no significant 
differences, p-value not 
reported
No change 10 9
Lightened 42 36
Missing data 2 1
Consistency of wax
Hardened 0 0 States no significant 
differences, p-value not 
reported
No change 6 5
Softened 46 40
Missing data 2 1
Objective hearing
Improved 7 (13%) 2 (4%) States no significant 
differences, p-value not 
reported
No change 45 (83%) 44 (96%)
Worsened 0 0
Missing data 2 (4%) 0DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Overall assessment
Investigator rated 
‘effective’
36 participantsa 22 participants Unclear if tested
Overall assessment
Participant rated 
‘effective’
25 (93%) participants 23 (100%) participants States no significant 
differences, p-value not 
reported
Tolerability  2 (both slight irritation to 
the ear)
2 (1 slight itch, 1 buzzing noise 
after use)
Subgroup data of 25 participants (12 Audax, 13 Cerumol) with abnormal hearing on entry.
a  It is unclear if this is an error, as there only 27 participants in the group or if this should have said number of ears 
instead of patients as stated in the study.
Objective hearing
Improved 7 2 p < 0.05 (p-value not 
reported for other change 
variables)
No change 4 11
Worsened 0 0
Missing data 1 0
Comments: No baseline scores reported for any of these measures.
Methodological comments
Allocation to treatment groups: States ‘allocated at random’ but no further details of randomisation schedule or allocation 
concealment
Blinding: States single-blind (investigator), but no details of how this was maintained
Comparability of treatment groups: States treatment groups were well matched for age, sex and objective hearing
Method of data analysis: Each ear was assessed separately (100 in total) and tests for differences between treatments were 
made between patients; p < 0.05 statistically significant. Mann–Whitney U-test for amount, colour, consistency, global 
efficacy. Fisher’s exact test for hearing test. Demographics chi-squared test
Sample size/power calculation: Not reported
Attrition/dropout: Missing data shown in tables, but reasons for missing data unclear
General comments
Generalisability: Difficult to assess as minimal demographic characteristics presented
Outcome measures: Unclear how valid, objective, or consistently applied the outcome measures used were
Intercentre variability: Not applicable
Conflict of interests: States supported by Napp Laboratories, who manufacture Audax
F, female; M, male; RCT, randomised controlled trial; TM, tympanic membrane.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Partial
5. Were outcome assessors blinded to the treatment allocation? Inadequate
6. Was the care-provider blinded? Inadequate
7. Was the patient blinded? Inadequate
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Inadequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.Appendix 3
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Fahmy and Whitefield54
Extracted by: EL Checked by: AC
Reference and design Intervention Participants Outcome measures
Author: Fahmy and 
Whitefield54
Year: 1982
Country: UK
Study design: CCT
Number of centres: One for 
study 1 and 2, multicentre 
for study 3, but number of 
centres not reported
Setting: Studies 1 and 2 in 
secondary care, study 3 in 
primary care
Funding: Not reported
Study 1:
1. Exterola
2. Glycerol control
Study 2:
1. Exterol
2. Cerumolb
Study 3:
1. Exterol
2. Cerumol
Study 4:
1. Exterol (data not 
reported here as no 
comparison)
For all studies 
participants instilled 5–10 
drops twice per day
Duration of treatment: 1 
week
Other interventions used:
a  Urea hydrogen 
peroxide, 5% in 
anhydrous glycerol
b  Arachis oil 
preparation with 2% 
paradichlorobenzene, 
5% chlorbutol, 10% 
turpentine oil
Number of participants:
Study 1: 40 participants (80 ears) 
completed the study
1. Exterol: 20 people
2. Glycerol control: 20 people
Study 2: 50 patients (100 ears) 
completed the study
1. Exterol: 25
2. Cerumol: 25
Study 3: 160 patients (286 ears) 
completed the study
1. Exterol 157 ears
2. Cerumol 129 ears
Sample attrition/dropout: Not reported 
but reports numbers as those 
‘completing’ the study.
Inclusion criteria for study entry: States 
as far as possible the protocol 
remained identical (for all studies); 
patients presenting with earwax 
problems
Exclusion criteria for study entry: 
Patients with inflammation of the 
external meatus, middle ear pathology, 
e.g. mastoid cavities, or perforation of 
the TM; a scarred membrane did not 
constitute a contraindication
Primary outcomes: 
(Not defined as 
primary or secondary.) 
Wax occlusion, wax 
consistency, ease of 
syringing
Method of assessing 
outcomes: States each 
ear was assessed 
independently. 
No definitions of 
classification of 
outcomes noted
Length of follow-up: 1 
week
Baseline characteristics of participants
Study 1, no. of ears
p-value Exterol (n = 20, 40) Glycerol control (n = 20, 40)
Degree of wax occlusion (ears)
Total 36 36 Not reported to be 
tested Partial 4 4
Consistency of wax (ears)
Very hard 20 16 Not reported to be 
tested Hard 20 24
Study 2, no. of ears
p-value Exterol (n = 25, 50) Cerumol (n = 25, 50)
Degree of wax occlusion (ears)
Total or subtotal 23 19 Not reported to be 
tested Partial 27 31
Consistency of wax (ears)
Very hard 12 8 Not reported to be 
tested Hard 33 27
Soft 5 15DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Study 3, no. of ears
p-value Exterol (n = 157) Cerumol (n = 129)
Degree of wax occlusion (ears)
Total or subtotal 97 86 Not reported to be 
tested Partial 60 43
Consistency of wax (ears)
Hard 114 97 Not reported to be 
tested Soft 43 32
Results
Study 1, no. of ears
p-value
Exterol  
(n = 20, 40 ears)
Glycerol control  
(n = 20, 40 ears)
Initially very 
hard wax
Initially hard 
wax
Initially very 
hard wax
Initially 
hard wax
Wax dispersed without 
syringing
– 6 – – Not stated
Wax syringed easily 15 14 2 18
Wax syringed with 
difficulty
5 – 14 6
Comments: When the number of ears not requiring syringing is added to the number syringed easily, Exterol was 
statistically significantly superior to the control group; p < 0.001. After treatment with Exterol a significant number ears did 
not require syringing compared with glycerol.
Study 2, no. of ears:
p-value
Exterol (n = 25, 50 ears) Cerumol (n = 25, 50 ears)
Initially 
very 
hard
Initially 
hard
Initially 
soft
Initially 
very 
hard
Initially 
hard
Initially 
soft
Wax dispersed without 
syringing
4 14 2 – – 5 See comments
Wax syringed easily 6 18 3 – 10 9
Wax syringed with 
difficulty
2 1 – 8 17 1
Comments: the number of ears not requiring syringing is markedly greater with Exterol than with Cerumol, p < 0.001. 
When the number of ears not requiring syringing is added to the number syringed easily, Exterol was statistically 
significantly superior to Cerumol; p < 0.001.
Study 3, no. of ears
p-value
Exterol (n = 157) Cerumol (n = 129)
Initially hard 
wax
Initially soft 
wax
Initially 
hard wax
Initially soft 
wax
Wax dispersed without 
syringing
45 19 12 15 See comments
Wax syringed easily 60 22 52 14
Wax syringed with 
difficulty
9 2 33 3
Comments: The number of ears not requiring syringing is markedly greater after treatment with Exterol than with 
Cerumol; p < 0.001. When the number of ears not requiring syringing is added to the number syringed easily, Exterol was 
statistically significantly superior to Cerumol; p < 0.001.Appendix 3
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Methodological comments
Allocation to treatment groups: Participants presenting with earwax were treated with alternate preparations on a sequential 
basis
Blinding: Not reported
Comparability of treatment groups: No baseline characteristics reported
Method of data analysis: analysed by t-test and chi-squared test; appears to be selective statistical testing of differences
Sample size/power calculation: Not reported
Attrition/dropout: Text states numbers completing the study therefore unsure if any participants were potentially included, 
but not reported upon
General comments
Generalisability: No baseline demographic characteristics, UK population
Outcome measures: Unclear how valid, objective or consistently applied the outcome measures were
Intercentre variability: Not reported
Conflict of interests: Dermal Laboratories supplied the Exterol and control preparations
CCT, controlled clinical trial; TM, tympanic membrane.
Quality criteria for assessment of controlled clinical studies
Item Judgementa
Were the groups similar at baseline in terms of prognostic factors? Unknown
Were the eligibility criteria specified? Partial
Were outcome assessors blinded to the treatment allocation? Unknown
Were the point estimates and measure of variability presented for the primary outcome measure? Partial
Did the analyses include an ITT analysis? Unknown
Were withdrawals and dropouts completely described? Unknown
Were participants likely to be representative of the intended population? Unknown
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Jaffe and Grimshaw50
Extracted by: EL Checked by: AC
Reference and design Intervention Participants Outcome measures
Author: Jaffe and 
Grimshaw50
Year: 1978
Country: UK
Study design: RCT
Number of centres: Up 
to 15
Setting: Primary care
Funding: None reported
1. Otocerol,* 4 drops at night, for 
3 nights
2. Cerumol,* 5 drops at night, for 
3 nights
Duration of treatment: 3 nights
Other interventions used: Patients 
were asked to gently cleanse 
the ear with cotton wool the 
following morning
*No details of constitution of the 
treatment
Number of participants: 106
Otocerol: 53
Cerumol: 53
Sample attrition/dropout: Not 
reported
Inclusion criteria for study entry: 
Patients presenting with wax 
in their ears and who would 
normally be prescribed a 
cerumenolytic
Exclusion criteria for study entry: 
Overt perforation of the drum 
or severe infection
Primary outcomes: (Not 
defined as primary or 
secondary). Ease of 
syringing, doctors overall 
impression, adverse 
effects
Secondary outcomes: See 
above
Method of assessing 
outcomes: Not reported
Length of follow-up: 
Patients asked to 
revisit GP after three 
instillations
Baseline characteristics of participants
Otocerol (n = 53) Cerumol (n = 53) p-value
Gender M/F 32/21 25/28 χ2 = 1.86, no p-value 
given
Gender distribution
p-value Age Male Female Total Male Female Total
0–9 years 0 0 0 1 0 1 Reports not statistically 
significant using the 
Kolmogorov–Smirnov 
test, but value itself not 
reported.
10–19 years 5 0 5 0 1 1
20–29 years 3 1 4 6 3 9
30–39 years 6 2 8 2 4 6
40–49 years 5 2 7 1 4 5
50–59 years 6 6 12 7 8 15
60–69 years 5 4 9 3 3 6
70–79 years 1 6 7 3 4 7
80–89 years 1 0 1 2 1 3
Grade of impaction
Mild 13 10 Not statistically 
significant, χ2 = 1.37, no 
p-value given
Moderate 26 32
Severe 14 11
Comments: Degree of impaction classified as mild (soft wax, which could be syringed at once if necessary), moderate 
(small plug of hard wax for which a cerumenolytic would usually be used before syringing) or severe (large plug of hard 
wax for which a cerumenolytic would be essential). Grades on presentation were more widely spread in the Otocerol 
group with more mild and severe cases but this was not statistically significant.
Duration of symptoms, 
median
21 days 14 days
Results: primary outcomes
Syringing needed
Otocerol (n = 53) Cerumol (n = 53) p-value
Yes 39, no 14 Yes 47, no 6 Difference in those 
requiring syringing 
χ2 = 3.94, p < 0.05Appendix 3
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Syringing needed by grade at entry
Mild Yes 6, no 7 Yes 6, no 4
Moderate Yes 19, no 7 Yes 30, no 2
Severe Yes 14, no 0 Yes 11, no 0
Comments: 
Results: secondary outcomes
Doctor reported ease of syringing, where required, n (%)
Otocerol (n decline from 53) Cerumol (n declines from 53) p-value
Ease of syringing by grade at entry
30/39 (76.9) 34/47 (72.3)
χ2 = 0.25, not 
significant
Mild Easy 5, not easy 1 Easy 5, not easy 1
Moderate Easy 14, not easy 5 Easy 25, not easy 5
Severe Easy 11, not easy 3 Easy 4, not easy 7
Adverse effects, total 
no, with side effects
7 10 Not statistically 
significantly different
Effects reported
Pain on application 0 1
Irritation on application 3 8
Pain during use 1 1
Irritation during use 4 4
Slight giddiness 1 0
Unpleasant smell such 
that patient would not 
use again
0 1
Doctor reported would 
not use product again, n 
patients
8 9
Overall judgement 
effectiveness successa
38 33 Overall response better 
for Otocerol, but not 
statistically significantb
Failurec 10 13
Partiald 5 7
Comments:
a  Defined as those in whom syringing was not required or where it was easy and no reports of side effects.
b  The ratio of success–failure was highly significant in each group (p < 0.001 Otocerol, p < 0.01 Cerumol).
c  Defined as those in whom syringing was difficult (with or without side effects).
d  Defined as those who reported side effects but in whom the doctor found it easy to syringe and had no reservations 
about using the product again.
Methodological comments
Allocation to treatment groups: States randomly allocated to either treatment according to a previously determined scheme 
(scheme not outlined)
Blinding: States double-blind, but no other descriptions given
Comparability of treatment groups: Slightly higher male–female ratio in the Otocerol group, but this was not statistically 
significant, neither was the age distribution between the two groups
Method of data analysis: By chi-squared test, no other details reported
Sample size/power calculation: Not reported
Attrition/dropout: Not reported, from numbers assume none. Some outcomes reported subsets of patientsDOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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General comments
Generalisability: Minimal detail of participant demographics, children and adults in sample
Outcome measures: Unclear how valid, objective or consistently applied the outcome measures were
Intercentre variability: 15 GPs took part in the trial, unclear if all from different centres, but the majority likely to be
Conflict of interests: None reported
F, female; M, male; NS, normal saline; RCT, randomised controlled trial.
Quality criteria for assessment of RCTs (NHS CRD) 
Item Judgementa
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Partial
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Partial
7. Was the patient blinded? Partial
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Inadequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.Appendix 3
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Carr and Smith52
Extracted by: EL Checked by: AC
Reference and design Intervention Participants Outcome measures
Author: Carr and Smith52
Year: 2001
Country: USA and/or 
Canada
Study design: RCT
Number of centres: Unclear
Setting: Primary care – 
self-treatment
Funding: Not reported
1. Aqueous sodium 
bicarbonate,10%
2. Aqueous acetic acid, 2.5%
Duration of treatment: 4 drops 
daily for 14 days
Other interventions used: No 
other ear drops during the 
duration of treatment
Number of participants: 69
Sodium bicarbonate: 35
Acetic acid: 34
Sample attrition/dropout: Two 
participants out of the acetic 
acid group discontinued due 
to stinging in the ear canal
Inclusion criteria for study 
entry: Those with occlusive 
cerumen in at least 1 ear; 
most presented with other 
complaints and ceruminosis 
was noted incidentally
Exclusion criteria for study 
entry: History of TM 
perforation, present 
ventilation tubes, a mastoid 
cavity, otitis externa, or 
unwillingness to participate 
in the 2-week treatment 
regimen
Primary outcomes: Degree of 
cerumen
Secondary outcomes:
Method of assessing outcomes: 
Degree of cerumen scored 
by 1 of the 2 examiners 
from 1–4 (1 = none, 2 = small 
amount on canal walls, 
3 = TM visible but significant 
amount of cerumen present, 
4 = occlusive cerumen). 
Reports based on scale used 
by Schwartz and colleagues94 
(study looked at otitis 
media). Tested for reliability 
by 3 observers measuring 
60 ears of people not in the 
study. Average change in 
score was averaged across 
both ears if both ears initially 
scored > 1. Maximum change 
was the best score in each 
participant
Length of follow-up: 14 days
Baseline characteristics of participants
Sodium bicarbonate 
(n = 35) Acetic acid (n = 34) p-value
Mean age, years 27.0 25.3
N, ears 70 68
Degree of cerumen Not reported Not reported
Results
Primary outcomes 
Sodium bicarbonate 
(n = 35) Acetic acid (n = 34) p-value
Mean change degree of 
cerumen
0.66 0.78 No difference, p-value not 
given
Mean maximum change 1.00 1.00
Comments: Multivariate analysis showed that differences in maximum scores were significantly related to age; children had 
higher average and maximum scores.
Subgroup analyses, 
children onlya
Sodium bicarbonate 
(n = 16, 26 ears)
Acetic acid  
(n = 20, 29 ears) p-value
Mean age, years 8.7 7.26
Mean change 0.92 0.93
Mean maximum change 1.31 1.25
Category change, n (ears)
Change = 0 10 9
Change = 1 10 15
Change = 2 4 3
Change = 3 2 2DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Comments:
a  For the child group the power to detect a difference was measured a priori and therefore subgroup reported here. 
Change scores between children and adults also presented, but not extracted here as no evidence it was an a priori 
decision.
Adverse events: no cases of otitis externa or external auditory canal dermatitis.
Methodological comments
Allocation to treatment groups: Each participant was given a dropper bottle of the study solution chosen randomly by the 
patient from a box where only the identical bottle caps were visible
Blinding: Each bottle was marked as either A or B so that both patient and investigator were blinded to the solution 
used. Bottles were prepared by a hospital pharmacy, with unblinding occurring after completion of all data collection and 
analysis. Also states that although patients could detect the odour of acetic acid, in no case could the examiner detect it
Comparability of treatment groups: No discussion from authors. Minimal demographic information reported, ages appear to 
be similar. No baseline scores of the primary end point
Method of data analysis: Analysis done for average change in score and maximum change in score per patient using a Mann–
Whitney U-test. Paediatric results were separated from the group and analysed independently. Interobserver difference in 
scoring cerumen was 0.76
Sample size/power calculation: The power to detect a difference of one category (paediatric group) (on the degree of 
cerumen) if it existed in the data was reported to be 85%. No other details of this calculation reported, nor any power 
calculation for the rest of the study
Attrition/dropout: Two participants in the acetic acid group were withdrawn and reasons given, unclear whether an ITT 
analysis was undertaken
General comments
Generalisability: Unclear as minimal characteristics of participants given
Outcome measures: Unclear how valid and objective the outcome measures were. Inter-rater reliability was assessed, 
however, and was good
Intercentre variability: Unclear how many centres were involved
Conflict of interests: None noted
ITT, intention to treat; RCT, randomised controlled trial; TM, tympanic membrane.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Adequate
2. Was the treatment allocation concealed? Adequate
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Partial
7. Was the patient blinded? Partial
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Adequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.Appendix 3
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Lyndon and colleagues45
Extracted by: EL Checked by: AC
Reference and design Intervention Participants Outcome measures
Author: Lyndon and 
colleagues45
Year: 1992
Country: UK
Study design: RCT
Number of centres: 
Unclear
Setting: Primary care
Funding: Not reported
1. Audax* ear drops, 
am and pm (self 
administered)
2. Earex** ear drops, 
am and pm (self 
administered)
Duration of treatment: 4 
days (patients returned 
to clinic on fifth day for 
syringing)
Other interventions used:
States all centres used 
a standardised syringing 
procedure using tepid tap 
water
*Choline salicylate (20%) 
and ethylene oxide-
polyoxypropylene glycol 
(analgesics) combined with 
glycol and glycerol
**Arachis oil, almond oil 
and rectified camphor oil
Number of participants: 36
Audax: 38 ears (19 participants)
Earex: 34 ears (17 participants)
Sample attrition/dropout: 35 attended 
on both assessment days (1 Earex 
participant failed to return)
Inclusion criteria for study entry: 
Patients presenting in general 
practice with symptoms of 
hardened earwax in either or 
both ears requiring cerumenolytic 
treatment; patients aged 16 years 
or over
Exclusion criteria for study entry: 
Inflammation of the external 
auditory meatus, middle ear 
pathology or perforation of the TM, 
pre-existing ear infection requiring 
treatment with systemic antibiotics, 
known salicylate sensitivity
Primary outcomes: (Not 
defined as primary or 
secondary.) Degree of 
impaction, ease of syringing, 
global impression of efficacy. 
Side effects/discomfort.
Secondary outcomes: (see 
above)
Method of assessing outcomes: 
Separate assessments were 
carried out at all times for 
the left and right ear. The 
degree of wax impaction 
was rated as non-existent 
(excluded the patient), mild 
(could be syringed once if 
necessary), moderate (small 
plug of hard wax) or severe 
(large plug of hard wax). 
Ease of syringing rated as 
not required, easy, difficult, 
impossible
Length of follow-up: 5 days
Baseline characteristics of participants
All participants p-value
Male–female ratio 19 : 17
Mean age 52 years (range 19 to 86 years)
Pretreatment degree of impaction
Audax, no. of ears = 38 Earex, no. of ears = 34 p-value
None 2 1
Mild 7 8
Moderate 26 22
Severe  3 3
Results
Post-treatment score
Degree of impaction Audax, no. of ears = 38 Earex, no. of ears = 34 p-value
None
Mild
Moderate (Mod)
Severe (Sev)
Missing data
10
17
9
2
6
11
12
3
2
See below
Degree of impaction 
at end point by 
pretreatment score
Post-treatment Post-treatment p-value
None Mild Mod Sev None Mild Mod Sev
None 1 1 0 0 1 0 0 0 See below
Mild 3 4 0 0 2 4 0 0
Moderate 6 12 8 0 3 7 11 1
Severe 0 0 1 2 0 0 1 2
Comments: Although the difference between the two groups did not reach statistical significance, a trend was seen 
towards less impaction post-treatment in the Audax group than the Earex group.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Ease of syringing, ears
Not required 15 7 p < 0.005a
Easy 22 12
Difficult 1 11
Impossible 0 0
Missing data 0 4
Comments: Paper states that six patients in the Audax group and three in the Earex group did not require syringing 
of either ear. This does not correspond with the number of ears reported as not requiring syringing in the table (and 
extracted above).
a  Significant difference in favour of Audax in that syringing was more frequently scored as ‘not required’ or ‘easy’.
Investigator’s global impression efficacy (states no. ears, but n’s do not add up so assume no. patients)
Completely effective 8 5
Very effective 9 1
Fairly effective 2 7
Not effective 0 3
Missing data 0 1
Total 19 17
Participants’ global impression efficacy (states no. ears, but n’s do not add up so assume no. patients)
Completely effective 8 5
Very effective 9 2
Fairly effective 2 7
Not effective 0 2
Missing data 0 1
Total 19 17
Comments: States there was a statistically significant difference in favour of Audax (p < 0.01). ‘Not effective’ and ‘fairly 
effective’ categories were merged for the analysis. Unclear if this is investigator rating alone, participant rating alone or 
some combination.
AEs or discomfort 0 1 (slight irritation), 1 (smell 
unacceptable)
Methodological comments
Allocation to treatment groups: States ‘according to a pre-determined randomisation allocation schedule’
Blinding: Not reported
Comparability of treatment groups: No baseline characteristics reported between groups. Baseline degree of impaction 
appear to be similar
Method of data analysis: Chi-squared test to compare reduction in impaction from pretreatment to post-treatment for each 
treatment, and the difficulty of syringing between treatments
Sample size/power calculation: Study was designed to have 50 completing patients, although limited recruitment only 
generated complete data on 36 patients. This provided sufficient power, however, to differentiate between the two 
treatments. No details of sample size calculation to establish this is reported
Attrition/dropout: One participant failed to return (no reason documented)
General comments
Generalisability: People over 16 years (19 years and over)
Outcome measures: Unclear how valid, objective and consistently applied outcome measures were
Intercentre variability: Uncertain how many centres
Conflict of interests: None noted
AE, adverse event; RCT, randomised controlled trial; TM, tympanic membrane.Appendix 3
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Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Unknown
7. Was the patient blinded? Unknown
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Adequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Burgess43
Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: Burgess43
Year: 1966
Country: UK
Study design: CCT
Number of centres: One
Setting: Primary care
Funding: None reported
1. Dioctyl-medo (in maize 
oil): 1 capsule (0.5 ml) am 
and pm*
2. Maize oil capsules*
Duration of treatment: 4 days
Other interventions used: 
Syringing (Bacon syringe)
*Participants were supplied 
with 1 box (10 capsules) and 
capsules were instilled 4–10 
times
Number of participants: 50 
(74 ears)
1. Dioctyl-medo: 33 ears
2. Maize oil: 41 ears
Sample attrition/dropout: Not 
reported
Inclusion criteria for study 
entry: More than one-half of 
an ear occluded by wax
Exclusion criteria for study 
entry: None reported
Outcomes: Average total of 
water used, ease of removing 
wax and character of wax, side 
effects
Method of assessing outcomes: 
Number or fraction of 
syringefuls required. Removal 
of wax: easy, difficult, partial 
and failed. Character of wax 
removed: liquid, shredded and 
lumps
Length of follow-up: Between 2 
and 7 days
Baseline characteristics of participants
All (n = 50, 74 ears) p-value
Age 18–75 years No p-values reported
Gender M/F 32 : 18
Ears completely occluded 
(%)
59 (79.7)
Results
Outcomes Dioctyl-medo (ears = 33) Maize oil (ears = 41) p-value
Average water volume 111 ml 81 ml No p-values reported
Removal of wax, number of ears
Easy 19 33
Difficult 11 5
Partiala 3 3
Faileda 1 0
Character of removed wax, number of ears
Liquid 1 4
Shredded 5 6
Lumps 27 31
Side effects 0 0
Comments:
a  All the partially successful removals and the one failed removal occurred in ears not completely occluded at baseline.
Methodological comments
Allocation to treatment groups: Unknown – used coded capsules for treatment, with code unbroken until trial finished
Blinding: Both GP and patient blinded to treatment
Comparability of treatment groups: No details reported
Method of data analysis: None reported
Sample size/power calculation: None reported
Attrition/dropout: None reported
General comments
Generalisability: No breakdown of baseline characteristics between groups provided, adult UK population.
Outcome measures: It is unclear how valid or objective the measures are
Intercentre variability: N/A
Conflict of interests: Medo Chemicals Ltd supplied Dioctyl-medo ear drops
CCT, controlled clinical trial; F, female; M, male; N/A, not applicable.Appendix 3
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Quality criteria for assessment of controlled clinical studies
Item Judgementa
1. Were the groups similar at baseline in terms of prognostic factors? Unknown
2. Were the eligibility criteria specified? Partial
3. Were outcome assessors blinded to the treatment allocation? Adequate
4. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
5. Did the analyses include an ITT analysis? Inadequate
6. Were withdrawals and dropouts completely described? Inadequate
7. Were participants likely to be representative of the intended population? Unknown
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
133
Eekhof and colleagues53
Extracted by: EL Checked by: PH
Reference and design Intervention Participants Outcome measures
Author: Eekhof and 
colleagues53
Year: 2001
Country: The 
Netherlands
Study design: RCT
Number of centres: Four
Setting: Primary care
Funding: Not reported
1. Water at body 
temperature
2. Control group – 
self administered ‘oil’ 
each night for 3 days
Duration of treatment: 
15 minutes
Other interventions 
used: After 15 
minutes a series of 
attempts at syringing 
was made (syringing 
methodology 
standardised, and 
method reported) 
for the intervention 
group, for the control 
group syringed after 
3 days
Number of participants: 130 participants 
(224 ears) initially syringed of which 42 
had persistent earwax and randomised 
(59 ears)
Intervention: 22
Control: 20
Sample attrition/dropout: None reported
Inclusion criteria for study entry: All 
patients with complaints resulting from 
earwax offered syringing. After each 
attempt at syringing the auditory canal 
was checked with an auriscope and the 
extent of blocking noted (obstruction 
levels of 0–25%, 25–49%, 50–74% and 
75–100%) were used. If earwax was 
persistent (> 75% after 5 attempts at 
syringing) then patient was eligible to 
be included in the study
Exclusion criteria for study entry: 
TM perforation, middle ear 
operation, otitis externa, swimming 
within previous 72 hours, use of 
cerumenolytics in the previous 72 
hours
Primary outcomes: Number 
syringing attempts needed to 
remove wax
Secondary outcomes: None
Method of assessing outcomes: 
Unclear
Length of follow-up: Immediate 
for water group, but 3 days 
for oil group
Baseline characteristics of participants
All patients p-value
Gender: M/F 20/22
Mean age 51 years (SD 16)
Results
Primary outcomes  Water (n = 22) Oil (n = 20) p-value
Mean number syringing 
attempts
3.0 (95% CI 2.4, 3.6) 2.4 (95% CI 1.7, 3.1) Difference between means 
0.6 (95% CI –0.3, 1.5), 
p = 0.18
Number of syringing attempts needed per patient by intervention group
Number of patients in which the earwax was removed 
after each attempt at syringing
Mean no. attempts Water group Oil group p-value
1 4 6 Not reported to be tested
1.5 1 2
2 2 5
2.5 3 1
3 2 2
3.5 4 0
4 2 0
5 3 4
6 1 0
Comments: Authors report, therefore, that water leads to comparable results; however, study not powered for 
equivalence but superiority.Appendix 3
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Methodological comments
Allocation to treatment groups: States ‘randomised’ study – allocation to groups by birth year, even or odd. In patients with 
both ears having persistent wax, both had the same strategy
Blinding: None
Comparability of treatment groups: Not reported
Method of data analysis: Means compared with t-test. In patients with wax in both ears, the mean number of syringing 
attempts needed for both ears in one patient were used for the calculations. All ears still with persistent wax after 5 
syringing attempts were given the value of 6 for the calculations
Sample size/power calculation: A difference of 2 syringing attempts between the mean of the groups was found to be 
clinically significant, 13 people were therefore needed in each group. With groups of 20 and 22 patients a difference of 1.6 
between means would be statistically significant
Attrition/dropout: Not reported and n’s appear to add up
General comments
Generalisability: Minimal details of population group reported; however, all included studies had five failed syringing 
attempts
Outcome measures: Unclear how valid, objective and consistently applied the measures were. Number of attempts at 
syringing is a proxy for adequacy of clearance of wax
Intercentre variability: No details reported, four centres included
Conflict of interests: No funding source reported, reviewer assumes not funded directly (trainee GPs and no pharmaceutical 
agents used)
CI, confidence interval; F, female; M, male; RCT, randomised controlled trial; SD, standard deviation; TM, tympanic 
membrane.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Inadequate
2. Was the treatment allocation concealed? Inadequate
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Unknown
7. Was the patient blinded? Unknown
8. Were the point estimates and measure of variability presented for the primary outcome 
measure?
Adequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Unknown
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Appendix 4  
Data extraction forms: secondary care setting
Caballero and colleagues55
Extracted by: EL Checked by: PH
Reference and design Intervention Participants Outcome measures
Author: Caballero and 
colleagues55
Year: 2005
Country: Spain
Study design: RCT
Number of centres: One
Setting: Assume 
secondary care from 
author affiliation
Funding: Not reported 
1. Chlorobutanol: 2 ml, no 
further details
2. Sodium carbonate: 2 ml, 
no further details
3. Saline: 2 ml
Duration of treatment: 15 
minutes
Other interventions used: 
after 15 minutes the ear 
was irrigated with 50ml of 
tepid water
Number of participants: 90:
1. Chlorobutanol n = 32
2. Sodium carbonate n = 29
3. Saline n = 28
Sample attrition/dropout: Not 
reported
Inclusion criteria for study entry: 
Adults with total cerumen 
obstruction
Exclusion criteria for study entry: Not 
reported
Primary outcomes: 
Proportion of TM 
completely visualised
Secondary outcomes: Not 
reported
Method of assessing 
outcomes: Not reported
Length of follow-up: 
Immediate
Baseline characteristics of participants (all participants aged 19–78 years)
Results
Primary outcomes 
Chlorobutanol 
(n = 32)
Sodium carbonate 
(n = 29) Saline (n = 28) p-value
Proportion of TM 
completely visualised
21/32 (65.6%) 16/29 (55.2%) 12/28 (42.9%) p = 0.209
Comments: unsure if p-value relates to comparison across all three groups
Secondary outcomes 
Chlorobutanol 
n = 32
Sodium carbonate 
n = 29 Saline n = 28 p-value
Comments:
Note: If reviewer calculates a summary measure or confidence interval please indicate.
Methodological comments
Allocation to treatment groups: States randomised, but no further details reported
Blinding: Not reported
Comparability of treatment groups: States groups were similar in age, race, sex, ear enrolled and wax consistency, but no 
data reported
Method of data analysis: States variables were analysed with chi-squared test; p = 0.05 was statistically significant
Sample size/power calculation: Not reported
Attrition/dropout: None reported but numbers do not add up to 90 so assume one withdrew/dropped out
General comments
Generalisability: Unclear population
Outcome measures: Unclear how valid the outcome measures were
Intercentre variability: Not applicable
Conflict of interests: Unknown
RCT, randomised controlled trial; TM, tympanic membrane.Appendix 4
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Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Partial
5. Were outcome assessors blinded to the treatment allocation? Unknown 
6. Was the care-provider blinded? Unknown
7. Was the patient blinded? Unknown
8. Were the point estimates and measure of variability presented for the primary outcome 
measure?
Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Inadequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Dubow57
Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: Dubow57
Year: 1959
Country: USA
Study design: RCT
Number of centres: At least 
two
Setting: Assume secondary 
as paediatric clinic
Funding: None reported
1. Hydrogen peroxide 
(USA household 
antiseptic of 3% solution)
2. Mineral oil
3. Cerumenex
Duration of treatment: 
Treatment administered 
by parents and left in 
ear overnight, followed 
by irrigation with warm 
water the following 
morning
Other interventions used: 
Dropper bottle of liquid 
test material and a 2-oz 
Davol rubber ball and 
nozzle-type syringe
Number of participants: 60
1. Peroxide solution: n = 20
2. Mineral oil: n = 20
3. Cerumenex: n = 20
Sample attrition/dropout:
1. n = 0
2. n = 1
3. n = 0
Inclusion criteria for study entry: 
children with at least 1 completely 
cerumen-occluded ear canal, 
without regard to other disorders, 
presenting in a paediatric clinic and 
in ‘office practice’
Exclusion criteria for study entry: 
acutely ill children, were the illness 
would prevent follow-up visit
Primary outcomes: Wax 
clearance
Secondary outcomes: None 
reported
Method of assessing 
outcomes: Otological 
examination prior and after 
treatment
Length of follow-up: 
Immediate
Baseline characteristics of participants:
All (n = 60) p-value
Age 3–12 years No p-values
reported Race All (including white, coloured and Chinese)
Moderate – severe pain 3
Results: 
Primary outcomes 
Hydrogen peroxide 
(n = 20)
Mineral oil 
(n = 19)
Cerumenex 
(n = 20) p-value
Clearance: n (%) 7 (35%) 8 (42%) (14) 70% No p-values reported
Comments: Number of patients calculated from percentages by reviewer.
Secondary outcomes
Hydrogen peroxide 
(n = 20)
Mineral oil 
(n = 19)
Cerumenex 
(n = 20) p-value
Comments: AE – one itching erythematous eruption of the external auditory meatus and surrounding area of the pinna of 
the ear.
Methodological comments
Allocation to treatment groups: Group was formed from children presenting themselves for paediatric examination. Children 
were randomly assigned to a group, unless there were language difficulties or other inability to achieve understanding by 
the parents, as procedure ‘would not be carried out properly’
Blinding: No details reported.
Comparability of treatment groups: No details reported
Method of data analysis: None reported
Sample size/power calculation: None reported
Attrition/dropout: One child in mineral oil group refused to be treated by parents
General comments
Generalisability: No baseline characteristics provided, population based on American children in late 1950s
Outcome measures: It is unclear how the primary outcome was measured, how valid or objective the measure was or how 
many paediatricians took part in the examinations (consistency)
Intercentre variability: N/A
Conflict of interests: Cerumenex distributed by Purdue Frederick Co., New York, NY
AE, adverse event; N/A, not applicable; RCT, randomised controlled trial.Appendix 4
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Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Inadequate
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Unknown
7. Was the patient blinded? Unknown
8. Were the point estimates and measure of variability presented for the primary outcome 
measure?
Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Adequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Chaput de Saintonge and Johnstone59
Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: Chaput de Saintonge 
and Johnstone59
Year: 1973
Country: UK
Study design: Double-blind 
RCT
Number of centres: One
Setting: Secondary care
Funding: None reported
1. Triethanolamine polypeptide 
oleate condensate (TP)
2. Olive oil
Duration of treatment: 20 
minutes
Other interventions used: 
Syringing by nursing staff with a 
hand syringe
Number of ears: 67
1. TP: n = 32
2. Olive oil: n = 35
Sample attrition/dropout: Not 
reported
Inclusion criteria for study 
entry: Any patient with 
impacted wax attending 
outpatients
Exclusion criteria for study 
entry: None reported
Outcomes: Total volume of 
water and amount of wax 
removed
Method of assessing: 
Water used in syringing 
measured to nearest 
50 ml
Amount of wax removed: 
Complete, partial or 
negligible
Length of follow-up: 
Immediate
Baseline characteristics of participants: not reported
TP ears = 32 Olive oil ears = 35 p-value
Results
Outcomes
TP ears (n = 32) Olive oil ears (n = 35) p-value
Volume of water useda
150 ml 7 1 p < 0.05
TP needs smaller volumes 
water than olive oil
300 ml 14 14
450 ml 4 6
600 ml 2 2
750 ml 0 2
900 ml 1 7
Amount of wax removed
Complete 20 21 States not significant, but 
no p-values reported Partial 12 10
Negligible 0 4
Comments:
a  Estimated from graph by reviewer, TP needed a significantly smaller volume of water for syringing than olive oil.
Methodological comments
Allocation to treatment groups: Treatments were allocated in random order, no other details reported
Blinding: Study states double-blind method was used and treatments were supplied in identical coded bottles, with codes 
not broken until trial completion
Comparability of treatment groups: No details reported
Method of data analysis: Mann–Whitney U-test used to test for differences in volume of water used
Sample size/power calculation: None reported
Attrition/dropout: None reported
General comments
Generalisability: No baseline demographic characteristics, UK population
Outcome measures: It is unclear how valid or objective the measures were
Intercentre variability: N/A
Conflict of interests: None reported. HR Napp Ltd supplied TP ear drops and assisted in setting up the trial
N/A, not applicable; RCT, randomised controlled trial.Appendix 4
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Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Adequate
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Inadequate
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Adequate
7. Was the patient blinded? Adequate
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Inadequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Keane and colleagues4
Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: Keane and 
colleagues4
Year: 1995
Country: Ireland
Study design: Double-
blind RCT
Number of centres: One
Setting: Secondary care
Funding: None reported
1. Cerumol:a 4 drops twice 
daily
2. NaHCO3 (sodium 
bicarbonate):b 4 drops 
twice daily
3. Sterile water: 4 drops 
twice daily
4. Control: No treatment
Duration of treatment: 5 days
Other interventions used:
aCerumol: Chlorbutol 5%, 
paradichlorobenzene 2%, 
arachis oil 57.3%
bSodium bicarbonate: 
NaHCO3 5 g, glycerol and 
purified water
Number of participants: n = 113, 97 
randomised (155 ears)
Cerumol: n = 24 (40 ears)
Sodium bicarbonate: n = 25 (39 ears)
Sterile water: n = 24 (38 ears)
Control: n = 24 (38 ears)
Sample attrition/dropout: 13 went 
home and 3 died, 97 completed 
study
Inclusion criteria for study entry: 
One or both ears impacted
Exclusion criteria for study entry: 
Known pathology of the ear canal 
and/or TM and those already on 
ear drops
Primary outcomes: 
Percentage clearance and 
number of ears (clearance 
is explained by the ‘natural 
expulsion of earwax’)
Secondary outcomes: AE
Method of assessing 
outcomes: Auditory canal 
classification – 1. impacted 
wax in the external canal, 2. 
moderately clear external 
canal or 3. completely clear 
external canal. Examination 
and re-examination carried 
out by the same observer
Length of follow-up: 5-day 
trial
Baseline characteristics of participants
None reported
Results
Primary outcomes: clearance % (no. of ears)
Cerumol 
(n = 24)
NaHCO3 
(n = 25) Water (n = 24)
Control 
(n = 24) p-value
Impacted 40.0 (16) 53.8 (21) 47.4 (18) 68.4 (26)
Moderately clear 37.5 (15) 25.6 (10) 31.6 (12) 26.3 (10) p < 0.05 Cerumol vs control
Completely clear 22.5 (9) 20.6 (8) 21.0 (8) 5.3 (2) p < 0.05 Cerumol vs control
p < 0.05 NaHCO3 vs control
p < 0.05 water vs control
Comments: No significant differences between Cerumol, NaHCO3 or water.
Secondary outcomes
Cerumol 
(n = 24)
NaHCO3 
(n = 25) Water (n = 24)
Control 
(n = 24) p-value
Comments: AE – no cases of irritation or contact sensitivity.
Methodological comments
Allocation to treatment groups: Participants were randomly divided into four groups. States treatment was allocated in 
random order and the ‘code was not broken until the trial was complete’. No other information provided. Unclear 
reporting over randomisation of participants in respect of number randomised
Blinding: Authors state double-blind trial. The only information provided is that the drops were administered by nursing 
staff and that ears were examined and re-examined by same observer
Comparability of treatment groups: Unknown, no baseline reported
Method of data analysis: t-test, paired samples only; no adjustment for multiple comparisons made
Sample size/power calculation: Not reported
Attrition/dropout: No dropouts after randomisation. Poor reporting means it is unclear whether the 16 additional 
participants received any treatment
General comments
Generalisability: Possibly elderly hospitalised patients, but exact patient group unclear
Outcome measures: Unclear how valid and objective the outcome classification was
Intercentre variability: N/A
Conflict of interests: None reported
AE, adverse event; N/A, not applicable; RCT, randomised controlled trial; TM, tympanic membrane.Appendix 4
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Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Unknown
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Unknown
7. Was the patient blinded? Unknown
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Adequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Fraser60
Extracted by: AC Checked by: PH
Reference and design Intervention Participants Outcome measures
Author: Fraser60
Year: 1970
Country: UK
Study design: RCT
Number of centres: Six 
hospitals
Setting: Secondary care
Funding: Not stated
1. Sodium bicarbonate 
(BPC)
2. Olive oil
3. Cerumol
4. Waxsol
5. TP
6. Dioctyl capsules
Duration of treatment: Ear 
drops were instilled once 
daily for 3 days prior to 
syringing for 15 minutes, 
except TP, which was used 
15–30 minutes before 
syringing due to its claimed 
rapid action
Other interventions used: 
None stated 
Number of participants: 248 ears 
from 124 people, with 1 ear per 
person providing a test and control 
ear
Intervention: 124 ears
Control: 124 ears
Sample attrition/dropout: 18 patients 
failed to complete the trial due to 
errors in the procedure and 3 died
Inclusion criteria for study entry: 
Participants had bilateral hard 
earwax that occludes the external 
auditory meatus in both ears; 
patients were from geriatric 
attendees at hospitals
Exclusion criteria for study entry: 
None stated
Primary outcomes: Ease of 
syringing, frequency of 
syringing, appearance of 
wax removed
Secondary outcomes: see 
above
Method of assessing 
outcomes: Not stated
Length of follow-up: At 
least 3 days
Baseline characteristics of participants
None reported
Results
Outcomes
Ease of syringing
Sum scores
Difference (mean rank) Test ears Control ears
Cerumol (24 ears) 92 122 +30a (+11.9)b
Olive oil (25 ears) 116 140 +24 (+3.4)
Waxsol (26 ears) 110 128 +18 (+2.8)
Sodium bicarbonate  
(124 ears)
Control  0 (–3.5)
TP (24 ears) 118 107 –11 (–9.0)
Dioctyl capsules (25 ears) 119 107 –12 (–9.1)
Comments: The lower the score the easier the syringing. A positive difference indicates that the test were easier to 
syringe than the control ears.
a  Cerumol differed significantly from sodium bicarbonate (p < 0.05), all other comparisons were not significant.
b  When mean ranks were compared, Cerumol was significantly better than dioctyl and TP; p < 0.05.
Frequency of syringing 
successes and failures
No. of patients in which:
Product better Scores equal Control better
Cerumol (24 ears) 15 5 4
Olive oil (25 ears) 10 6 9
Waxsol (26 ears) 11 6 9
TP (24 ears) 7 7 10
Dioctyl capsules (25 ears) 8 5 12Appendix 4
144
No. of ears in which 
very forceful syringing 
failed Test ears Control ears
Cerumol (24 ears) 1 5
Olive oil (25 ears) 2 4
Waxsol (26 ears) 3 5
TP (24 ears) 5 3
Dioctyl capsules (25 ears) 5 2
Appearance of wax 
removed by syringing
Percentage of  
lumps
Percentage partially  
broken up
Percentage completely 
broken up
Oil-based solvents:
Cerumol (24 ears) 46 37 17
Olive oil (25 ears) 40 44 16
TP (24 ears) 42 25 33
Dioctyl capsules (25 ears) 36 44 20
Water-based solvents:
Waxsol (26 ears) 15 46 39
Sodium bicarbonate (124 
ears)
33 43 24
Comments: Frequency of otitis externa (redness of the external meatus): total of 12 ears (4%); in 3 ears it was bilateral 
and probably not due to the study; of the remaining 6 ears, 3 ears had received sodium bicarbonate, 2 Waxsol and 1 TP.
Methodological comments
Allocation to treatment groups: Sodium bicarbonate was used in one ear and another product in the other ear. Products 
were given code letters and were allocated at random to patients by an assistant. The ear in which the product was used 
was similarly randomised
Blinding: Except for TP, the surgeon performing the syringing was neither aware of which drops a patient received, nor 
which was the test ear. For TP, the surgeon knew it had been used but not in which ear
Comparability of treatment groups: No comparison made of participants baseline characteristics, although each patient had a 
test ear and a comparator ear to try and minimise differences
Method of data analysis: Scores, difference in scores, mean rank and Wilcoxon one-sample ranking test used
Sample size/power calculation: Not stated
Attrition/dropout: Of 142 participants originally identified, 18 failed to complete the trial due to procedure errors and 3 
died, leaving 124 participants
General comments
Generalisability: Unknown
Outcome measures: Ease of syringing was compared for each preparation against sodium bicarbonate, with the difference 
between test and control ear calculated and tested for significance using the Wilcoxon one-sample ranking test. 
Differences in scores between test and control ears were ranked over all products. The sum of ranks and the mean rank 
for each product were compared with each other. Frequency of syringing and appearance of wax were other outcomes. 
Limited information is provided as concerns the definitions of outcome measures
Intercentre variability: Syringing techniques were standardised and undertaken by one operator
Conflict of interests: None stated
RCT, randomised controlled trial; TP, triethanolamine polypeptide.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Inadequate
2. Was the treatment allocation concealed? Inadequate
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Unknown
5. Were outcome assessors blinded to the treatment allocation? Inadequate
6. Was the care-provider blinded? Inadequate
7. Was the patient blinded? Inadequate
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Inadequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.Appendix 4
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Pothier and colleagues56
Extracted by: AC Checked by: PH
Reference and design Intervention Participants Outcome measures
Author: Pothier and 
colleagues56
Year: 2006
Country: UK
Study design: RCT 
(unblinded)
Number of centres: One
Setting: Otolaryngology 
outpatient clinic
Funding: None reported
1. Intervention: endoscopic 
de-waxing using a 
Karl–Storz 4-mm 0o 
otoendoscope and 
portable light-emitting 
diode light source
2. Control: Microscopic 
de-waxing using a Zeiss 
OPMI microscope with a 
Toynbee aural speculum
Duration of treatment: 
Treated and assessed 
on initial visit, unless 
cerumenolytics used and 
then unspecified delay
Other interventions used: 
Wax was removed with 
a Jobson–Horne probe 
or a wax hook (91%) 
or crocodile forceps or 
Zoellner Sucker (9%)
Number of participants: n = 100
Intervention: n = 50
Control: n = 50
Sample attrition/dropout: No 
dropouts.
Inclusion criteria for study entry: 
Patients requiring removal of 
earwax from the ear canal to 
allow full view of the TM with a 
history of earwax
Exclusion criteria for study entry: 
People with active or previous 
external or middle ear pathology 
[i.e. mastoid cavities, active ear 
infections or any abnormality of 
TM (perforation or retraction)]
Primary outcomes: Levels 
of pain and discomfort 
for patient, ease of de-
waxing, time taken to 
de-wax
Secondary outcomes: see 
above
Method of assessing 
outcomes: Assessed by 
patient questionnaire 
(VAS) and through 
assessment by 
endoscopist
Length of follow-up: 
Treated and assessed 
on initial visit, unless 
cerumenolytics used and 
then unspecified delay
Baseline characteristics of participants
Endoscopic (n = 50) Microscopic (n = 50) p-value
Mean age (SD, range) 
years
57.2 (16.86, 16–87) 58.3 (17.3, 18–91) Not stated
Male–female ratio (%) 60:40 62:38 Not stated
Mean % wax obscuring 
TM
72.0 65.5 Not stated
Number (%) of patients 
with TM completely 
obscured
20 (40) 26 (52) 0.69
Results
Primary outcomes
Endoscopic (n = 50) Microscopic (n = 50) p-value
Discomfort – median 
score on VAS (0–100)
5 25 0.002
Pain – median score on 
VAS (0–100)
3.5 10 0.075
Difficulty in de-waxing 
– median score on VAS 
(0–100)
9 20 0.005
Time taken to perform 
de-waxing (minutes)
1.8 3.3 0.001
Comments: No complications were reported during de-waxing, however, one patient from each group sustained minor 
bleeding from ear canals. Five patients from the endoscope group required conversion to microscope (three successfully 
de-waxed, two sent home with cerumenolytics before finishing de-waxing) and two microscope patients converted to 
endoscope (one successfully de-waxed, one sent home with cerumenolytics).DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Methodological comments
Allocation to treatment groups: Opaque envelopes with single proforma with group marked
Blinding: Blindly selected at random by patient. Endoscopist performing procedure informed patient of allocation
Comparability of treatment groups: Study identified that patient groups were similar at baseline in terms of age, sex and 
proportion of TM obscured
Method of data analysis: Data on discomfort, pain and difficulty were analysed using Mann–Whitney U-test and data on time 
taken used an unpaired t-test to compare means. ITT analysis was used
Sample size/power calculation: Sample of 50 participants would provide power of 90% to detect a mean difference of 10 
points assuming a standard deviation of 15, using a two-group test, at 5% significance
Attrition/dropout: No patients dropped out
General comments
Generalisability: Patients from an otolaryngology outpatient clinic with a previous history of earwax, 60% male, mean age 
57–58 years old
Outcome measures: Levels of pain (0 = no pain; 100 = very painful) and discomfort (0 = no discomfort; 100 = very 
uncomfortable) were recorded by the patients using a visual analogue score sheet. Clinician assessed on a VAS the ease of 
de-waxing, the percentage of TM obscured by wax prior to randomisation and the time taken to de-wax. VASs have not 
been formally validated
Intercentre variability: Not applicable
Conflict of interests: None stated. Karl Storz loaned otoendoscopes and GVR Products loaned portable light sources
ITT, intention to treat; RCT, randomised controlled trial; SD, standard deviation; TM, tympanic membrane;  VAS, visual 
analogue scale.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Partial
2. Was the treatment allocation concealed? Inadequate
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Inadequate
6. Was the care-provider blinded? Inadequate
7. Was the patient blinded? Inadequate
8. Were the point estimates and measure of variability presented for the primary outcome 
measure?
Inadequate
9. Did the analyses include an ITT analysis? Adequate
10. Were withdrawals and dropouts completely described? Adequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.Appendix 4
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Saloranta and colleagues58
Extracted by: EL Checked by: AC
Reference and design Intervention Participants Outcome measures
Author: Saloranta and 
colleagues58
Year: 2005
Country: Finland
Study design: RCT
Number of centres: Two
Setting: Secondary care 
and community home 
for people with learning 
difficulties
Funding: None reported
1. Skin oil Ceridal 
lipolotion* emollient, 
2 ml, self administered 
except in those with 
learning difficulties
2. No treatment
Duration of treatment: 
Once a week for 12 
months. Patients kept a 
diary of their treatment
Other interventions used: 
Patients all had removal 
of the impacted earwax 
prior to randomisation, 
unclear by what method
*Contains paraffinum 
liquidum, cyclomethicone 
and Buxus chinensis, Stiefel 
Laboratories (Ireland) Ltd
Number of participants: 39
Ceridal: n = 20 (13 analysed, 16 
ears)
Control: n = 19 (18 analysed, 29 
ears)
Sample attrition/dropout: Numbers 
analysed were:
Ceridal: 13 (1 death mother, 1 
decrepitude, 2 lost to follow-
up, 1 death, 2 excluded due to 
cholesteatoma)
Control: 18 (1 death)
Inclusion criteria for study entry: 
History of impacted cerumen, 
with symptoms like impaired 
hearing or sensation of blocked 
ear canal more often than once 
per year and earwax completely 
obstructing the ear canal at the 
point of inclusion
Exclusion criteria for study entry: 
None noted
Primary outcomes: (Not 
defined as primary or 
secondary.) Recurrence of 
cerumen impaction, AEs
Secondary outcomes: see above
Method of assessing outcomes: 
No details
Length of follow-up: 12 months 
(visits also at 3 months and at 
a point of recurrence)
Baseline characteristics of participants (reported for those analysed not those recruited)
Ceridal (n = 13) Control (n = 18) p-value
M/F 7/6 8/10
Mean age (range), years 34 (4–52) 44 (1–74)
Learning difficulties 9 10
No treated ears 16 29
Results
Primary outcomes
Ceridal (n = 13) Control (n = 18) p-value
Recurrence 3 (23%) 11 (61%) p < 0.05
Recurrence in treated 
ears
3/16 (19%) 15/29 (52%) p < 0.05
Comments: There was also a trend in the timing of recurrent impaction; 73% of the control ears recurred within 3 months 
compared with 40% in the Ceridal group.
Secondary outcomes
Ceridal (n = 13) Control (n = 18) p-value
AEs 0 0
Comments:DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Methodological comments
Allocation to treatment groups: After removal of impacted cerumen, patients were randomised. Randomisation was 
undertaken for the whole study in advance by a co-worker. Forty envelopes were consecutively numbered – half of them 
randomly containing the treatment code and half of them the control code. This was carried out after extraction of the 
impacted earwax
Blinding: No blinding evident, participants were seen and evaluated by one of the authors
Comparability of treatment groups: No statistical analysis or comment from authors, mean age appears to be lower in the 
Ceridal group
Method of data analysis: Differences between groups tested by Fisher’s exact test
Sample size/power calculation: Not reported, however this is reported to be a pilot study
Attrition/dropout: Numbers and reasons given
General comments
Generalisability: Large proportion of participants had learning difficulties
Outcome measures: Unknown how valid or objective the outcome measures were
Intercentre variability: None noted
Conflict of interests: None noted
AEs, adverse events; F, female; M, male; RCT, randomised controlled trial.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Inadequate
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Unknown
7. Was the patient blinded? Unknown
8. Were the point estimates and measure of variability presented for the primary outcome 
measure?
Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Adequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Appendix 5  
Data extraction forms: self-
care and other care settings
Harris64
Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: Harris64
Year: 1968
Country: Ireland
Study design: RCT
Number of centres: One
Setting: Primary care
Funding: TP and bulb 
syringes supplied by 
HR Napp Ltd
1. Intervention: TP (enough ear 
drops to fill the ear and left in 
overnight) plus self-syringing 
with warm water the morning 
after
2. Control: None, self-syringing 
with warm water in the 
morning only
Duration of treatment: 12–24 hours
Other interventions used: self-
syringing with a maximum of 12 
squirts of warm water using a  
2 fl oz, soft rubber bulb, rat-tailed 
syringe the morning after the 
treatment, followed by auroscopic 
examination in the evening. If 
self-syringing was unsuccessful 
syringing was repeated at the 
surgery after the examination. 
Number of participants: 45
TP: 24
Control: 21
Sample attrition/dropout: No 
dropouts
Inclusion criteria for study entry: 
All participants attending 
surgery and complaining of 
symptoms directly attributable 
to ceruminosis
Exclusion criteria for study entry: 
Underlying systemic disease, 
perforated TM, chronic otitis 
externa or middle ear disease
Outcomes: (Not stated as 
primary or secondary)
Wax clearance
Meati clearance
Colour cerumen
Symptoms
AEs
Method of assessing 
outcomes: auroscopic 
examination
Length of follow-up: 1 day
Baseline characteristics of participants
Comments: majority of participants had earwax in both ears, but no breakdown provided.
Ceruminosis symptoms 
across both groups
Partially obscured TM 
(n = 17)
Completely obscured 
TM (n = 28)
Impaired hearing 8 28
Tinnitus 9 10
Vertigo 3 5
Irritation 2 2
Pain 2 1
Cerumen colour (n = 45) across both groups
Partial obstruction Total obstruction
Yellow, n = 6 3 3
Brown, n = 13 0 13
Black, n = 12 0 12
Comments: Baseline degree of obstruction reported (see results below).Appendix 5
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Results
Outcomes
TP (n = 24) Control (n = 21) p-value
Completely cleared
Partially or not cleared
18
6b
1a
20c
p < 0.005 (χ2 = 19.862)
Comments:
Six TP participants had softened wax cleared at surgery with gentle syringing after examination. Nineteen participants in 
the control group had wax cleared with normal syringing after examination at the surgery.
a  Meatus cleared.
b  Partial clearance.
c  Not cleared.
TP (n = 24) Control (n = 21)
p-value
State of meati
Obscured 
completely
Obscured 
partially
Obscured 
completely
Obscured 
partially
Before treatment Within group 
comparison, before 
and after
TP > 0.05 (not 
significant)
(χ2 = 3.657)
Control: not 
significant
14 10 14 7
After treatment
Meati cleared 8 10 0 1
Meati not cleared 6 0 14 6
Comments: The colour of wax had no effect on clearance or by treatment in either group (p-value not provided).
AEs 1a 0
Comments:
a  Participant suffered erythema around the external auditory meatus, most likely due to TP. Resolved within 48 hours 
of treatment with topical corticosteroid cream. Some TP participants noted brownish liquid on pillow, presumed to be 
liquefied cerumen; no other details reported.
Methodological comments
Allocation to treatment groups: States randomly assigned, no further details
Blinding: Blinding not reported
Comparability of treatment groups: Unknown, no details reported
Method of data analysis: Chi-squared test for small numbers with Yates’ correction was calculated (fourfold table)
Sample size/power calculation: None reported
Attrition/dropout: None
General comments
Generalisability: UK Primary Care practice population during 1968, suffering from ceruminosis predominantly in both ears
Outcome measures: Unclear how valid, objective, or consistently applied the outcome measures used were
Intercentre variability: N/A
Conflict of interests: TP and bulb syringes supplied by HR Napp Ltd
AEs, adverse events; N/A, not applicable; RCT, randomised controlled trial; TM, tympanic membrane; TP, 
triethanolamine polypeptide.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Unknown
4. Were the eligibility criteria specified? Partial
5. Were outcome assessors blinded to the treatment allocation? Unknown
6. Was the care-provider blinded? Unknown
7. Was the patient blinded? Unknown
8. Were the point estimates and measure of variability presented for the primary outcome measure? Inadequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Adequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.Appendix 5
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Coppin and colleagues63
Extracted by: AC Checked by: PH
Reference and design Intervention Participants Outcome measures
Author: Coppin and 
colleagues63
Year: 2008
Country: UK
Study design: RCT
Number of centres: Seven 
primary care practices
Setting: Primary care
Funding: Royal College 
of General Practitioners 
Science Foundation Board 
and UK Department of 
Health Support for Science 
Fund
1. Intervention: Ear drops 
(sodium bicarbonate) for ≥ 2 
days (unless drops already 
used), bulb syringe (25 ml) 
and instructions for self-
treatment
2. Control: Ear drops (sodium 
bicarbonate) for ≥ 2 days 
(unless drops already used), 
irrigation by GP or practice 
nurse
Duration of treatment: 1–2 
weeks
Other interventions used: none 
stated
Number of participants: 
n = 237
Intervention: n = 118
Control: n = 119
Sample attrition/dropout: 
Due to main outcome not 
documented.
Intervention: n = 14
Control: n = 17
Inclusion criteria for study 
entry: Adults consulting a 
GP or practice nurse with 
symptoms of occluding 
earwax (itching, sensation 
of blockage, reduced 
hearing) consenting to 
inclusion in study
Exclusion criteria for study 
entry: None stated
Primary outcomes: Reported 
symptoms and wax clearance
Secondary outcomes: Further 
treatment required and 
acceptability of treatment
Method of assessing outcomes: 
Practice nurse (n = 230) or 
GP (n = 7) undertook initial 
assessment and practice 
nurses undertook all follow-
up assessments. Other 
outcomes were assessed by 
patient questionnaire
Length of follow-up: 1–2 
weeks for comparison of 
interventions; within 6 
weeks for assessment of 
further treatment, adverse 
effects, rates and reasons for 
non-participation or non-
compliance
Baseline characteristics of participants
Bulb (n = 118) Irrigation (n = 119) p-value
Mean symptom scorea at 
baseline (n = 205)
2.37 (SD 1.44) 2.41 (SD 0.90) Not stated
Right ear completely 
obstructed with wax, n (%)
73/116 (63) 72/116 (62) Not stated
Left ear completely 
obstructed with wax, n (%)
78/116 (67) 79/114 (69) Not stated
Male–female ratio (%) 66 : 34 63 : 37 Not stated
Mean (SD) age, years 57 (14) 55 (16) Not stated
Results
Primary outcomes
Bulb (n = 118) Irrigation (n = 119)
Difference between 
groups (95% CI); p-value
Mean (SD) change in 
symptom score from 
baseline
–0.81 (1.44) –1.26 (1.15) –0.45 (–0.11 to –0.79); 
p = 0.01 (0.02)b
Treatment discomfort 
(slight or more), n (%)
43/110 (39) 35/108 (32) 7% (–6% to 19%); p = 0.30
Treatment dizziness (slight 
or more), n (%)
14/110 (13) 14/108 (13) 0% (–9% to 9%); p = 0.96
Use same treatment again, 
n (%) (agreed slightly or 
more)
82/110 (75) 106/106 (100) 25% (17% to 25%); p < 0.001
Wax clearance (obstruction 
score 0 or 1), n (%)
50/104 (48) 64/102 (63) 15% (1% to 28%); p = 0.03
Comments:
a  Symptoms score: 0 = no symptom to 6 = severe.
b  Kruskal–Wallis test.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Secondary outcomes
Bulb (n = 118) Irrigation (n = 119)
Difference between 
groups (95% CI); p-value
Treatment convenient 
(agreed slightly or more), 
n (%)
84/110 (76) 95/105 (90) 14% (4% to 24%); p < 0.01
Satisfied with treatment, 
n (%) (agreed slightly or 
more)
78/110 (71) 105/106 (99) 28% (19% to 29%); p < 0.001
Requires no further 
clearance (based on normal 
clinical practice), n (%)
51/100 (51) 66/95 (69) 18% (5% to 32%); p < 0.01
Infection, n (%) 1/97 (1) 1/93 (1) 0% (–3% to 3%); p = 1.00a
Perforation, n (%) 1/97 (1) 1/94 (1) 0% (–3% to 3%); p = 1.00a
Signs of trauma, n (%) 1/97 (1) 1/94 (1) 0% (–3% to 3%); p = 1.00a
Adverse events: 1 patient in the irrigation group had bilateral otitis externa and 2 patients had perforation (1 old scarring 
TM and 1 pre-existing cholesteatoma)
Comments:
a  Fisher’s exact test used.
Methodological comments
Allocation to treatment groups: Using sealed envelopes randomised using random number tables by person not involved data 
collection or recruitment
Blinding: Patients received an envelope questionnaire and a box containing either ear drops, a bulb syringe and instructions 
or ear drops and a roll of card of similar weight to bulb and instructions on other treatment. Process was audited to assess 
whether recruitment was selective and confounded. Assessment of wax clearance could not be blinded
Comparability of treatment groups: Baseline data on age, sex and ear obstruction were similar between groups
Method of data analysis: States that ITT analysis using analysis of covariance and Kruskal-Wallis test for continuous 
outcomes and chi-squared test or Fisher’s exact test for dichotomous variables. Although it states ITT analysis was 
undertaken, denominators appear to vary with outcomes. Clustering was assessed and found not to affect outcomes
Sample size/power calculation: Observed wax clearance was used for sample size calculation (α = 0.05 and power 80%) 
assuming clearance of wax by bulb of 75% and syringe 90% it was estimated that 100 patients per group and 236 in total if 
there was a loss to follow-up of 15%
Attrition/dropout: Of the 434 patients invited, 69 declined/excluded, 237 randomised, a further 128 not randomised had 
notes searched. Of 237 randomised, 206 were followed up and 31 were lost to follow-up due to main outcome not 
documented (14 people from the intervention and 17 from the control group). Nurses monitored follow-up and noted all 
patients allocated to bulbs used them
General comments
Generalisability: Participants were from 7 primary care practices in Hampshire (UK), with over 60% male and a mean age 
between 55 and 57 years
Outcome measures: Overall symptoms and acceptability of treatment were assessed using questions (7-point scale) validated 
in pilot study. Wax obstruction was measured by a practice nurse using previously described 4-point score (0 = no or 
minimal wax with TM fully visible; 1 = minor amount of wax with TM essentially visible; 2 = moderate amount of wax with 
TM partially obscured; 3 = complete occlusion of TM. (Note 0 and 1 were combined to form clinically clear)
Intercentre variability: Not reported
Conflict of interests: None stated
CI, confidence interval; ITT, intention to treat; RCT, randomised controlled trial; SD, standard deviation; TM, tympanic 
membrane.Appendix 5
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Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Adequate
2. Was the treatment allocation concealed? Adequate
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were the eligibility criteria specified? Unknown
5. Were outcome assessors blinded to the treatment allocation? Inadequate
6. Was the care-provider blinded? Not applicable
7. Was the patient blinded? Not applicable
8. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Partial
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Roland and colleagues62
Extracted by: EL PH
Reference and design Intervention Participants Outcome measures
Author: Roland and 
colleagues62
Year: 2004
Country: USA
Study design: RCT
Number of centres: One
Setting: Corporate 
research clinic
Funding: Funded by Alcon 
Research Ltd
1. Cerumenex ear drops*
2. Murine ear drops**
3. Placebo***
Duration of treatment: Each 
treatment consisted of up to 
two 15-minute applications of 
treatment/placebo
Other interventions used: Ear drops 
were followed by a standardised 
irrigation procedure using a 
WaterPik Oral Jet Irrigator. 
Irrigation consisted of 50 ml of 
lukewarm water. If cerumen was 
cleared after a single application 
and irrigation, the second 
application was not conducted
*10% triethanolamine polypeptide 
oleate condensate, Purdue 
Frederick Company
**6.5% carbamide peroxide, 
Abbott Laboratories
***BBS sterile irrigating solution 
(saline containing 0.64% sodium 
chloride and physiological 
concentrations of multiple 
electrolytes), Alcon Laboratories
Number of participants: 230 
screened, 74 qualified for 
enrolment: 1, n = 24; 
2, n = 26; 3, n = 24
Sample attrition/dropout: 
None reported
Inclusion criteria for study 
entry: Volunteers from 
company employees who 
had excessive or impacted 
cerumen. Required to 
be ≥ 18 years with mild, 
moderate, or complete 
cerumen occlusion, 
as measured against a 
previously established 
4-point scale (see outcomes 
for details)
Exclusion criteria for study 
entry: Ear anomalies, 
diabetes, allergies to study 
medications, were pregnant 
or nursing or had instilled 
anything other than water 
in their ear in the previous 
72 hours
Primary outcomes: Post-
treatment level of occlusion
Secondary outcomes: 
Otological signs and 
symptoms
Method of assessing 
outcomes: Assessed by 
‘qualified specialist’
For degree of occlusion a 
scale of 0–3 used as follows:
•  0 = no occlusion, no 
effective impairment of 
TM visualisation due to 
cerumen
•  1= mild occlusion
•  2 = moderate occlusion
•  3 = complete occlusion
Unclear how valid and 
reliable this test is
Adverse events
Length of follow-up: 
Immediate
Baseline characteristics of participants
All (n = 74) p-value
Mean age, years (range) 45 (22–66)
Mild occlusions 10
Moderate occlusions 26
Complete occlusions 38
Gender, M/F (M/F ratio) 51 : 23 (2.2 : 1)
Results
Primary outcomes
Cerumenex 
(n = 24)
Murine  
(n = 26)
Placebo  
(n = 24) p-value
No occlusion 7(29.2%) 4 (15.4%) 10 (41.7%) Cerumenex vs 
placebo; p = 0.37
Murine vs placebo; 
p = 0.06
Mild, moderate or 
complete occlusion
17 (71%) 22 (85%) 14 (58%)
Comments: Statistical analysis of Cerumenex vs placebo was by chi-squared test, but analysis of Murine vs placebo was by 
Fisher’s exact test.
Change from baseline in 
occlusion (estimated from 
figure)
Resolved: 30% Resolved: 16% Resolved: 42% Not tested
Improved: 8% Improved: 7% Improved: 22%
No change/worse: 
62%
No change/worse: 
77%
No change/worse: 
38%Appendix 5
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Secondary outcomes
Cerumenex 
(n = 24)
Murine  
(n = 26)
Placebo  
(n = 24) p-value
AEs related:
Ear pruritis 1 (4%) 2 (8%) 0
Ear discomfort 0 0 1 (4%)
Contact dermatitis 1 (4%) 0 0
AEs not related:
Vertigo 1 (4%) 0 0
Comments: Number of applications – overall 90.5% required 2 applications, 9.5% had successful treatment outcome after 
1 application and irrigation [Cerumenex: 2 (8%), Murine: 3 (12%), placebo: 2 (8%)]. Of those with a single application there 
were no differences between the interventions (p-value not reported).
Methodological comments
Allocation to treatment groups: States randomly assigned, no further details
Blinding: States observer- and participant-blind study. The outcome assessors and the participant were masked from 
treatment allocation by storing test articles out of view and administration was by clinic staff who did not perform the 
clinical assessments
Comparability of treatment groups: States no statistically significant differences between demographic characteristics (age 
and gender) or between baseline degree of occlusion were observed between groups. No data reported, however, 
between groups
Method of data analysis: Summary statistics (mean ± SD) calculated and either a chi-squared test or a t-test used
Sample size/power calculation: No power calculations were undertaken as ‘planned as a descriptive study’
Attrition/dropout: None reported
General comments
Generalisability: American volunteer participants between ages 22 and 66 years employed by the study sponsor (self-
selection bias), so may not be representative of the total population in terms of being likely to have earwax problems
Outcome measures: Unclear how valid or reliable the outcome measure is. Authors acknowledge that the distinction 
between mild and moderate occlusion is somewhat subjective
Intercentre variability: Not applicable
Conflict of interests: Funded by a private research company, unclear whether the company has any relation to the 
treatments compared. Drs Roland and Gross served as paid consultants for Alcon Research Ltd
AEs, adverse events; F, female; M, male; RCT, randomised controlled trial; SD, standard deviation.
Quality criteria for assessment of RCTs (NHS CRD)
Item Judgementa
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Inadequate
4. Were the eligibility criteria specified? Adequate
5. Were outcome assessors blinded to the treatment allocation? Adequate
6. Was the care-provider blinded? Partial
7. Was the patient blinded? Adequate
8. Were the point estimates and measure of variability presented for the primary outcome 
measure?
Adequate
9. Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? Adequate
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Hinchcliffe61
Extracted by: PH Checked by: EL
Reference and design Intervention Participants Outcome measures
Author: Hinchcliffe61
Year: 1955
Country: UK
Study design: CCT
Number of centres: One
Setting: Military
Funding: Not reported
1. Sodium bicarbonate BPC: 
5 drops
2. Cerumol: 5 drops
3. Hydrogen peroxide BPC:  
5 drops
4. Olive oil BP: 5 drops
5. Control: No treatment
Duration of treatment: half 
hour
Other interventions used: 
Syringing with warm tap 
water
Number of readings: n = 185, 37 
ears per group
Sample attrition/dropout: N/A
Inclusion criteria for study entry: 
Air Force personnel with 
obscured TM, hard wax in the 
meatus in one or both ears
Exclusion criteria for study entry: 
None reported
Outcomes: No. of occasions 
wax meatus was not cleared 
within specified time (see 
below)
No. of cases with symptoms 
of discomfort
Method of assessing outcomes:
The treatment was 
considered a failure if more 
than 5 minutes of syringing 
was needed to clear the wax
AEs: Tingling or symptoms of 
irritation were noted before 
the ear/s was syringed
Length of follow-up: Immediate
Baseline characteristics of participants
Sodium 
bicarbonate 
(ears = 37)
Cerumol 
(ears = 37)
Hydrogen 
peroxide 
(ears = 37)
Olive oil 
(ears = 37)
Control 
(ears = 37) p-value
None reported
Results
Outcomes
Sodium 
bicarbonate 
(ears = 37)
Cerumol 
(ears = 37)
Hydrogen 
peroxide 
(ears = 37)
Olive oil 
(ears = 37)
Control 
(ears = 37) p-value
No. of occasions 
meatus not cleared
6 7 4 2 9 See comment field
No. of AEs 4 22 6 4 0
Comments: It is stated that only olive oil was significantly better than no treatment at all, but no further data is reported 
to support this. It is also reported that symptoms of discomfort for Cerumol occurred significantly more often than any 
other preparation, but again no further data is reported to support this.
Methodological comments
Allocation to treatment groups: The four treatment bottles were used in alphabetical order, with each fifth participant left 
untreated as a control
Blinding: Treatments were contained in bottles labelled A, B, C and D, with no distinguishing marks. The doctor syringing 
the ears was not informed of which treatment if any had been used. Initial otoscopic examination carried out by a alternate 
doctor
Comparability of treatment groups: Not reported
Method of data analysis: Chi-squared test for small numbers was used
Sample size/power calculation: None reported
Attrition/dropout: None reported
General comments
Generalisability: Adult entrants to the Royal Air Force in the 1950s, found to have hard wax obscuring the meatus on 
entrant examination
Outcome measures: Unclear how valid, objective or consistently applied the outcome measure was
Intercentre variability: N/A
Conflict of interests: Not reported
AEs, adverse events; BP, British Pharmaceutical grade; BPC, British Pharmaceutical Codex; CCT; controlled clinical trial; 
N/A, not applicable; TM, tympanic membrane.Appendix 5
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Quality criteria for assessment of controlled clinical studies
Item Judgementa
1. Were the groups similar at baseline in terms of prognostic factors? Unknown
2. Were the eligibility criteria specified? Adequate
3. Were outcome assessors blinded to the treatment allocation? Partial
4. Were the point estimates and measure of variability presented for the primary outcome 
measure?
Inadequate
5. Did the analyses include an ITT analysis? Inadequate
6. Were withdrawals and dropouts completely described? Unknown
7. Were participants likely to be representative of the intended population? Unknown
ITT, intention to treat.
a  Adequate, inadequate, partial, reported, unknown.DOI: 10.3310/hta14280  Health Technology Assessment 2010; Vol. 14: No. 28
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Appendix 6  
Excluded studies
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Population 0
Outcomes 0
Study design 16
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Appendix 7  
Variables included in the 
probabilistic sensitivity analyses
parameters of distributions used. T
able 40 lists variables included in probabilistic 
sensitivity analyses (PSA), distributions and 
TABLE 40  Variables included in PSA, distributions and parameters of the distribution
Variable Distribution Parameters
Probability of spontaneous earwax removal (no treatment) Beta Alpha = 40.5, beta = 769.5
Probability of successful earwax removal with the use of 
softeners only
Beta Alpha = 33.9, beta = 135.8
Probability of successful earwax removal with self-syringing Beta Alpha = 21.7, beta = 23.5
Probability of successful earwax removal with syringing 
administered by nurse at primary care
Beta Alpha = 15.6, beta = 9.6
Proportion of TM cases in the total number of SAEs Beta Alpha = 28.3, beta = 57.4
Probability of SAE associated with both active treatments Beta Alpha = 15.4, beta = 25,578.9
Hospital admission for either myringoplasty or treatment of a 
serious infection
Beta Alpha = 40.5, beta = 769.5
Probability of partial permanent hearing loss if myringoplasty is 
only partially successful
Beta Alpha = 31.8, beta = 95.3
Disutility associated with the loss of hearing Gamma Alpha = 3600, lambda = 600,000
Cost of GP referral to OTL Gamma Alpha = 96.04, 
lambda = 0.703589744
Cost of self-syringing Gamma Alpha = 96.04, 
lambda = 16.03338898
Cost of nurse visit Gamma Alpha = 96.04, lambda 
=10.79101124
Cost of earwax removal without SAE at primary care Gamma Alpha = 96.04, 
lambda = 2.653038674
Cost of assessment and referral primary care associated with 
SAE
Gamma Alpha = 96.04, 
lambda = 0.558696917
Cost of secondary care treatment of serious infection Gamma Alpha = 96.04, 
lambda = 0.250234497
Cost of secondary care treatment of TM Gamma Alpha = 96.04, 
lambda = 0.133019391
Cost of hospital admission for serious infection treatment Gamma Alpha = 96.04, 
lambda = 0.045733333
Cost of hospital admission for TM Gamma Alpha = 96.04, 
lambda = 0.067113906
Cost of softeners Gamma Alpha = 96.04, 
lambda = 131.5616438
Cost of de-waxing Gamma Alpha = 96.04, 
lambda = 0.562624487
OTL, otolaryngologist; SAE(s), serious adverse event(s); TM, tympanic membrane.Health Technology Assessment reports 
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Feedback
The HTA programme and the authors would like to know 
your views about this report.
The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish  
your comments. If you prefer, you can send your comments  
to the address below, telling us whether you would like  
us to transfer them to the website.
We look forward to hearing from you.